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Ischaemic heart disease represents a restriction of blood, and therefore oxygen, supply to the 
myocardium. This leads to a remodelling of cardiac metabolism, which can exacerbate production of 
damaging reactive oxygen species and tissue necrosis upon reperfusion. In a different paradigm of 
metabolic disease, the type-1 diabetic heart becomes more dependent upon the oxidation of fatty 
acids (FAO) for ATP synthesis due to an inability to regulate blood glucose concentration. The work 
presented in this thesis aimed to further our understanding of substrate selection and metabolism in 
the ischaemic and type-1 diabetic hearts. 
A mathematical network model for tracing universally-13C labelled metabolic substrates through the 
Krebs cycle using mass spectrometry was developed and presented. Experimentally-observed 
isotopologue distributions of Krebs cycle intermediates and proxies were interpreted using this model 
to determine the percentage of acetyl-CoA oxidised in the Krebs cycle which originated from the U-
13C labelled substrate.     
In the Langendorff perfused rat heart, perfusion with intralipid resulted in greater functional recovery 
following ischaemia/reperfusion. Supplementation with dietary nitrate ablated this cardioprotective 
effect, but this highlights the importance of fatty acid oxidation to recovery from 
ischaemia/reperfusion injury. 
Ketogenesis was found to occur in the ischaemic heart, and was not specifically dependent upon either 
fatty acid or glucose oxidation. Its inhibition resulted in improved recovery of contractile function 
following ischaemia/reperfusion, suggesting the ketogenesis which occurs during cardiac ischaemia is 
a detrimental process. 
Isoprenaline administration conserved mitochondrial respiratory capacity and energetics in the type-
1 diabetic rat heart. 10 weeks following removal of 90% of the pancreas (Px), mitochondrial respiratory 
capacity was impaired, with a substrate switch towards fatty acid oxidation (FAO) observed alongside 
greater expression of FAO-related enzymes and evidence of oxidative stress. Isoprenaline 
administration also impaired respiratory capacity, but enhanced flux through glycolysis. In the hearts 
of isoprenaline treated Px rats, mitochondrial respiratory capacity and energetics were conserved.  
In conclusion, cardiac ischaemia and type-1 diabetes both represent diseases where metabolic 
substrate oxidation is perturbed. FAO is not detrimental to the ischaemic or type-1 diabetic heart 
without associated loss of metabolic flexibility, and even appears beneficial to recovery following 
ischaemia/reperfusion.     
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STATEMENT OF RELEVANCE 
Myocardial infarction, the underlying cause of a heart attack, has a vast social and economic impact 
on the UK and is the largest single cause of mortality. 433000 hospital admissions and 66000 deaths 
are the result of a heart attack each year in the UK (BHF, 2018b, 2018a). Furthermore, even those who 
survive treatment following a heart attack are likely to face secondary complications and spend the 
rest of their lives taking drugs for symptoms. In the US those who have previously suffered a heart 
attack are 2.8 times more likely to be diagnosed with heart failure in future (Hugli et al., 2001), and 
between 10-20% of those hospitalised for heart failure have previously been admitted for a heart 
attack (Fang et al., 2008; Hugli et al., 2001). Direct costs of heart attack related healthcare in the UK 
are estimated to be around £3bn, while the total loss to the economy is thought to be as high as £7-
10bn (Astrazeneca, 2009; Liu et al., 2002). 
On top of the mortality it causes in its own right, Diabetes Mellitus represents a further cause of 
mortality through increasing susceptibility to several forms of heart disease. 40% of those presenting 
with acute heart failure syndrome have a history of diabetes (Gheorghiade and Pang, 2009), and the 
risk of suffering a heart attack is 3.5 times greater for sufferers of type 1 diabetes than for a non-
diabetic individual (NHS, 2017). £51m and £31m are estimated to be spent annually on diabetic 
patients who contract ischaemic heart disease or heart failure, respectively (Hex et al., 2012). 
Both ischaemia and diabetes are essentially metabolic diseases. Ischaemia stems from the occlusion 
of blood and oxygen supply to the heart, and as oxygen is directly involved in energy metabolism as 
the final electron acceptor of the electron transport chain this drastically disrupts metabolism. 
Diabetes mellitus meanwhile leads to dysregulation of blood sugar and fatty acid levels, and since 
these are both important metabolic substrates this also has a severe impact upon cardiac metabolism 
as is discussed in greater depth in Chapter 6. Study and manipulation of the heart’s metabolism is 
therefore essential to further understanding the mechanisms of these diseases, and offers a direct 
opportunity for interventions which may lessen or reverse symptoms and hopefully in the long run 
improve the mortality statistics mentioned above.   
This work is funded by the British Heart Foundation, who have a goal to eradicate all cardiovascular 
disease. Through helping understand the metabolic mechanisms behind ischaemia and type 1 
diabetes in the heart, the work in this thesis aligns with this goal, and will hopefully lead to better 
understanding and identification of targets for treating these diseases in the future. 
 
 




1.1 ENERGY, METABOLISM AND THE ROLE OF OXYGEN 
Electrons and protons obtained from the catabolism of high energy substrates play a crucial part 
in generating the energy all organisms require to function. These are themselves generated 
through the sequential catabolism of macromolecules such as fatty acids, carbohydrates and 
proteins. However, whilst the generation and manipulation of these sub-atomic particles is key to 
the process of converting stored energy into a useable form, they can be highly damaging to the 
cell if allowed to accumulate. 
Oxygen is therefore employed to facilitate safe excretion of subatomic catabolic products while 
enabling continuation of energy metabolism. Readily available as an atmospheric gas and highly 
electronegative, O2 can react with protons and electrons to form water, a safe and stable vehicle 
molecule for electron disposal which may also be further be employed by the cell in catabolic 
reactions. Oxygen is the final electron acceptor of the respiratory chain, with its point of action 
coming after the electrons have passed along the mitochondrial electron transport chain (ETC) to 
drive oxidative metabolism (Figure 1.1). When electrons reach complex IV, four of these electrons 
are accepted by oxygen, along with four protons, in order to form two molecules of H2O. 
Metabolic oxygen consumption is therefore directly related to the flow of electrons through the 
electron transport chain. Electrons harvested from catabolic metabolism are transferred via NADH 
or FADH2, until entering the mammalian ETC through one of three main points. Complex I provides 
an interface for the acceptance of electrons carried by NADH, using the energy released to pump 
four protons into the intermembrane space. Meanwhile, complex II catalyses the removal of 
electrons from succinate via FADH2. The FADH2 which is generated from the β-oxidation of fatty 
acids donates its electrons similarly through the electron transferring flavoprotein (ETF). All three 
electron receptors transfer electrons to complex III via the ubiquinone pool, which passes them 
along to cytochrome c in a reaction further associated with protons being pumped into the 
intermembrane space. Cytochrome c oxidase (complex IV) pumps two further protons across the 
membrane upon receipt of these electrons, the energy for this being released during the 
acceptance of the electron by oxygen. 






1.1.2 Oxidative Phosphorylation 
This cascade of electrons through the ETC generates a proton gradient, ΔµH+, which is harnessed 
by ATP synthase to generate the cellular energy currency (ATP) (Mitchel, 1961). The flow of 
protons from the intermembrane space back into the mitochondrial matrix is dependent upon the 
magnitude of ΔµH+, and drives the rotation of the ATP synthase subunits which catalyse 
phosphorylation of ADP to ATP (Jonckheere et al., 2012). 
 
1.1.3 ATP as a Vector for Energy Transfer 
Hydrolysis of the high energy phosphate bonds of ATP to produce ADP and an inorganic phosphate 
molecule serves to provide most cellular processes with the energy they require. The free energy 
yielded by ATP hydrolysis, ΔG’ATP, is a function of both the standard free energy of ATP (ΔGOATP) 
and of the ratio of ATP/ADP in the cell, which is maintained at a high level by mitochondrial 
metabolism. ΔG’ATP may thus be represented as           , where R is the 
gas constant and T temperature in degrees Kelvin (Veech et al., 2001) 
Figure 1.1: The Electron Transport Chain and Oxidative Phosphorylation. Schematic of 
mitochondrial respiratory chain consisting of complexes I, II, III, IV and V (ATP synthase). NADH 
supplies electrons to complex I, whilst complex II accepts electrons from the conversion of succinate 
to fumarate via FADH2. The electrons are then shuttled to complex III via ubiquinone, before being 
accepted by cytochrome c and transferred to complex IV, at which point they are accepted by 
oxygen. Protons are pumped into the inter-membrane space at complexes I, III and IV, generating 
a proton-motive force which drives phosphorylation of ADP to ATP by ATP synthase. 
ΔG’ATP= ΔGOATP + RTln[ADP][Pi] 
            [ATP] 
 




The ratio of ATP to ADP in the cell is therefore crucial both to the availability of ATP to power 
reactions, and because it affects the amount of energy available from the hydrolysis itself (Veech 
et al., 2001). The amount of ATP generated per gram of metabolic substrate and per molecule of 
oxygen impacts upon this ratio, allowing metabolism of some substrates to reach functional levels 
of ΔG’ATP more efficiently than the metabolism of others depending upon the amount of reducing 
intermediates they yield in the Krebs cycle and proceeding metabolic pathways. 
 
1.1.4 The Krebs Cycle 
Under oxidative conditions, the majority of the NADH and FADH2 which provides reducing power 
to the ETC is yielded by the Krebs cycle. Conceptualised by Hans Krebs in 1937, the Krebs cycle 
constitutes a mitochondrial cycle of enzymatic reactions which harvest reducing power from 
carbon-based intermediates in a stepwise process (Kornberg, 2000; Krebs and Johnson, 1937, 
1980). One of the major vectors for carbon input into the Krebs cycle is acetyl-CoA, which citrate 
synthase combines with oxaloacetate to form the six carbon molecule citrate (Krebs et al., 1938). 
Over a sequence of enzymes and intermediates detailed in Figure 1.2, CO2 and reducing power 
are stripped from citrate and its derivatives, with the end result being regeneration of 





Figure 1.2: The Krebs Cycle. Acetyl-CoA is combined with oxaloacetate to form citrate by citrate 
synthase, initiating a cyclic series of reactions which culminate in the regeneration of oxaloacetate 
following the production of NADH, CO2 and GTP. GTP is readily converted into ATP for cellular 
processes. 




1.1.5 Metabolic Substrates 
Catabolism of glucose, fatty acids, ketone bodies and amino acids can all yield high energy 
electrons for oxidative phosphorylation. Metabolic selection of which substrate to oxidise can 
depend upon many things, including current energetic demand of the tissue, substrate and oxygen 
availability. Generally, fatty acids, glucose and ketone bodies all feed into the Krebs cycle as acetyl-
CoA, whilst amino acids are capable of entering following conversion to intermediates including 
pyruvate, glutamate and fumarate.  
 
1.1.6 Fatty Acid Metabolism 
The Carnitine Shuttle 
Fatty acids are initially converted to acyl-CoAs via addition of coenzyme A by the enzyme acyl-CoA 
synthase. Conditional upon the length of their carbon chain, these acyl-CoAs are prepared for 
uptake to the mitochondria via conversion to acyl-carnitines by carnitine palmitoyl transferase 1 
(CPT-1), the cardiac isoform of which is CPT-1b. Carnitine acylcarnitine translocase (CACT) 
subsequently transports the fatty acids into the mitochondria in their acyl-carnitine form, where 
CPT-2 reverses the transformation into acyl-CoA esters which may then undergo FAO (Houten and 
Wanders, 2010). 
β-Oxidation 
For the most part fatty acid oxidation (FAO) begins with the conversion of fatty acids to acetyl-
CoA via β-oxidation (Figure 1.3). Acyl-CoA dehydrogenases specific to the length of fatty acid (VL 
(Very Long chain), L (Long chain), M (Medium chain) and S (Short chain) ACAD) serve to prepare 
the Acyl-CoA for metabolism by the mitochondrial trifunctional protein (MTP) or cytosolic 
equivalents (Chegary et al., 2009). MTP performs hydration of the double bond for long chain 
CoAs, dehydrogenation of the resulting L-3-hydroxy-acyl-CoA to 3-keto-acyl-CoA, and thiolytic 
cleavage of the 3-keto-acyl-CoA to yield an acyl-CoA that is two carbons shorter and acetyl-CoA 
(Houten et al., 2018). Medium (< 10 carbons) and short chain acyl-CoAs (2-4 carbons) are 
metabolised by enoyl-CoA hydratase, the medium and short chain hydroxyacyl-CoA 
dehydrogenase HOAD, and medium chain 3-ketoacyl-CoA thiolase (MCKAT) instead of MTP. 
Following the release of each acetyl-CoA molecule, the newly shortened chain re-enters β-
oxidation in a repetitive cycle until it has been completely metabolised to acetyl-CoA (Schulz, 
1991).  





1.1.7 Glucose Metabolism 
The six carbon molecule glucose is either taken up from the bloodstream or catabolised from 
internal glycogen stores for metabolism. Glucose Transporter 1 (GLUT1) is constitutively 
expressed and allows a basal rate of glucose uptake, while upregulation of Glucose Transporter 4 
(GLUT4) allows post-prandial adjustment of glucose uptake in response to the secretion of insulin 
by the pancreas when blood glucose levels are high. The initial phase in glucose metabolism, 
glycolysis, is triggered by hexokinase mediated phosphorylation of the glucose. Glucose is then 
sequentially converted to the three carbon molecule pyruvate (Figure 1.4, overleaf) (Li et al., 
2015; Lunt and Heiden, 2011). Under aerobic conditions, pyruvate is decarboxylated to acetyl-CoA 
by pyruvate dehydrogenase following the transport of pyruvate into the mitochondria by the 
mitochondrial pyruvate carrier (Mccommis and Finck, 2016; Schell and Rutter, 2013). Under 
anaerobic conditions, glycolysis supplies some limited ATP, with pyruvate being converted to 
either lactate or alanine rather than entering the mitochondria (Folbergrová et al., 1974; Li et al., 
2015; Zhou et al., 2005). 
Figure 1.3: β-oxidation. Acetyl-CoA is yielded from the cyclic decomposition of fatty acyl-CoAs. 
Following import into the mitochondria via the carnitine shuttle, fatty acyl-CoAs are sequentially 
dehydrated, hydrated, dehydrated and thioytically cleaved by ACAD, enoyl-CoA hydrase, HOAD 
and MCKAT to generate acetyl-CoA and a shorter acyl-CoA which may undergo the process again. 





Figure 1.4: Glycolysis. Glucose is converted into pyruvate which can be taken up into the 
mitochondria via sequential enzyme catalysed reactions. The process consumes two moles of ATP 
per mole of glucose, but yields four. In anaerobic conditions, pyruvate is diverted to lactate and 
alanine in order to permit the continued production of this ATP. 




1.1.8 Ketone Body Metabolism 
The ketone bodies, β-hydroxybutyrate, acetoacetate and acetone, are another energy substrate 
which are typically produced by the liver and oxidised by other tissues including the heart during 
fasting or starvation (Grabacka et al., 2016). While acetone is metabolised through a different 
pathway, β-hydroxybutyrate is oxidised by the enzyme β-hydroxybutyrate dehydrogenase to 
acetoacetate, which is subsequently converted to acetoacetyl-CoA by the enzyme SCOT. 
Acetoacetyl-CoA can then be converted to acetyl-CoA for entry into the Krebs cycle (Grabacka et 
al., 2016). Alternatively, the interchange between acetoacetyl-CoA and acetoacetate may be 
mediated via a HMG-CoA intermediate by the enzymes HMG-CoA synthase and HMG-CoA lyase 
through a pathway which is commonly thought of as ketogenic rather than ketolytic and yet 
consists of enzymes which catalyse bidirectional reactions (McGarry and Foster, 1976). Ketone 
bodies are a very oxygen efficient fuel which increase the oxygen efficiency of the working heart 
by 25% when supplied in addition to 10mM glucose (Sato et al., 1995). They are oxidised 
preferentially to fatty acids and glucose through their inhibition of the other substrates’ oxidation 
(Le Foll et al., 2014; Sato et al., 1995; Stanley et al., 2003). 
For a more thorough introduction to cardiac metabolism of ketone bodies, see the introduction 
to Chapter 5. 
  




1.2 SPECIFIC METABOLIC TRAITS OF THE HEART 
The metabolic demands of the heart are amongst the greatest of any organ. With the human 
body’s surface area to volume ratio being too low to support sufficient gas diffusion directly into 
the tissues, the survival of every organ is contingent upon the action of the heart to supply oxygen 
as well as other essential nutrients and components. Under normal physiological conditions this 
tonic contraction consumes about 35 kg of ATP per day (Taegtmeyer and de Villalobos, 1995; 
Ferrari et al., 2018), but cardiac energy requirements must also be met under more strenuous 
conditions such as exercise, hypertension or chronic stress.  
The heart is a metabolic omnivore because it can oxidise a range of different substrates for ATP. 
However, it relies heavily on FAO in its healthy state because fatty acids are the most energy dense 
metabolic substrate, producing ~2.4 times more ATP per gram dry substrate than glucose (Darvey, 
1998). The healthy human heart can derive almost 100% of its ATP from fatty acids in appropriate 
circumstances, although on average the percentage of ATP derived from fatty acids is ~50-90% 
(Neely et al., 1972; Lopaschuk et al., 2010; Brinkmann et al., 2002). The heart mostly oxidises 
exogenous substrate because its daily energy demands are greater than the amount of substrate 
it can store, but can also utilise internal stores of triglyceride (Lahey et al., 2014; Lopaschuk et al., 
2010). 
However, metabolic plasticity is a hallmark of cardiac function, and when circumstances dictate 
other substrates are just as readily oxidised. Glucose is a more oxygen-efficient fuel than fatty 
acids, so when oxygen is a limiting factor, for example during exercise induced exertion, or in the 
hypoxic and foetal hearts, it is common to find a shift towards glucose oxidation at the expense of 
fatty acids (Horscroft et al., 2015; Onay-Besikci, 2006; Opie and Sack, 2002; Taegtmeyer and 
Lubrano, 2014).  
Such a shift can also be effected by alterations in the availability of substrates, as would occur due 
to a sustained dietary change. Generally, the heart takes up all of its oxidisable substrates from 
the blood, and, even though it has internal stores of both fatty acids and glucose, substrate 
selection is heavily influenced by the levels of circulating metabolites (Brinkmann et al., 2002). 
Long term dietary changes can have lasting influence upon what the heart can take up and 
therefore oxidise. For example, a high protein diet results in a lower rate of glucose oxidation (Linn 
et al., 2000), high fat diets suppress glucose oxidation and enhance FAO (An et al., 2013), and low-
carbohydrate diets have similar effects while also enhancing the oxidation of ketone bodies 
(Manninen, 2004). 




When ability to switch substrates for oxidation is impaired, the heart loses its ability to respond 
to metabolic stimuli, and this is often associated with pathology. Diabetes Mellitus, a group of 
metabolic diseases defined by high blood sugar levels over a prolonged period, represents one 
well characterised example of a condition which results in such an impairment of metabolic 
flexibility, and also increased mortality from cardiovascular disease (Bayeva et al., 2013). The 
diabetic heart becomes more reliant upon oxidation of fatty acids for ATP production due to the 
resultant dysregulation of glucose metabolism. The increased cardiovascular disease risk 
associated with diabetes highlights the importance of metabolic flexibility to the function of the 
heart, although it is unknown whether loss of metabolic flexibility is a symptom or a cause of heart 
disease in diabetics. This is addressed, and a more thorough introduction to metabolism in the 
diabetic heart presented in Chapter 6. 
Regardless of the level of FAO, some oxidation of glucose is always required to facilitate Krebs 
cycle function (Paoli et al., 2013). As with any system which comprises bi-directional reactions, 
there can be a net loss of carbon molecules from the TCA cycle over time where reactions 
converting its intermediates to other molecules proceed at a greater rate than their reverse 
direction. This necessitates the replacement of carbon in order for production of sufficient levels 
of NADH and FADH2 to continue. For regeneration of overall carbon levels in the Krebs cycle, 
acetyl-CoA cannot contribute for two reasons. The first is that for every acetyl-CoA molecule which 
enters the Krebs cycle, two carbons are subsequently lost as CO2, meaning that there is no net 
gain or loss of carbon. Secondly, without entry of molecules larger than two carbons to the Krebs 
cycle the net carbon loss will mean that there are fewer molecules of oxaloacetate for the acetyl-
CoA to bind to. The mitochondria metabolise fatty acids to acetyl-CoA, which can only fix two 
carbons into the Krebs cycle, and subsequently produces two molecules of CO2. On the other 
hand, glucose is initially metabolised into the three carbon unit pyruvate, which may then 
supplement carbon levels in the Krebs cycle through conversion to oxaloacetate by the enzyme 
pyruvate carboxylase. This replenishment of Krebs cycle intermediates is an example of 
anaplerosis. Pyruvate carboxylase is the main anaplerotic enzyme, although certain amino acids 
may also contribute to anaplerosis (Manninen, 2004; Owen et al., 2002). Pyruvate and amino acids 
may function as anaplerotic substrates because they contribute more carbons to the Krebs cycle 
than the two which are removed as CO2, whereas acetyl-CoA derived from FAO only contributes 
two carbons and so its incorporation does not represent a net gain of carbon for the Krebs cycle.    
 
 





Cardiac ischaemia stems from the occlusion or cessation of blood flow, and therefore supply of 
oxygen and metabolic substrates, to an area of cardiac tissue. This is the most common cause of 
heart attacks. Cardiac ischaemia usually follows blockage of one or more coronary arteries which 
prohibits all, or more commonly, most, blood supply to the myocardium. For such an energetically 
demanding tissue, this loss of oxygen and therefore capacity for oxidative metabolism can be 
catastrophic. Time is a crucial factor during ischaemia as the longer an area of the heart is 
subjected to ischaemia, the greater the likelihood of the affected area of tissue undergoing 
necrosis and forming an infarct which can cause ongoing issues such as angina or heart failure 
even if reperfused with oxygenated blood (Debrunner et al., 2008). 
1.3.1 Disruption of Contractile Function 
Ischaemia has an instant effect upon contractile function of the heart. Contractile function is 
directly linked to metabolism, and therefore when oxygen supply is attenuated and metabolism 
affected, regular contractile function ceases. This has an immediate effect upon the rest of the 
body, since the supply of oxygen and nutrients to other tissues is disturbed.  
Collapse of calcium homeostasis during ischaemia also contributes to the failure of contractile 
function. Ordinarily in the heart, calcium influx from the extracellular space leads to further 
release of calcium from the sarcoplasmic reticulum (SR), which binds to troponin C to potentiate 
the association of myosin and actin, the hydrolysis of ATP and generation of contractile force 
(Wier, 1990). This influx of calcium is then rapidly cleared in preparation for the next contractile 
cycle by the action of the Ca2+/Na+ transporter, which harnesses the influx of Na+ to the cell down 
its concentration gradient to remove Ca2+ from the cytosol (Barry, 1991). However, the decreased 
ability to produce ATP in ischaemia impairs the activity of the cellular Na+/K+ pump, leading to an 
increase in intracellular Na+ (Hasin and Barry, 1984). This initially decreases the Na+ gradient into 
the cell, and therefore the rate of calcium efflux, but eventually leads to calcium influx through 
reversal of the direction of the transporter. Increased intracellular Ca2+ decreases the response to 
SR calcium release in part due to a decreased gradient from SR to cytosol, but also due to 
desensitisation of the Ca2+ response (Lee and Allen, 2006). 
1.3.2 Reactive Oxygen Species 
The altered reductive environment in ischaemia can lead to the production of reactive oxygen 
species (ROS) (Becker, 2018). ROS are potentially-damaging free radicals and non-radical oxidising 




agents most commonly including hydrogen peroxide (H2O2) and superoxide (•O2-) (Panth et al., 
2016), which may cause cellular damage and even direct necrosis via peroxidation of lipid 
membranes and damage to proteins (Becker, 2018). The process of ROS generation is highly 
oxygen dependent, occurring at both high and low oxygen tensions. Despite it being 
counterintuitive that in an oxygen-limited environment there is damaging levels of oxygen radical 
production, the process is observable via the use of fluorescent probes (Becker et al. 1999; Zhu & 
Zuo 2013; Panth et al. 2016). It appears therefore that in a redox-reduced cell the ETC is capable 
of “leaking” electrons to what little oxygen remains in order to produce reactive anions (Nohl and 
Werner, 1986).    
The major source of ischaemic ROS is ETC complex III, with some contribution from other 
complexes (Bleier and Dröse, 2013; Guzy and Schumacker, 2006). While reverse electron flow has 
been postulated as a mechanism for ROS generation from complex I during ischaemia, it has been 
shown that reverse electron flow actually decreases through an ischaemic period due to 
uncoupling, making this unlikely (Ross et al., 2013). Complex I and complex II do have the ability 
to contribute some ROS production, although this is rendered negligible by mitochondrial 
antioxidant defences (Chen et al., 2003; Turrens, 2003). Blockade of electron flow at complex III, 
which occurs as a response to ischaemia and hypoxia, results in a much higher rate of ROS 
production, and this is further supported by evidence that inhibition of electron flow to complex 
III through complex I greatly reduces this ROS production and damage sustained to complex III 
(Chen et al., 2003, 2007; Guzy and Schumacker, 2006; Heather et al., 2010). 
 
1.3.3 The Metabolic Response to Ischaemia 
Ischaemia represents a severe and immediate effector of change to metabolism. Attenuation of 
oxygen supply to the myocardium leads almost immediately to a near total ablation of oxidative 
metabolism, and while a tiny amount of oxidative metabolism still occurs, the majority of the ATP 
which the cells need to survive must be generated anaerobically.  
During ischaemia, there is a swift switch towards glycolytic metabolism. Ischaemia represents a 
disease where oxygen supply is limiting, and induces a diversion of pyruvate through lactate 
dehydrogenase (LDH) to form lactate (Li et al., 2015; Zhou et al., 2005) as part of anaerobic 
respiration. Glycolytic respiration produces far less ATP per glucose molecule than oxidation 
would, but is able to proceed in the absence of oxygen.  




Accumulation of lactate itself can cause damage to the heart without blood flow to facilitate its 
excretion, however. Lactate is a proton donor, and can cause acidification of the cytosol, damaging 
cellular superstructures and interfering with pH dependent reactions (Kraut and Madias, 2014; 
Marcinek et al., 2010). During ischaemia, where there is low coronary perfusion, lactate is present 
to a high concentration in the coronary effluent (Goodwin and Taegtmeyer, 1994). Because of the 
accumulation of lactate and the associated low ATP yield, anaerobic respiration is not conducive 
to sustaining healthy cells over longer periods, but some ATP is preferable to none early during 
the insult. Whilst anaerobic respiration may therefore be beneficial during the early stages of 
ischaemia therefore, there comes a point at which the damage caused may outweigh the benefits. 
Of the oxidative metabolism which does still occur, there is debate over whether fatty acid or 
glucose oxidation is favoured during ischaemia. While oxidation of both substrates is severely 
ablated relative to before the ischaemic insult, glucose oxidation has been documented in some 
sources to predominate that oxidation which does still occur (Yao et al., 2015). This would appear 
to make sense given it is a more oxygen efficient substrate than fatty acids. Moreover, the highly 
reductive environment during ischaemia, typified by enhanced NADH/NAD+ ratios, would act to 
inhibit β-oxidation.  
However, it has also been argued that fatty acid oxidation can come to dominate in the ischaemic 
heart due to dysregulation through malonyl-CoA. Malonyl-CoA is a product of the carboxylation 
of acetyl-CoA by acetyl-CoA carboxylase (ACC), and has an inhibitory effect upon uptake of fatty 
acids into the mitochondria via CPT-1 (Dyck et al., 2004; Stanley et al., 2005). In the ischaemic 
heart, AMP kinase (AMPK) is thought to be activated by the associated metabolic stresses, 
particularly  the drop in ATP and PCr levels (Fillmore et al., 2014; Kantor et al., 1999). AMPK 
phosphorylates and inactivates ACC, compromising its inhibition of CPT-1 and thus making it 
possible that there is increased capacity for mitochondrial fat uptake/oxidation during ischaemia 
(Figure 1.5) (Lopaschuk et al., 2010). 






Whichever of glucose or fatty acid oxidation comes to dominate during ischaemia will inhibit the 
other via the Randle cycle. On a cellular level, the balance between glucose and fatty acid 
oxidation is given an extra dimension of control by this cycle of mutual inhibition (Hue et al., 2009). 
FAO leads to increased ratios of acetyl-CoA/CoA and of NADH/NAD+, both of which are factors 
inhibiting the activity of PDH (Guo, 2015; Randle et al., 1963). Meanwhile, there is thought to be 
an increase in cytosolic citrate levels, leading to inhibition of 6-phosphofructo-1-kinase and a 
resultant increase of glucose-6-phosphate, which inhibits hexokinase (Hue et al., 2009). On the 
other hand, glucose oxidation leads to an inhibition of fatty acid oxidation through enhanced 
production of malonyl-CoA as described above (Lopaschuk et al., 2010).  
In addition to the debate over whether fat oxidation is inhibited or potentiated during ischaemia, 
there is contention over whether it might be beneficial or pathological under these conditions. 
High levels of fatty acids detected clinically in circulation during ischaemia and reperfusion have 
Figure 1.5: Inhibition of Fatty Acid Oxidation by Malonyl-CoA and Putative Release of Inhibition 
during Ischaemia. Acetyl-CoA from the mitochondrial matrix is exported from the mitochondria via 
an acetyl-carnitine intermediate by carnitine acetyl-translocase under aerobic conditions. In the 
cytosol it is converted to malonyl-CoA by acetyl-CoA carboxylase, and comes to inhibit further 
uptake of fatty acids to the mitochondria by inhibiting the action of CPT-1. However, during 
ischaemia, when AMP kinase is activated, Lopaschuk et al. hypothesise an inhibition of acetyl-CoA 
carboxylase, resulting in a lesser conversion rate of acetyl-CoA to malonyl-CoA and therefore 
greater capacity for fatty acid uptake to the mitochondria.  




been correlated with the severity of the incident, and one suggestion has been that increased 
oxidation of fatty acids at the expense of glucose might promote higher rates of glycolysis at the 
expense of glucose oxidation and therefore acidification of the myocardium (Jaswal et al., 2011; 
Lopaschuk et al., 1993). However, in the absence of a previous severe ischaemic insult, presence 
of fatty acids in cardiac tissue has not been found to impair recovery of function post-reperfusion 
(Johnston and Lewandowski, 1991; Taegtmeyer and Stanley, 2011). In fact, with a variety of 
differing types of fatty acid in the perfusion buffer including both intralipid (a commercially 
available triglyceride mixture) and palmitate it has been found that functional recovery has 
actually been enhanced, suggesting that the presence of fatty acids is actually beneficial in 
restoring the ATP debt established during ischaemia (King et al., 2001; Liedtke et al., 1988; Lou et 
al., 2014a). It is even possible that rather than being a contributor to the damage sustained 
following ischaemia, the high levels of circulating fatty acids detected clinically may actually be a 
symptom or beneficial response – the liver and adipose tissue being stimulated to release more 
fatty acids to aid recovery or damaged heart tissue leaking more fatty acids the more severe the 
insult is. It is therefore currently unclear whether increased oxidation of fatty acids is beneficial or 
detrimental during ischaemia, and more definitive experiments are required before a consensus 
on this can be reached.  
Genes related to FAO generally come under the direct transcriptional control of a set of enzymes 
known as the peroxisome proliferator associated receptors, or PPARs (Roberts et al., 2011). These 
transcription factors can up- or down-regulate enzymes involved in FAO in association with dietary 
or environmental stimuli. For this reason, these transcription factors have been identified as a 
potential avenue for therapeutic treatment in the diabetic and failing hearts, where there is an 
imbalance between FAO and glucose oxidation (Fillmore et al., 2014; How et al., 2007). PPAR 
agonists are of debateable use clinically due to side effects such as genotoxicity and heart failure 
(Home, 2011). However, PPAR agonists and NOx species such as nitrate have been documented 
to stimulate PPAR in a range of tissues, which could be of scientific interest across a broad range 
of cardiac metabolic perturbances (An et al., 2018; Ashmore et al., 2014a, 2015; Huang et al., 
2017). However, another question to which the answer is not yet clear is whether modulation of 
FAO related gene transcription using such agents could be effective if used as a protective strategy 








1.4 REPERFUSION INJURY 
Perhaps counterintuitively, the greater damage to the heart is actually mediated upon reperfusion 
following ischaemia. At this point, the most reactive oxygen species are produced, probably due 
to the damage sustained during ischaemia being put under greater strain by the sudden increase 
in oxidative phosphorylation associated with restored blood supply to the myocardium (Chen et 
al., 2007). Plentiful supply of oxygen also means there is greater capacity for the generation of 
radicals, and so immediately following reperfusion there is often a damaging burst of ROS 
(Granger and Kvietys, 2015). ROS are also produced from other cellular sources upon reperfusion, 
such as NADPH oxidase (NOX), which can further trigger ROS release from the mitochondria by 
stabilising opening of the mitochondrial permeability transition pore (mtPTP) (Granger and 
Kvietys, 2015).  
The burst of ROS upon reperfusion overwhelms cellular antioxidant defences (e.g. superoxide 
dismutase, glutathione peroxidase etc.) (Kalogeris et al., 2014). Once this has occurred, apoptosis 
can be caused by ROS-induced lipid peroxidation and weakening of cellular membranes, leading 
to cell rupture as well as further damage to the mitochondria (Chen et al., 2003; Kalogeris et al., 
2014) (Figure 1.6).  
 
 
Figure 1.6: ROS mediated mechanisms of apoptosis upon reperfusion. ROS produced at 
complexes I & III of the ETC, or by NADPH oxidase (NOX) may trigger apoptosis via activation of the 
caspase pathway, necrosis via direct peroxidation of the plasma membrane, and ROS-induced ROS 
release through induction of mtPTP opening. Cytochrome c release from the mitochondria can 
further activate the caspase pathway, while Hypoxia Inducibe Factor 1a (HIF-1a) and Hexokinase II 
migrate to the mitochondria and stabilise the opening of the mtPTP in conditions of oxidative 
stress  




Reperfusion is thought to lead to increased opening of the mitochondrial permeability transition 
pore (mtPTP), a phenomenon preceding leakage of pro-apoptotic factors and eventual cell death. 
The composition of the mtPTP remains contested, but is thought to involve a dimer of ATP 
synthase (Bonora et al., 2013). Its opening leads to a sudden permeability transition which permits 
ions and larger molecules to exit the mitochondria in an uncontrolled manner (Zorov et al., 2014). 
While mtPTP remains largely closed during the ischaemic period due to acidosis, reperfusion leads 
to its opening being mediated through ROS, HIF-1a and hexokinase-II (Kim et al., 2018). Opening 
mtPTP results in H+ and Ca2+ entering the mitochondria, and prolonged opening leads to 
uncoupling and loss of the proton gradient. Cessation of ATP production is the consequence, and 
cytochrome-c efflux interacts with the caspase cascade to trigger apoptosis. 
Myocardial ischaemia/reperfusion further induces an acute inflammatory response, both locally 
and in distal sites. Prolonged blockage of oxygen supply to the myocardium results in cell death 
and the release of their contents, which in turn recruits neutrophils and macrophages to the injury 
site (Von Hundelshausen and Weber, 2007). This is mediated by ROS released acutely during 
ischaemia, which induce leukocyte release of chemokines and also platelet aggregation (Canoso 
et al., 2018; Lakshminarayanan et al., 2001). These chemokines include interleukins and TNF, 
which may cause systemic inflammation and which correlate strongly with the severity of the 
insult (Debrunner et al., 2008; Prondzinsky et al., 2012). The recruited white blood cells may 
produce their own ROS, as well as degranulating proteases and cytokines which cause further cell 
death in the infarcted area and fibrosis which may then further impair contraction (Frangogiannis, 
2015; Ruparelia et al., 2016). Reduction of damage sustained during ischaemia would therefore 
have the secondary advantage of preventing leukocyte recruitment, systemic inflammation and 
further cell death.  
 
1.4.1 The Metabolic Response to Reperfusion 
Metabolic pathways remaining adapted to low oxygen concentrations when oxygen and nutrients 
become re-available upon reperfusion is a key factor in reperfusion-injury. Since reperfusion is the 
major stimulant for mitochondrial ROS production, adaptation of metabolism to cope with this 
new availability affects how well the heart can recover. 
The myocardium is thought to swiftly recover its ability to oxidise fatty acids post-reperfusion. 
Both enzyme activity studies and direct measurements indicate that fat oxidation capacity is  
maintained or higher relative to pre-ischaemic rates (Liedtke et al., 1988; Lopaschuk et al., 1990; 




Nellis et al., 1991). FAO, as previously discussed, has a greater yield of ATP/g substrate than 
glucose, but also leads to a greater degree of uncoupling and ROS production (Boudina et al., 2005, 
2007; Cole et al., 2011; Echtay et al., 2002; Murray et al., 2005, 2008). It is likely that the demand 
for ATP to sustain contraction and restore cellular ion balance influences this early drive to restore 
a high level of fat oxidation. Even those who have argued that FAO oxidation is decreased and 
glucose oxidation increased in the reperfused heart conclude that FAO still accounts for the 
majority of ATP production upon reperfusion (Myears et al., 1987). 
Despite quickly restored FAO rates though, glycolysis after reperfusion continues to underlie the 
success of recovery. Hearts immediately after reperfusion display a much worse ability to cope 
with the inhibition of glycolysis than those which have never suffered an ischaemic insult or where 
glycolysis is inhibited further after reperfusion (Richmond et al., 1992). Initial high rates of 
glycolysis may be critical to provide cytosolic ATP, aiding homeostatic ion transport while the 
majority of mitochondrial ATP goes to support contractile function (Mcnulty et al., 2000; Weiss 
and Hiltbrand, 1985). Meanwhile, fat oxidation supports less efficient contraction than glucose 
respiration, so for the initial energy burst needed to get circulation re-started it may be the case 
that cardiac energy levels require supplementation from glucose (Johnston and Lewandowski, 
1991).  
These two statements are not necessarily contradictory despite appearances. FAO is dependent 
upon some glucose oxidation supplying carbon to the Krebs cycle through anaplerosis (Owen et 
al., 2002), so it makes sense that in a heart more dependent upon FAO high rates of glycolysis are 
critical to recovery. Furthermore, FAO inhibits glucose oxidation, but not glycolysis, via the Randle 
cycle (Randle et al., 1963), meaning more glucose metabolism will be anaerobic and able to satisfy 
the cytoplasmic ATP demand (Mcnulty et al., 2000). Also, despite FAO having been stated to 
account for the majority of ATP produced upon reperfusion (Lopaschuk et al., 1990; Myears et al., 
1987; Nellis et al., 1991), this does not mean that this is the state of affairs most beneficial to 
functional recovery and could be a pathological response. Promoting glucose oxidation upon 
reperfusion could well enhance recovery then, as has been demonstrated by Lopaschuk et al. 
(1990), without contradicting any of these statements at all. Figure 1.7 shows suggested figures 
for the breakdown of total ATP production in the “healthy” heart and upon reperfusion based 
upon these papers. 













Whether it is most beneficial to promote FAO or glucose oxidation following reperfusion is a 
matter of controversy. Etomoxir inhibition of CPT-1 (and therefore FAO) during reperfusion 
stimulates glucose oxidation, and this has been shown to increase the rate of functional recovery 
(Lopaschuk et al., 1990). However, it has also been shown that presence of fatty acids in the 
perfusion buffer is protective against ischaemia/reperfusion injury, with improved recovery of 
contractile function following ischaemia (Lou et al. 2014 A; King et al. 2001). More conclusive 
evidence is needed before this controversy can be resolved. 
 
 
1.4.2 Long Term Repercussions of Reperfusion Injury 
Sustaining too much damage during ischaemia and/or subsequent reperfusion can lead to cell 
death – controlled (apoptotic) or uncontrolled (necrotic). Release of cytochrome c and ROS during 
reperfusion injury activates the caspase pathways and lead to apoptosis, providing radical 
mediated damage to the tissue doesn’t first lead to tissue necrosis (Gottlieb, 2011; Piper and 
Ovize, 1998). A further mechanism of cell death can occur through the opening of the mtPTP, 
leading to exchange of mitochondrial pro-apoptotic factors with cytosolic water which causes 
swelling and lysis of the mitochondria (Halestrap, 1998). Following myocardial infarction, up to 1 














Figure 1.7: Graph Showing Suggested Figures for Percentage of Total ATP Production Accounted 
for by Each Source in a “Healthy” Heart and Immediately After Ischaemia/Reperfusion.  




regenerate. Fibroblasts mediate fibrosis of the necrotic region, and reactive fibrosis can even lead 
to further fibrosis in the borderline region where the cells could otherwise have eventually 
recovered to viability (Shinde and Frangogiannis, 2014; Talman and Ruskoaho, 2016). The result is 
a non-contractile, refractory area of the heart. 
Over longer periods an infarcted region may cause further complications. Even if the infarct size 
is small enough that overall cardiac function is not compromised and the heart can continue to 
supply the body with enough blood to survive, the excess strain upon the heart can lead to 
remodelling and heart failure (Dargie, 2005; Heusch and Gersh, 2018; Heusch et al., 2014). In the 
US those who have previously suffered a heart attack are 2.8 times more likely to be diagnosed 
with heart failure in future (Hugli et al., 2001). Heart failure is defined as the inability of the heart 
to pump sufficient blood to the tissues of the body (including the heart itself) to meet metabolic 
demands, and when a portion of myocardium is afunctional this means that the remaining viable 
myocardium must work harder to supply itself and the body with enough blood and oxygen. 
Working harder means that demand for oxygen increases, effecting uncoupling and alterations to 
metabolism (Murray et al., 2008). Infarct size correlates directly to the progression of heart failure 
(Stone et al., 2016), and therefore reducing I/R injury and damage will help to reduce the 
prospects of developing heart failure as well as immediate mortality.   
Chronic infarctions may also underlie arrhythmias as a further complication. Healthy cardiac tissue 
conducts the electrical impulses generated by the sino-atrial node (SAN) to maintain synchronised 
contractility, yet a region of fibrotic tissue is incapable of passing these signals along (Francis et 
al., 2016). Further electrophysiological remodelling may occur in the border zone to the infarct, 
including reduction of conduction components and intracellular calcium mishandling, which can 
trigger malignant arrhythmias. The scar itself can lead to tachycardia (Ripplinger et al., 2009), 
while the disordered conductive structure of the border zone can lead to areas of blocked or cyclic 











1.5 AIMS OF THE THESIS 
The overall aims of this thesis were to investigate substrate oxidation in the heart, and how this is 
influenced by ischaemia and reperfusion as well as other metabolic perturbations.  
In Chapter 3, the target was to develop a reliable model for determining the relative oxidation of 
glucose and fatty acids with respect to each other and other substrates in the Krebs cycle. A 
network model was generated to model the movement of 13C labelled carbons through the Krebs 
cycle when different proportions of [1,2-13C]acetyl-CoA enter the Krebs cycle. This model was 
developed to interpret the experimentally derived isotopologue distributions of key Krebs cycle 
intermediates and proxies in order to determine the proportion of glucose or FA oxidation in the 
experimental setup. In order to validate the model, the perfusion buffer for Langendorff perfused 
hearts was supplemented with a known percentage of U-13C labelled glucose in order to follow 
the progress of labelled carbons derived from these substrates through the Krebs cycle. Following 
the achievement of steady state, the hearts were snap frozen, and the isotopologue distribution 
of key Krebs cycle intermediates or proxies were measured using LC-MS/MS.  
Chapter 4 aimed to address the questions of whether dietary nitrate supplementation could 
protect against a future ischaemia/reperfusion insult, and whether FAO during and following 
ischaemia was beneficial or detrimental. Dietary supplementation with sodium nitrate has been 
shown to both protect the heart against hypoxia (Ashmore et al., 2014a), and enhance β-oxidation 
in a variety of tissues including the heart itself (Ashmore et al., 2014a, 2015; Roberts et al., 2015). 
This being the case, if FAO were beneficial to the ischaemic and reperfused heart then dietary 
nitrate supplementation might be expected to protect against ischaemia, an insult which has a 
strong hypoxic component. Hearts from rats fed either a sodium nitrate or sodium chloride (as a 
control) supplemented diet were perfused in the Langendorff mode either with or without 
intralipid, a triglyceride mixture, in the perfusion buffer. Following 32 minutes aerobic perfusion 
at 100 mmHg, 32 minutes low-flow ischaemia (0.32 ml/min/gww) and 32 minutes reperfusion at 
100 mmHg, functional recovery of the hearts from ischaemia was assessed. Respirometry was 
used to assess oxygen consumption in the reperfused LV immediately at the end of reperfusion to 
determine whether there had been a protective effect upon the electron transport chain. Tissue 
frozen at the same stage was subsequently analysed using LC-MS/MS for energetics, oxidative 
stress markers and metabolite levels.  
An interesting and surprising finding from Chapter 4 was that the ketone body β-hydroxybutyrate 
was synthesised in the ischaemic heart, in a process previously thought only to occur in the liver. 
Chapter 5 focussed on further characterising this ketogenesis and its impact upon the heart. LC-




MS was used to assess levels of β-hydroxybutyrate in both LV tissue and coronary effluent from 
Langendorff hearts pre-ischaemia, post-ischaemia and post-reperfusion. Oxygen consumption 
supported by the different ETC complexes and metabolic fluxes was measured alongside cardiac 
triglyceride uptake and the isotopologue distributions of β-hydroxybutyrate and Krebs cycle 
intermediates in order to assess whether ischaemic ketogenesis was a function of capacity for β-
oxidation exceeding mitochondrial demand. Inhibitors of both LDH and of HMG-CoA synthase, an 
enzyme involved in the ketogenic pathway, were employed in order to manipulate ketogenesis 
and determine whether ischaemic ketogenesis was detrimental or beneficial to the heart. 
Chapter 6 aimed at investigating cardiac substrate utilisation in a different paradigm of metabolic 
perturbation – the type-1 diabetic heart. As discussed above, the loss of metabolic flexibility in the 
heart has been associated with pathological consequences, and this chapter investigated whether 
altered flexibility impaired the capacity of the diabetic heart to respond to metabolic stress. Rats 
which had undergone either 90% pancreatectomy or a sham operation were administered 1 
mg/kg isoprenaline, a β-adrenergic agonist, daily over a period of 10 days from 5 weeks post-
operation, in order to determine how the type-1 diabetic myocardium coped with a metabolic 
stimulus. 10 weeks post-operation, and upon termination, fresh LV tissue was examined using 
high-resolution respirometry to assess function of the ETC and metabolic flux. LC-MS/MS was 
utilised to examine levels of energetic compounds in the tissue as well as markers of oxidative 
stress, while RNAseq gave an indication of left-ventricular gene expression. This chapter was 
undertaken as part of a larger concerted characterisation of the model at Gubra ApS, Horsholm, 
Denmark, which included measurements of cardiac function and morphology using 
echocardiography and histology by a team led by Louise Thisted, Dr. Nora Zois and Dr. Elisabeth 









2 GENERAL MATERIALS AND METHODS 
The methods outlined in this chapter are used throughout the thesis. For methods specific to Chapters 
3, 4, 5 and 6, see the relevant sections in each chapter. All animal work detailed in Chapters 3, 4 and 
5 was conducted in accordance with UK Home Office regulations under the Animals in Scientific 
Procedures Act. Protocols were performed by a personal licence holder under a project licence, and 
received prior approval from the University of Cambridge ethical review board. In Chapter 6, all animal 
work was carried out at Gubra ApS, Hørsholm, Denmark under the auspices of their ethical approval. 
Materials 
All reagents and chemicals were obtained from Sigma-Aldrich Ltd (UK or DK) unless otherwise stated. 
 
  




2.1 LANGENDORFF PERFUSION 
2.1.1. Concept of Langendorff Perfusion 
Retrograde (Langendorff) perfusion is a technique initially developed by Oskar Langendorff for 
investigation of the function of the isolated heart. The technique involves supplying the ex vivo heart 
with a blood substitute through the aorta (Bell et al., 2011; Herr et al., 2015; Lateef et al., 2015). While 
the aorta is generally the vessel through which blood is pumped from the heart to supply the rest of 
the body, in a live mammal the mean arterial blood pressure generated in systole causes the closure 
of the aortic valve during diastole. This, coupled with diastolic relaxation of the myocardium which 
was constricting the coronary arteries during systole, allows pressure-driven flow of oxygenated blood 
through the coronary arteries in order to supply the myocardium (Figure 2.1). The Langendorff 
preparation works on the principle that delivering a sufficient pressure of oxygenated fluid in reverse 
through the aorta will result in the same valve closure and thus provide a route of supply to the cardiac 
tissue through the coronary arteries (Figure 2.2). When the oxygen and metabolic substrate demands 
of the heart are met in this manner, contraction will occur provided that the correct external 
concentrations of electrolytes are provided, as the sino-atrial node (SAN) generates and paces action 
potentials in the heart independently of the central nervous system.   
 
 
Image from Patton and Thibodeau, (2013) 
 
Figure 2.1. Back-pressure generated by the elasticated aorta closes the aortic valve at the end of 
systole, diverting blood flow to supply the myocardium via the coronary arteries.  

















2.1.2. Experimental Protocol 
Preparation and mounting of the heart 
The hearts used for Langendorff perfusion in this thesis came from rats which were between 300 and 
350 g in bodyweight, and therefore had similar sized aortas which were wide enough to accommodate 
the cannula (4 mm in diameter). Rats were euthanised by rising CO2 levels and cervical dislocation, 
and, following removal from the chest cavity, the heart and thymus were swiftly transferred to a vessel 
of ice cold Krebs-Henseleit (KH) buffer (Appendix II). Excess fat and any attached lung tissue and 
thymus was removed to expose the aorta, which was cut below the aortic branch (Figure 2.4). Hearts 
were then mounted on the cannula via the aorta before undergoing retrograde perfusion at 38˚C (core 
body temperature for a rat (Lomax, 1966)) using KH buffer containing substrate combinations detailed 
Figure 2.2. Diversion of perfusate into the coronary arteries of a heart perfused in Langendorff 
mode  




in the methods section of the appropriate chapter. The buffer was continually gassed with 95% O2, 5% 
CO2 gas at pH 7.4, recirculated, and filtered using an in-line pre-filter with 0.8 and 0.45 µm filters to 
remove any detritus washed out of the heart. The pulmonary artery was incised to prevent build-up 
of pressure in the right ventricle. All hearts were perfused at a constant pressure of 100 mmHg for 
lengths of time detailed in the individual chapters’ methods sections, with the exception of during 
ischaemia when the hearts were perfused at a constant flow rate (again specified in the respective 












Figure 2.4. Preparation of the heart for perfusion in Langendorff mode. (A) The aortic branch is 
































Measurement of Cardiac Function 
Measurements of cardiac contractile function were made using a fluid filled PVC balloon inserted into 
the left ventricle (Liao et al., 2012; Transonic, 2018). The balloon was initially inflated to produce a left 
ventricular end-diastolic pressure (LVEDP) of ~4 mmHg, and was attached via a catheter to a pressure 
transducer (ADInstruments) which was regularly calibrated. The output from the pressure transducer 
was interpreted and recorded using a PowerLab and LabChart software (ADinstruments). Rather than 
constantly adjusting the LVEDP throughout the protocol as would have interfered with the measured 
results, the measured LVEDP was allowed to decrease naturally while the pre-ischaemic perfusion 
period progressed and the heart relaxed, therefore presenting a lightly loaded perfused heart model. 
The pressure difference between the forces exerted by the heart on the balloon during systole and 
during diastole was calculated to give the left ventricular developed pressure (LVDP), and a measure 
of the force of contraction. The number of systole/diastole cycles per minute was recorded to give 
heart rate, in beats per minute (bpm), and through multiplication of LVDP and heart rate a 
measurement of RPP, or rate-pressure product, was obtained. In ischaemia/reperfusion experiments, 










Figure 2.5. A sample trace of the measurements obtained during ischaemia and reperfusion. (A) 
Pressure exerted on the balloon by the left ventricle (mmHg). (B) Heart rate (Beats per minute, 
BPM). (C) Left Ventricular Developed Pressure (mmHg). (D) Left Ventricular End-Diastolic Pressure 

























0.3 ml.min-1gww-1 Low Flow Ischaemia 100 mmHg 100 mmHg 




2.1.3. Ischaemia Reperfusion Protocols 
During this thesis, subjection of perfused hearts to ischaemia was employed for two purposes: 
assessment of metabolism in cardiac tissue during ischaemia; and assessment of the extent to which 
the heart recovered functionally from ischaemia following reperfusion. In all cases, low-flow ischaemia 
was implemented by using a three-way tap to divert the flow of oxygenated buffer to the heart 
through a low-flow peristaltic pump (Gilson Minipuls 3). Two separate ischaemic flow rates were 
employed during this thesis:  
1) 30 min at 0.3 ml.gww-1min-1, which test runs had shown to yield a functional recovery of 65-70% 
pre-ischaemic LVDP and RPP following reperfusion, was used to assess functional recovery from 
ischaemia/reperfusion when different conditions were imposed. 
2) 20 min at 0.56 ml.gww-1min-1, which resulted in 100% functional recovery following 20 min 
ischaemia and was used to assess metabolism during ischaemia and reperfusion while attempting to 
minimise the effect of differences in cardiac work-rate and structural damage caused by I/R upon the 
results. 
Reperfusion of the hearts was achieved by returning the three-way tap to the pre-ischaemic position, 
restoring 100mmHg constant pressure perfusion for the desired period (specified in the individual 
results chapter methods sections). 
Heart temperature was monitored by thermometer and maintained at 38°C throughout the 
ischaemia/reperfusion protocol.  




2.1.4. The Langendorff Apparatus Used in this Thesis 
The Langendorff apparatus used in this thesis (Figure 2.3) was designed, built and optimised by myself 
in accordance with the following specifications. Custom made glassware was obtained from 
Cambridge Glass Blowing, including a 1-litre reservoir for the perfusion buffer, from which Krebs-
Henseleit (KH) buffer was pumped by a peristaltic pump (Watson Marlow 323S) to the oxygenation 
lung. Here it was gassed to saturation with 95% O2, 5% CO2 carbogen gas. The oxygenated buffer 
descended under the control of gravity to a stainless steel cannula (4 mm diameter) via a bubble trap 
designed to prevent any bubbles reaching and causing an embolism in the coronary arteries, 
producing a pressure of 100 mmHg at the end of the cannula. The heart itself was mounted upon this 
cannula. Cardiac temperature was measured using a type T thermocouple probe (Thermo Fisher), and 
maintained at a constant temperature of 38°C by a water-jacketed heart chamber. Flow into the 
bubble trap and cannula could be limited using a flow rate adjustor during the process of mounting 
the heart. The heart chamber also served to collect the coronary effluent which has passed through 
the heart, channelling it back to the reservoir or for sampling. 
 
 






Figure 2.3. Schematic demonstrating the Langendorff rig used in this thesis. Krebs-Henseleit 
buffer from the reservoir was pumped by a peristaltic pump to the oxygenation lung, where it was 
continually gassed with 95% O2/5% CO2 carboxygen gas. A perfusion pressure of 100 mmHg to the 
heart was maintained by force of gravity from the level of buffer in the oxygenation lung.  
 





Figure 2.4. Photograph of the Langendorff perfusion apparatus setup used throughout this 
thesis. 




2.2 HIGH RESOLUTION RESPIROMETRY 
2.2.1 Concept of Respirometry 
Mitochondrial respirometry measures the rate of oxygen consumption at the mitochondrial electron 
transport chain. It may be used to obtain an in depth analysis not only of broader oxidative capacity, 
but even of the functionality of individual ETC constituents. 
Cellular consumption of oxygen, which as discussed in chapter one is the final electron acceptor of the 
ETC, is directly linked to the rate of mitochondrial metabolism. Despite other enzymes such as 
xanthine oxidase having the capacity to consume some oxygen, the predominant source of cellular 
oxygen consumption is at the ETC; unlike other metabolic indicators such as NADH and ATP which are 
consumed and regenerated in multiple cellular processes. Measurement of cellular oxygen 
consumption while controlling the metabolic conditions can therefore be used to accurately and 
sensitively make a measurement of electron flux through various components of the ETC. 
 
2.2.2 Oxygen Sensing Apparatus 
The respirometry conducted in this thesis employed the Oxygraph 2K (Oroboros Instruments, Austria), 
a highly sensitive set of oxygen detecting polarographic electrodes. The Oxygraph comprises two 
sealed 2 ml chambers, which are separated from the oxygen electrodes by a selectively permeable 
membrane. Behind the membranes, the electrodes themselves are in a 10 mM KCl electrolyte 
solution. At the gold cathode, oxygen reacts with water, while at the anode silver reacts with the 
chloride ions in the electrolyte solution as follows: 
O2 + 2H2O + 4e- → 4OH- 
Reaction 2.1. At the cathode. 
4Ag + 4Cl- → 4AgCl + 4e- 
Reaction 2.2. At the anode    
The current passing between the electrodes is therefore directly limited by oxygen availability. The 
rate at which biological samples placed in the chamber consume oxygen can therefore be measured 
via the accompanying reduction in current. 






Oxygen consumption and current passed through the electrodes vary in a directly linear fashion 
through the experimental range, so a two point calibration was used to ensure that variations in 
conductivity over time did not affect the experimental results. The chamber was calibrated by 
equilibration firstly using air saturation as a known value (194.20 µM in MiR05 at 37˚C), and then by 
adding an oxygen scavenger, sodium dithionate, to the chamber to remove all oxygen from solution 
as the second calibration point. 
The chambers were constantly maintained at 37°C by a copper heating block controlled by a feedback 
loop. Constant mixing ensured that substrate and oxygen concentration was maintained throughout 
the chamber. Periodic injections of pure oxygen into an introduced air gap were used to maintain the 
oxygen concentration of the buffer between 200µM and 400µM. The rate of oxygen consumption was 
calculated and acquired using DatLab data acquisition software (Oroboros Instruments, Austria). 
Figure 2.5. An Oxygraph in use measuring mitochondrial function in Hørsholm, Denmark during 
data collection for chapter 6 of this thesis.  






2.2.3. Preparation of the Biological Samples for Respirometry 
It is possible to selectively permeabilise the plasma membrane, allowing access for substrates and 
inhibitors while maintaining overall tissue structure, and that is the method which has been employed 
in this thesis. The permeabilising agents saponin and digitonin bind cholesterol, which is present to a 
much higher concentration in the cellular membrane than the mitochondrial membranes, forming 
pores which allow passage of mitochondrial substrates and inhibitors into the cell while leaving the 
mitochondrial membranes intact (Kuznetsov et al., 2008). Washing the permeabilised tissue 
preparation in this state allows removal of all endogenous substrates and ADP, meaning that 
measurements could be made in the confidence that leftover metabolites from before the preparation 
were not affecting the results. 
Figure 2.6. Configuration of the Oxygraph chamber 






Method for the Preparation of Permeabilised Cardiac Fibres 
Sections of left ventricle were permeabilised for respirometry using previously described methods. 
Placed immediately in ice cold BIOPS solution (Appendix II), the tissue was mechanically separated 
under a microscope using dissection forceps, so that individual myofibres of cardiac tissue were visible 
and medium would be able to move between them. The fibres were then incubated for 20 min, rocking 
on ice in the presence of 50 µg/µl saponin. The saponin was then washed out with 3 x 5 min washes 
with ice cold MiR05 (Appendix II), after which fibres were blotted dry on filter paper and a known 




Figure 2.7. Schematic of the selective permeabilisation of the plasma but not mitochondrial 
membranes using saponin. Diagram from Kuznetsov et al. (2008) 
 




2.2.4 Substrate Uncoupler Inhibitor Titration (SUIT) 
In the permeabilised preparation, a substrate-uncoupler-inhibitor titration (SUIT) was employed to 
address the biological questions. Various contributing factors to mitochondrial electron flux rate, such 
as β-oxidation and the activity of various constituents of the ETC can be assessed through serial 
administration of saturating concentrations of compounds. In this thesis, the SUIT detailed in Table 1 
was employed, with injections of substrates and inhibitors in the following order: 
Table 1. SUIT protocol used throughout this thesis 
STATE PATHWAY ADDITION CONCENTRATION FIGURE 
Leak  Malate 2 mM 2.8 
Leak β-oxidation Octanoyl- 
Carnitine 
0.2 mM 2.9 
Oxphos β-oxidation ADP 5 mM 2.10 
Oxphos β-oxidation + Pyruvate Pyruvate 20 mM 2.11 
Oxphos Complex I Glutamate 10 mM  
Oxphos Outer membrane 
integrity test 
Cytochrome C 10 mM 2.12 
Oxphos Complex I + II Succinate 10 mM 2.13 
Oxphos Complex II Rotenone 0.5 mM 2.14 
 
 
2.2.5 Explanation of the States and Mechanisms Investigated  
Leak State Respiration 
In the absence of ADP, ATP synthase cannot function to allow protons to flow from the inter-
membrane space into the matrix. This means that any flux of protons (and therefore electron transit 
through the ETC to restore ΔµH+ and the associated oxygen consumption) corresponds to leakage of 
protons in other manners, either slippage through proteins, membrane uncoupling or the leakiness of 








Priming the Krebs Cycle with Malate 
The initial addition of substrate for the experiments was malate, which primed the Krebs cycle for 
subsequent additions. The conversion of malate to oxaloacetate produces some NADH, which 
contributes to ETC flux through complex I (Gnaiger, 2008). However, the main advantage of adding it 
early in the protocol is because the subsequent production of oxaloacetate allows entry of acetyl-CoA 
to the TCA cycle through citrate synthase mediated combination of the two molecules to form citrate. 




β-oxidation Limited ETC Function 
Short to medium chain acyl carnitines, such as octanoyl carnitine which is used in this thesis, bypass 
CPT-I transport into the mitochondria through CACT and therefore allow assessment of the rate of 
function of the β-oxidation pathway directly. Both the cyclic oxidation of fatty acids and the 
combination of the resulting acetyl-CoA with malate to enter the TCA cycle result in the supply of 
electrons to the ETC, and so the rate limiting factor for oxygen consumption in the presence of 
octanoyl carnitine is β-oxidation capacity (Gnaiger, 2008).  
Figure 2.8. Leak State Respiration of Malate. Activated pathways are represented in green. In the absence 
of ADP, protons re-enter the mitochondrial matrix by leaking through the membranous proteins and the 
inner mitochondrial membrane itself, which allows O2 to be consumed at complex IV at a low rate. 







Oxphos Limited Respiration  
Oxidative phosphorylation was activated through the addition of saturating concentrations of ADP 
(Gnaiger, 2008). This potentiated flux through ATP synthase, allowing a much higher rate of ETC flux 
and therefore oxygen consumption to occur. Comparison of fluxes after and before addition of ADP 
allows an assessment of how coupled ΔµH+ is to ATP synthesis, with the ratio of post to pre-ADP 
addition therefore yielding an approximation of the respiratory acceptor control ratio (RCR), an 
indicator of mitochondrial coupling. 
Once ADP is present, the addition of saturating concentrations of various substrates and inhibitors can 
be used to address the maximal contribution of different pathways and ETC components to overall 
ETC flux. 
 
Figure 2.9. Leak State β-oxidation Supported Oxygen Consumption. Activated pathways are represented 
in green. Oxaloacetate formed from the dehydrogenation of malate allows acetyl-CoA produced by β- 
oxidation to enter the Krebs cycle. In the absence of ADP, protons continue to re-enter the mitochondrial 
matrix by leaking through the membranous proteins and the inner mitochondrial membrane itself, allowing 
a low rate of O2 consumption at complex IV 







Pyruvate, which enters the mitochondria via the mitochondrial pyruvate carrier, is converted to acetyl-
CoA by pyruvate dehydrogenase for entry into the Krebs cycle. Addition of pyruvate therefore assesses 
the maximal contribution of pyruvate to complex I via the Krebs cycle (succinate is cell permeable and 
so the respiratory rate supported by complex II cannot be assessed without saturating 
concentrations). Further, in combination with previous assessment of β-oxidation this allows 
determination of how much of the total Krebs cycle oxidation capacity β-oxidation is capable of 
accounting for through division of the β-oxidation supported oxphos respiration rate by the β-
oxidation + pyruvate supported oxphos respiration rate (Horscroft et al., 2015). 
 
Figure 2.10. β-oxidation Supported Oxphos. Activated pathways are represented in green. ADP allows 
the activation of ATP-synthase, and a higher rate of ETC activation and oxygen consumption at complex IV 






Complex I Linked Respiration 
In tandem with the previous addition of malate, addition of glutamate saturates complex I to achieve 
a measure of maximal complex I activity. Glutamate enters the mitochondria via the 
glutamate/aspartate antiporter and is rapidly converted to aspartate and α-ketoglutarate through 
reaction with oxaloacetate, thereby driving further NADH-producing conversion of malate to 
oxaloacetate. α-ketoglutarate is then further dehydrogenated in the Krebs cycle to produce more 
NADH. All of the NADH produced transfers its electrons to the ETC via complex I, saturating it and 
providing a measurement of total complex I activity. 
 
Validation of the Condition of the Mitochondrial Membranes 
To be assured that the mitochondrial membranes have not been damaged during the permeabilisation 
protocol, two tests were performed. The first, a test of inner membrane intactness, was performed 
intrinsically with the addition of ADP; if the inner mitochondrial membrane had been disrupted, the 
proton gradient would have dissipated with resultant loss of mitochondrial coupling. Therefore, any 
observation of an ADP response demonstrates that the mitochondrial inner membrane is intact. 
Figure 2.11. β-oxidation and Pyruvate Supported Oxphos. Activated pathways are represented in green. 
Pyruvate is also metabolised to acetyl-CoA, meaning the concentration of acetyl-CoA available to the Krebs 
cycle is no longer limited by β-oxidation. 




The second test, of outer membrane integrity, was performed through the addition of reduced 
cytochrome c. If the outer membrane were damaged, then some cytochrome c, an electron carrier of 
the ETC which operates in the inter-membrane space, would have been lost. In this scenario, addition 
of cytochrome c would result in a dramatic increase in oxygen consumption, and so lack of response 





Addition of succinate in excess saturated the activity of complex II. Succinate is converted to fumarate 
by complex II (succinate dehydrogenase) reducing FAD+, at which point the electrons this reaction 
yields enter the Krebs cycle via FADH2. Oxygen consumption in the presence of malate, glutamate and 
succinate in tandem therefore reflects the maximal capacity for the ETC to support oxphos, because 
complex I and complex II are each individually capable of enabling more electron flux into the ETC than 
complex III will allow when both are maximally supplied with electrons (Gnaiger, 2008). 
 
Figure 2.12. Cytochrome c Test of Membrane Integrity. Activated pathways and additions are represented 
in green. If there has been outer membrane rupture and loss of cytochrome c, addition of cytochrome c will 
enhance electron transfer and rate of oxygen consumption. 





Complex II Linked Respiration 
Since total oxphos represents a lower rate than the maximal complex I and maximal complex II 
respiration added together, subtracting complex I activity from complex I + II activity does not give  
the rate of saturated complex II activity. Instead, inhibition of complex I can be used to determine the 
maximal rate of complex II linked respiration. This was achieved using the complex I inhibitor 
rotenone, leaving succinate as the sole contributor of electrons to the ETC via complex II (Gnaiger, 
2008). 
Figure 2.13. Total Oxphos. Activated pathways and additions are represented in green. Succinate activates 
complex I in addition to the previously activated complex I, resulting in full input of electrons to the ETC. 






Figure 2.14. Complex II Function. Activated pathways and additions are represented in green. Inhibition of 
complex I with rotenone results in complex II becoming solely responsible for electron contribution to the 
ETC. 




2.3 LIQUID CHROMATOGRAPHY COUPLED MASS SPECTROMETRY 
2.3.1 Concept of Mass Spectrometry 
Mass spectrometry is the effective discrimination of compounds based upon their resultant 
mass/charge ratio (m/z) following ionisation. It can be performed in analytical chemistry on both single 
purified compounds and complex mixtures of compounds, such as that represented by a biological 
sample, and allows the high throughput detection of the concentrations of many metabolites present 
in a tissue or buffer sample (Heather et al., 2013).  
2.3.2 Tissue Extraction for Assessment Using Mass Spectrometry 
Metabolites were extracted from heart samples using a methanol/chloroform/water extraction 
method (Le Belle et al., 2002). Frozen tissues were added to 600 μL methanol/chloroform (2:1; v/v), 
and the samples were homogenized with a Tissuelyser (Qiagen, UK) for 5 min at a frequency of 20/s 
before 15 minutes of sonication. Water (200 μL) and chloroform (200 μL) were then added to the 
samples prior to centrifugation at 17000 g for 7 min. The resulting aqueous and organic phases were 
collected, and the extraction procedure was repeated for a second time on the protein pellets. 
Aqueous phases were dried down using an evacuated centrifuge, while the organic phase was dried 
by evaporation. Dried samples were stored at −20°C until further analysis. 
2.3.3 Separation of Compounds through Liquid Chromatography 
In order to gain extra resolution, compounds can be separated by factors such as solubility, size, 
charge and shape through liquid chromatography (LC). This has the advantage of both separating 
compounds out when they arrive at the detector to enable greater sensitivity of detection, and also 
allowing more accurate identification of compounds with different retention times (especially those 
with the same m/z, termed isobaric species). Liquid chromatography is conducted at high pressure by 
injecting a small volume of tissue extract in solution into a mobile phase, which carries the sample 
through a solid phase, or column, to separate compounds by their affinity for the solid phase. The 
mobile phase composition may also be altered through the run time for each sample, which varies 
both the solubility of compounds in the mobile phase and the pressure they experience across the 
column to further separate compounds arriving at the detector. 
In this thesis, two main liquid chromatography methods have been employed. The first, using a BEH 
amide column, has been developed to separate highly polar compounds and works best for separation 
of compounds including ATP and malonyl-CoA. The BEH amide column separates compounds using 
hydrophilic interaction chromatography (HILIC) to differentially retain polar compounds within the 




column, allowing separation of these compounds and greater detection capacity. The second method 
implements a C18pfp column to separate compounds. The C18 chain interacts with hydrophobic 
components of molecules to separate compounds using Van der Wall’s forces, while the 
pentafluorophenyl (pfp) component of the column is used for the separation of aromatic compounds 
and those with shape constraints. 
BEH Amide LC Methodology 
Aqueous extract fractions were reconstituted in an acetonitrile: 10 mM ammonium carbonate 
solution (7:3 v/v, 100 μl) containing a 10 μM mixture of internal standards (Appendix B). The column 
used was a 1.7 μm BEH amide column (150x2.1 mm), coupled to a Vanquish UHPLC+ series (Thermo 
Scientific, UK) LC system and a TSQ Quantiva Triple Quadrupole Mass Spectrometer (Thermo 
Scientific). The mobile phase was pumped at 600 μlmin-1 with mobile phase A 0.1% ammonium 
carbonate solution, and mobile phase B acetonitrile. Mobile phase A was held at 20% for 1.5 min, 
linearly increased to 60% over the next 2.5 min, held at 60% for 1 min, before being decreased back 
to the initial conditions (20% mobile phase A) in the next 0.1 min. The total run time was 6 min. 
Nitrogen at 48 mTorr, 420°C was used as a drying gas for solvent evaporation and the UPLC column 
was conditioned at 30°C.  
C18pfp LC Methodology 
Following reconstitution in a 10 mM ammonium acetate solution/internal standard mixture (200 µL; 
phenylalanine d5, Valine d8, leucine d10), samples were run for 6 min on either a Thermo Vanquish 
(coupled to a Thermo Quantiva triple quadrupole mass spectrometer) or a Thermo Dionex Ultimate 
3000 (coupled to a Thermo Elite orbitrap mass spectrometer) LC system using an ACE Excel-2 C18- 
PFP 5 μm column (100 A, 150x2.1 mm, 30°C). Mobile phase A was 0.1% formic acid, while mobile 
phase B was acetonitrile plus 0.1% formic acid. The LC gradient was as follows: 0% B for 1.6 min 
followed by a linear gradient up to 30% B for 2.4 min. There was a further linear increase to 90% B for 
30 s, following which B was held at 90% for 30 s before re-equilibration for 1.5 min. Drying gas was as 
used in the BEH amide method. 
 
2.3.4 Mass Spectrometry 
Mass spectrometry effectively utilises three stages to separate and quantify molecules by mass to 
charge. The first is ionisation of the compounds, the second is separation of the resultant ions by m/z 
ratio and other methods, and the third is detection of the separated ions. In this thesis, two different 




types of mass spectrometer have been utilised: a triple quadrupole mass spectrometer (Thermo 
Quantiva), and an orbitrap (Thermo Orbitrap Elite). 
Triple Quadrupole Mass Spectrometry (MS/MS) 
In this thesis, triple quadrupole mass spectrometry was used to assess levels of a known collection of 
compounds involved in metabolism, energy transduction and the response to oxidative stress. These 
compounds had been previously characterised, and so rather than scanning across the whole range 
of ions, greater discrimination was achieved by scanning known SRM transitions for the parent and 
fragmented ions. A table of the SRM values acquired for each of the methods used in this thesis can 
be found in Appendix II.  
An electrospray ionisation source was utilised, operated simultaneously in both negative and positive 
ionisation modes. The Thermo Quantiva uses an Ion Max NG ion source to spray electrons and convert 
the compounds into ions by either knocking off or adding on an electron. It is capable of rapidly 
switching between these two ionisation modes, allowing compounds which ionise in both manners to 
be detected in a single run. Varying the voltage rapidly switches the speed with which electrons collide 
with the sample molecules, determining whether an electron is knocked off or added on to induce 
positive or negative charged ionisation. In this instance, electrospray voltages of 3.5 kV and -2.5 kV 
were used to induce positive and negative ionisation, respectively. 
Triple quadrupole mass spectrometers make use of two quadrupoles and an intervening collision cell 
(the second “quadrupole”) to separate and aid in the identification of ions. Quadrupoles work on the 
principle of having two sets of interspaced charged cylinders (the poles), which alternate in charge. 
Depending upon the m/z ratio of the ion passing through, the alternating charge impedes their 
passage to differing extents, achieving separation of the ions. The collision cell promotes further 
fragmentation of the ions, allowing compounds to be identified by their fragmentation pattern. 
Finally, the ions arrive at a detector, an electron multiplier which measures analyte concentration as 

















Orbitrap Mass Spectrometry 
The Thermo Orbitrap Elite is an orbitrap based mass spectrometer which produces high resolution 
mass spectrometry (capable of discriminating ions with a few ppms m/z difference). This makes it 
more suited to open-profiling analysis where the target compounds to be measured are unknown, as 
well as measurement of compounds which do not easily fragment, as it does not need to be set to 
scan only specific mass ranges. 
Instead of the quadrupoles, the Elite separates ions using an orbitrap, a charged spindle which 
differentially traps ions due to their m/z specific flight patterns. This achieves greater separation of 
ions by m/z ratio, if slightly lower chromatographic resolution.  
In this thesis, the Thermo Orbitrap Elite was utilised for the measurement of β-hydroxybutyrate, which 
does not fragment easily, and lactate, as well as for the measurement of triolein levels in the coronary 
effluent and perfusion buffer as described in Chapter 5. Briefly, for the measurement of β-
hydroxybutyrate and lactate, run parameters were as follows: Heater temp 420˚C, sheath gas flow 
rate 60 units, Aux gas flow rate 20 units, Sweep gas flow rate 5 units. The spray voltage was -2.5, 
capillary temp 380˚C and S-lens RF level 60%. 
 
Figure 2.15. Configuration of a Triple Quadrupole Mass Spectrometer.  













2.3.5 Analysis of Data 
Peaks obtained using the above described LC-MS and LC-MS/MS methods were detected and analysed 
using Thermo Xcalibur software, and normalised to both internal standard values and the wet weight 
of tissue. 
  
Figure 2.16. An Orbitrap Ion Trap. Upon entry, the molecular ions establish an orbital pattern 
around the spindle specific to their individual m/z ratios, becoming differentially separated by 
mass.  




2.4 STATISTICAL ANALYSIS 
Results are expressed throughout as the mean ± the standard error of the mean (SEM). Data was 
visualised in Excel before either Student’s T-test or 2-way analysis of variance (ANOVA) was used to 
determine statistical significance alongside any appropriate post-hoc test as detailed in the methods 





A Model for Determining Mitochondrial Substrate 
Utilisation using 13C-labelled Metabolites 
 
  




ABSTRACT     
As a sequence of enzymatic reactions which represent a major source of reducing potential for 
oxidative phosphorylation, the Krebs cycle is a focal point of oxidative metabolism. The relative 
oxidation rates of different substrates via the Krebs cycle varies both physiologically and 
pathologically, and it therefore constitutes an important area for investigation. Use of 13C labelled 
substrates has become a key tool for studying this - although the challenge of interpreting the data 
arising from such experiments has to date often been underestimated. Here, a network model is 
presented for the prediction of Krebs cycle intermediate isotopologue distributions yielded by any 
given proportion of 13C labelled acetyl-CoA entering the Krebs cycle, which may be used in conjunction 
with mass spectrometry to determine the relative contribution of the labelled substrate to the Krebs 
cycle.  The model was validated ex vivo using isotopic distributions measured from isolated hearts in 
which the labelled fraction of the total glucose content in the perfusion buffer had been varied by 
known amounts. Consistent prediction of the fraction of acetyl-CoA which was labelled was 
demonstrated across the whole range of possible fractions. The model was further employed to 
determine the relative contributions of glucose and triglyceride production of acetyl-CoA for oxidation 
in the Krebs cycle in an experiment in which both were present in the perfusion buffer (11 mM 
Glucose, 0.4 mM equivalent intralipid triglyceride mixture). Metabolism of glucose and triglyceride in 
the perfusion buffer were determined to contribute 58 ± 3.6% and 35.6 ± 0.8% of acetyl-CoA oxidised 
in the Krebs cycle, respectively. These results demonstrate the accuracy of a functional model of Krebs 
cycle metabolism and can lead to greater scientific value being derived from 13C substrate labelling 
experiments in the future. 
 
  





Stable isotope carbon labelling has proven to be an invaluable tool for studying metabolic fluxes. An 
important use of 13C labelled metabolites has been to investigate the proportional contribution of 
different substrates to the Krebs cycle in varying conditions and tissues, particularly in the heart which 
can metabolise a range of substrates (Aubert et al., 2016; Liu et al., 2016; Lloyd et al., 2004; Lloyd et 
al., 2003). However, interpreting the isotopic distribution of Krebs cycle intermediates arising in such 
studies is far from trivial, and over-simplified attempts to analyse labelling data have led to incorrectly 
analysed data in several previous publications.  
3.1.1 Current Methods of Analysing Labelling in the Krebs Cycle 
For many years Nuclear Magnetic Resonance (NMR) spectroscopy studies formed the basis of work 
tracking labelled carbons through the Krebs cycle. NMR can detect not only the labelled state of a 
given carbon but also its chemical environment, which has enabled studies to determine which carbon 
on the molecule is labelled (Lopaschuk, 1997). However, the sensitivity of detection with NMR 
remained an issue, with many metabolites including most of the Krebs cycle intermediates proving 
undetectable, and this led to the measurement of proxies which were assumed to be in chemical 
equilibrium (Burgess et al., 2001). Furthermore, NMR is based upon detection of individual carbons 
and their environments rather than the entire molecule; this means that the sensitivity of detection 
for two different carbons in a molecule could be different and that therefore it could be slower to 
detect incorporation of 13C in a particular location than in others (Lopaschuk, 1997). 
Mass spectrometry is an increasingly utilised approach to the measurement of levels of Krebs cycle 
intermediates and provides much more sensitivity, albeit without the insight into which carbon has 
been labelled (Katzs et al., 1993; Yang et al., 2008). Separating individual metabolites through 
chromatography allows the mass spectrometer to offer an accurate measurement of the atomic mass 
of individual Krebs cycle intermediates. The proportion of each of these which are 1-6 units heavier 
due to 13C labelling is then directly detectable, but a number of studies have misinterpreted this data 
and obtained an incorrect rate of labelling through neglecting to consider which carbon it is which has 
become labelled.   
3.1.2 Movement of Carbon labelling in the Krebs Cycle: Considerations for an 
Accurate Model 
13C originating from metabolism of U13C labelled fatty acids and carbohydrates primarily enters the 
Krebs cycle in identical units of two carbons as [1,2-13C2]acetyl-CoA. However, the stereochemistry 




and cyclic nature of the intermediates leads to a complex distribution of different isotopomers 
(molecules with equivalent numbers of labelled and unlabelled carbon atoms, but differing in their 
positions) and isotopologues (molecules with different numbers of labelled and unlabelled carbons) 
being produced at equilibrium. This means that incorporation of 2+ amu acetyl-CoA (labelled with two 
13C atoms) into the Krebs cycle, which leads to an m/z + 2 isotopologue of citrate initially, does not 
lead in a straightforward manner to the production of 2+ amu succinate, malate and other Krebs cycle 
intermediates when the tissue is analysed. It is therefore not sufficient to say, for example, that all 
isotopomers of citrate with 1+ amu result from a metabolic substrate which has been labelled to yield 
acetyl-CoA with 1+ amu, and that all citrate with 2+ amu isotopomers stem from acetyl-CoA with 2+ 
amu, as the full range of citrate isotopologues with 1-6 + amu can result from an input of acetyl-CoA 
with 2+ amu. 
The cyclic nature of the Krebs cycle (Krebs et al., 1938) leads to amplification of labelling at equilibrium. 
While the greatest mass increase an intermediate could gain from one turn of the cycle with [1,2-13C2] 
acetyl-CoA would be 2+ amu, metabolites recirculate continuously; so if a fraction of the oxaloacetate 
pool has been labelled 2+ in the first turn of the cycle this will result in 2+ and 4+ labelled citrate when 
combined with unlabelled and [1,2-13C2]acetyl-CoA respectively. Over a number of cycles towards 
steady state, this can increase carbon labelling in the Krebs cycle, complicating the situation much 
further than if entry of [1,2-13C2]acetyl-CoA to the Krebs cycle led only to the accumulation of 2+ amu 
citrate.   
Carbon loss also occurs during the cycle, with some carbons removed as CO2 with each turn 
indiscriminately of their atomic mass (Krebs et al., 1938). Following scrambling of label between the 
1,2 and 3,4 positions when fumarate is hydrated to malate (Figure 3.1), and further migration of 13C 
labelled carbons between positions when acetyl-CoA is complexed with a labelled oxaloacetate 
molecule by citrate synthase, each turn some 13C carbons arrive in positions where they are lost as 
13CO2. The outcome of this is that there is single 13C loss from labelled intermediates. The mass shift 
of each Krebs cycle intermediate when there is [1,2-13C2]acetyl-CoA input to the Krebs cycle is 
therefore not exclusively in multiples of 2+ amu gains, with 1+, 3+ or 5+ amu (depending upon the size 
of the Krebs cycle intermediate) isotopologues also generated. 
  





Figure 3.1: Movement of labelled carbons during one turn of the Krebs cycle. Black represents a 
13C labelled carbon, and red represents an unlabelled one. Labelled citrate with +2 amu, formed 
from oxaloacetate and labelled acetyl-CoA with +2 amu, is equally likely to produce one of two 
different isotopologues of oxaloacetate with +2 amu. 




This is made possible through generation and loss of stereochemical centres during the Krebs cycle. 
During the hydration of fumarate, which has no stereochemical centre, to malate, which does, there 
is an equally likely probability of the hydroxyl group being added to either carbon 2 or carbon 3 of 
fumarate. This controls whether carbon 1 or carbon 4 becomes the alpha carbon of oxaloacetate 
which is fated to be removed in the next turn of the cycle during the conversion of isocitrate to α-
ketoglutarate.   
The distribution of Krebs cycle isotopologues which results from administering 13C labelled substrates 
is therefore complex. To address this issue, this chapter presents a mathematical model capable of 
mapping 13C accumulation within the cycle to steady state, and calculating the relative oxidation of 
different metabolites in a perfused heart model. 
 
  




3.2 MATERIALS AND METHODS 
Materials 
All reagents and chemicals were obtained from Sigma-Aldrich Ltd (UK) unless otherwise stated. 
3.2.1 Generation of the Model 
Initial Conditions 
The initial proportion of 13C labelled Krebs cycle intermediates before the commencement of the 
labelling study was taken to be 0, and the proportion of entirely unlabelled intermediates 1. The 
proportion of the acetyl-CoA input which was [1,2-13C2]acetyl-CoA was designated α. 
Mapping the Relationships of Krebs Cycle Isotopomers 
The initial iterations of the Krebs cycle were worked through until every isotopomer possible for each 
intermediate had been introduced, and all were assigned a tag (C1,C2,… for citrate; A1, A2,… for α-
ketoglutarate etc.). Four metabolites were crucial to the modelling model – the six-carbon 
intermediate citrate; the 5-carbon intermediate α-ketoglutarate; the non-stereochemical 4-carbon 
succinate, and the stereochemical 4-carbon malate. The isotopologue or isotopomer distributions of 
each of the other intermediates were identical to one of these ‘crucial’ metabolites, and therefore did 
not need to be incorporated into the model for calculating enrichments.  
The relationships of each isotopomer at time T to the isotopomers of the preceding crucial metabolite 
in the cycle at time T-1 were drawn up as a set of differential equations. For example, if 1+ malate 
labelled on the alpha-carbon is designated M1, M1(T)= 0.5 S6 (T-1),  where S6 corresponds to the 1+ 
succinate isotopomer labelled on the carbon at the end of the chain. The fate of the 50% of S6 which 
is not converted to M1 is to become 1+ malate labelled at the carbon on the opposite end of the chain 
to the α- carbon, which we can designate M2 to get the equation M2(T)= 0.5 S6 (T-1) and so on. 
Next, a network model was generated with the programming assistance of Demetris Demetriou. This 
was done by multiplying a 1 by 78 vector comprising the 78 isotopomers of citrate, α-ketoglutarate, 
succinate and malate at time T with a 78 by 78 network matrix comprising the relationships of those 
isotopomers to each other.  
Experimentally obtained data could then be fitted to the model by running iterations to determine at 
which value of α the discrepancy between the predicted and experimental isotopic distributions was 
smallest.  




3.2.2 Validation of the Model in the Isolated Rat Heart 
Perfusion Protocols 
Male Wistar rats (300-350 g) were obtained from a commercial breeder (Charles River, UK). All 
procedures involving live animals were carried out by a licence holder in accordance with UK Home 
Office regulations, and underwent review by the University of Cambridge Animal Welfare and Ethical 
Review Committee. 
 
Hearts were excised and perfused in the Langendorff mode as described in Chapter 2. The perfusion 
medium was 250 mL of recirculated KH buffer with the basic composition 118 mM NaCl, 4.7 mM KCl, 
1.2 mM MgSO4, 1.3 mM CaCl2, 0.5mM EDTA, 25 mM NaHCO3 and 1.2 mM KH2PO4; pH 7.4.   
To determine α with differing input percentages of U13C labelled glucose, the KH buffer was 
supplemented with glucose and U13C labelled glucose in the following proportions:  
 For the 0% U13C labelled glucose hearts (n=3), with 11 mM unlabelled glucose 
 For the 25% U13C labelled glucose hearts (n=3), with 8.25 mM unlabelled glucose and 2.75 mM 
U13C glucose 
 For the 50% U13C labelled glucose hearts (n=3), with 5.5 mM unlabelled glucose and 5.5 mM 
U13C glucose 
 For the 75% U13C labelled glucose hearts (n=3), with 2.75 mM unlabelled glucose and 8.25 mM 
U13C glucose 
 For the 100% U13C labelled glucose hearts (n=3), with 11 mM U13C labelled glucose 
 
To determine the relative input of triglyceride and glucose from the perfusion buffer to the TCA cycle, 
hearts were perfused with either 25% U-13C labelled glucose or 25% U-13C labelled triglyceride 
(Cambridge Isotopes Laboratories) alongside 75% unlabelled substrate in each case. The KH buffer for 
the 13C glucose perfused hearts (n=6) contained 8.25 mM unlabelled glucose, 2.75 mM U-13C labelled 
glucose (Cambridge Isotopes Laboratories) and 0.4 mM Intralipid; while for the 13C triglyceride 
perfused hearts (n=6) it contained 11mM unlabelled glucose, 0.1 mM U-13C mixed triglycerides 
(Cambridge Isotopes Laboratories) and 0.3 mM unlabelled Intralipid. All hearts were perfused at a 
constant pressure of 100 mmHg for 32 min following an initial stabilisation period. 
Following the end of the perfusion protocol, the left ventricle was rapidly sectioned in transverse and 
snap frozen for analysis by LC-MS/MS 




3.2.3 Liquid Chromatography-Coupled Mass Spectrometry (LC-MS/MS) 
Metabolites were extracted from the frozen left ventricle, and isotopologue distributions of malate, 
citrate, glutamate (the cellular pool of which is in rapid interconversion with α-ketoglutarate) and 
succinate were determined using LC-MS/MS as described in Chapter 2.  
α-ketoglutarate was unable to be measured accurately, perhaps due to resistance to fragmentation 
or ionisation, and so glutamate was measured instead. Glutamate is interconverted rapidly with α-
ketoglutarate and therefore their labelling distributions are identical (Risa et al., 2011; Yu et al., 1995), 
so this was a convenient and accurate proxy. 
Likewise, the 6+ amu isotopologue of citrate also had a high limit of detection, and therefore in 
conditions where the 6+ amu isotopologue of citrate was expected citrate has not been considered in 











3.3.1 Prediction of Isotopologue Distribution in Krebs Cycle Metabolites  
In order to visualise the model, bifurcation plots were generated for the four key Krebs cycle 
intermediates (Figure 3.2). The model predicted the unlabelled isotopologue of each intermediate to 
decrease as the proportion of 2+ amu acetyl-CoA entering the cycle increases, eventually reaching 0. 
Meanwhile, the fully labelled isotopologue increased with rising α. Each of the other isotopologues 
are predicted to reach their own peak as α increases, and to then decrease again as the proportion of  
[1,2-13C2]acetyl-CoA entering the Krebs cycle continues to rise.  
 
The model allows us to predict the steady state isotopologue distributions of Krebs cycle 
intermediates resulting from different levels of acetyl CoA 13C enrichment. Figure 3.2 shows the 
Figure 3.2: Bifurcation plots showing how the relative proportions of key Krebs cycle intermediate 
isotopologues vary at equilibrium as the proportion of [1,2-13C2]acetyl-CoA entering the Krebs cycle 
(α) increases, as predicted by the model. 




bifurcation diagrams generated by plotting alpha, the proportion of acetyl-CoA entering the Krebs 
cycle which is 2+ amu labelled, against the isotopologue distributions of the key Krebs cycle 
intermediates once steady state has been achieved. This allows us to visualise how the labelling 
density of each intermediate would change according to label input, useful both in the interpretation 
of data resulting from an unknown influx and in optimising the design of experiments to achieve a 
certain labelling pattern. 
 
3.3.2 Validation of the Model 
Next, the model was validated experimentally. Glutamate, succinate and malate isotopologue 
distribution was measured using mass spectrometry in extracts from frozen tissue from hearts 
perfused to steady state with a known percentage of U13C labelled glucose in the buffer (Figure 3). The 
value for α obtained through iteration for each of these intermediates at each percentage of U13C 
buffer glucose is displayed in Figure 3.3, as is the value that gives the overall % buffer glucose oxidation 
in the Krebs cycle when extrapolated to account for all glucose in the buffer (labelled and unlabelled). 
The total percentage of glucose oxidation determined from analysis of the MS data with the model is 
largely consistent, ranging between 75 and 85%, and when factoring in SEM mostly encompassing 78-
80% glucose oxidation. When assessed by 2 way ANOVA, there was no effect of the percentage of 
buffer glucose which was U13C labelled, of metabolite assessed (succinate, glutamate or malate), or of 
any interaction between the two factors (all p>0.05) upon the predicted percentage of acetyl-CoA 
being oxidised in the Krebs cycle which was derived from glucose. This demonstrates that the α values 
predicted by the model from isotopologue distributions of each of the measured metabolites at each 
known percentage of U13C labelled glucose in the buffer are all from the same population. Therefore, 
it seems the model is a good representation of the way in which [1,2-13C2]acetyl-CoA is metabolised 
in the Krebs cycle across the whole range of labelled input. The remaining ~20% of acetyl-CoA entering 
the TCA cycle which was not accounted for by buffer glucose oxidation most likely stems from 
catabolism of the heart’s triglyceride and glycogen stores, which would be unlabelled in this scenario.  
 
  







α 0.198 ± 0.011 0.372 ± 0.01 0.597 ± 0.023 0.779 ± 0.013 
% Glucose Oxidation 79.2 ± 4.4 74.4 ± 4.0 79.6 ± 3.1 77.9 ± 1.3 
 
α 0.190 ± 0.009 0.381 ± 0.007 0.633 ± 0.025 0.833 ± 0.008 
% Glucose Oxidation 76.1 ± 3.7 76.2 ± 1.4 84.4 ± 1.1 83.3 ± 1.3 
 
α 0.189 ± 0.0006 0.41 ± 0.006 0.615 ± 0.02 0.784 ± 0.011 
% Glucose Oxidation 75.6 ± 0.2 82.0 ± 1.2 82.0 ± 2.7 78.4 ± 1.1 
Figure 3.3: Isotope distribution plots showing the labelling distribution of glutamate, succinate and 
malate when the percentage of glucose in the perfusion buffer which was U-13C labelled is varied 
through 0%, 25%, 50%, 75% and 100% (n=3).  

















3.3.3 Determination of the Relative Oxidation of Substrates in the Isolated Heart  
Cardiac Function Throughout the Protocol 
Table 1 shows cardiac function was consistent between all hearts perfused with 11mM glucose and 
0.4 mM intralipid, in terms of developed pressure, heart rate, and rate pressure product. The perfused 
rat hearts (n=12) had a rate pressure product of 35500 ± 2500 mmHg/min. 
Table 1: Pre-Ischaemic Cardiac Function 
LVDP  (mmHg) Heart Rate (bpm) RPP (mmHg/min) 
119 ± 7 300 ± 12 35500 ± 2500 
 
Determining the Contribution of Glucose to the Cardiac Krebs Cycle 
Figure 5B shows the LC-MS measured isotopologue distributions of the key Krebs cycle intermediates 
in cardiac tissue following 32 min of perfusion with 11 mM glucose (25% U13C labelled, 75% 
unlabelled), and 0.4 mM intralipid in the buffer. Again, as expected, the proportions of labelled Krebs 
cycle intermediates are lower than would be predicted if α were 0.25 due to competition for oxidation 
with acetyl-CoA derived from other substrates such as the perfused triglycerides, endogenous 
triglycerides, glycogen and amino acids. 
Figure 3.4: (A) Isotopologue distributions predicted by the model at α=0.145 for malate, citrate, α-
ketoglutarate and succinate. (B) Isotopologue distributions for malate, citrate, glutamate and 
succinate measured in heart tissue perfused with 25% U13C labelled glucose by LC-MS  
A B 





Fitting the experimentally observed isotopic distributions to the model tells us that the observed 
values for the isotopologue distribution in our heart tissue most closely fits the distribution predicted 
by the model when α = 0.145 (± 0.009). As we can see from Figure 5, the isotopologue distributions 
predicted for the key Krebs cycle metabolites with α = 0.145 closely matches the experimental data. 
The relative contribution of glucose to the Krebs cycle when 0.4 mM intralipid is present in the buffer 
is therefore 58 ± 3.6%  
Determining the Contribution of Fatty Acid Oxidation to the Cardiac Krebs Cycle 
The accuracy of the model in determining the contribution of glucose to the Krebs cycle could then be 
corroborated by using it to determine the value of alpha when the labelled acetyl-CoA originated from 
triglycerides in the perfusion buffer. Labelling 25% of the triglyceride available in the perfusion buffer 
resulted in a smaller proportion of labelled isotopologues than with the labelled glucose hearts when 
measured by LC-MS (Figure 6B), and the model determined α to be 0.089 ± 0.002 (a 35.6 ± 0.8% total 
contribution of perfusion buffer intralipid to the TCA cycle). As can be seen from Figure 6, the 
predicted isotopologue distribution for α=0.089 again closely matches the observed experimental 
data.  
 
Figure 5. A: Isotopologue distributions predicted by the model at α=0.089 for malate, citrate, α-
ketoglutarate and succinate. B: Isotopologue distributions for malate, citrate, glutamate and 
succinate measured in heart tissue perfused with 25% U13C labelled triglycerides by LC-MS.  
A B 





This helps confirm the validity of the model, as together triglyceride oxidation (35.6%) and glucose 
oxidation (58%) account for almost 100% of the acetyl-CoA oxidised in the Krebs cycle. The remaining 
6-7% of oxidised acetyl-CoA is likely to correspond to oxidation of endogenous lipid and glycogen 
stores. Despite FAO being thought to dominate in the heart, glucose is present at a much higher 
concentration in the perfusion buffer in order to facilitate uptake, and therefore it is not surprising to 
see it accounting for the greater proportion of oxidation here. 
 
  





This mathematical model for analysis of 13C labelling patterns has been developed to track labelled 
carbon through the Krebs cycle, and has been demonstrated to accurately predict isotopologue 
distribution across the whole range of different labelling inputs from U13C labelled substrates.  
3.4.1 Strengths and Limitations of the Model 
A great strength of this model relative to previous attempts to quantify substrate oxidation through 
Krebs cycle labelling is that it takes isotopologue distributions and the fate of the labelled carbons into 
account. Rather than assuming that more of a specific labelled isotopologue means more oxidation of 
the labelled substrate, as many studies have done (for example, Aubert et al., 2016; Liu et al., 2016; 
Lloyd et al., 2004; Lloyd et al., 2003), it is possible to see with this model that as α increases, the 
proportion of some labelled Krebs cycle intermediates (such as 2+ amu isotopomers) actually 
decreases. Indeed, the model also illustrates that most levels of 2+ amu intermediates can correspond 
to more than one value of α (Figure 3), and that it is therefore necessary to take into account the 
whole isotopologue distribution rather than only specific individual isotopologues when determining 
the proportion of labelled substrate oxidation a labelling pattern corresponds to. This averts the 
potential for the misinterpretation of data which could occur if it were assumed that greater 2+ amu 
labelling meant greater oxidation of the labelled substrate in one group, where in practice it may 
actually mean there is a lower oxidation of the labelled substrate as shown in the bifurcation plots in 
the results section. 
The use of mass spectrometry rather than NMR spectroscopy is also a strength of this study. The 
detection of the whole molecular ion and its fragments with LC-MS/MS negates any effects of certain 
carbon positions being detected with more sensitivity than others by NMR. This has potentially led to 
an assumption that late-stage Krebs cycle intermediates have been labelled before earlier 
intermediates via a back-flux through pyruvate carboxylase (Jones, 2014; Reed et al., 2016), with these 
carbons potentially more easily detectable early in the labelling process. The isotopologue 
distributions seen in this study do not show an enhanced number of the 3+ amu late Krebs cycle 
intermediates and citrate which would have to accompany significant flux through the pyruvate 
carboxylase pathway, suggesting that there isn’t significant flux through pyruvate carboxylase in the 
heart under these conditions. The findings in this chapter concur with previous studies (Kowalski et 
al., 2015; Tran-dinh et al., 1996), which show pyruvate carboxylase flux to be negligible and operating 
purely to top up Krebs cycle carbon when the circulating organic acids are depleted.  




One potential weakness of the study has been the difficulty in measuring some of the less well 
fragmenting Krebs cycle intermediates with enough resolution for a labelling study. While the total 
pool size of both α-ketoglutarate and oxaloacetate are sufficiently detectable with our method for 
inter sample comparisons, there is a high limit of detection (most likely due to the ketone group on a 
carbon neighbouring to a carboxylic acid group which is present on both molecules and may interfere 
with fragmentation or ionisation). This means that when the pool was split by differential labelling of 
isotopologues, some of the isotopologues present in lower concentrations weren’t easily enough 
detectable for accurate fitting of isotopologue distribution to the model. With α-ketoglutarate, this 
was relatively easy to circumvent, as the cellular glutamate pool is interconverted rapidly with α-
ketoglutarate and therefore their labelling distributions are identical (Risa et al., 2011; Yu et al., 1995), 
allowing its measurement as a proxy. However, it is still an indirect measurement and it would have 
been more ideal to be able to measure both metabolites. 
Two limitations of the model currently are its lack of ability to account for anaplerosis and that in its 
current state it only calculates labelling assuming that the input acetyl-CoA is 2+amu labelled. It could 
be programmed to account for unknown rates of anaplerotic flux, but this would greatly complicate 
the maths and amount of computing power required; and in the context of ischaemia in which it is 
used in this thesis, anaplerotic flux is known to be negligible so this does not impair the study (Kowalski 
et al., 2015; Tran-dinh et al., 1996). If however, the model were to be used in the context of another 
organ or model where anaplerotic flux were significant, this would first have to be adjusted. Likewise, 
no 1+amu acetyl-CoA was used in his thesis, but in future work where it was required this could easily 
be adjusted. Within these limitations which can be expected though, the model has shown itself to be 
a robust indicator of labelling in the Krebs cycle. 
 
3.4.2 Significance of Results 
Validation of the Model 
The model appears to offer a robust tool for determining the percentage oxidation of 13C labelled 
metabolic substrates in the mitochondria from the isotopologue distribution of different Krebs cycle 
intermediates. A consistent answer as to the percentage of total Krebs cycle oxidation accounted for 
by glucose oxidation was given even when the percentage of U-13C labelled glucose was varied, 
demonstrating that the model was accurate in predicting the proportion of oxidised acetyl-CoA which 
was [1,2-13C2]acetyl-CoA from the resultant isotopologue distributions in the Krebs cycle. 
The Predominance of Glucose Oxidation in the Langendorff Heart 




The heart is well documented to oxidise fatty acids to generate most of its ATP in physiological 
conditions, so it is interesting that in this preparation glucose oxidation accounts for the majority of 
Krebs cycle oxidation. When 0.4 mM equivalent intralipid was supplied in the perfusion buffer, glucose 
oxidation still accounted for 58 ± 3.6% of the total acetyl-CoA oxidised in the Krebs cycle. Two possible 
explanations for this discrepancy between previously measured physiological substrate oxidation 
ratios and that seen in this Langendorff preparation are that there may have been differences in tissue 
oxygenation or the proportions in which the substrates were delivered to the heart.  
KH buffer has a lower oxygen delivery capacity than blood or red blood cell supplemented buffer 
(Schenkman et al., 2003), which could suggest that the heart may favour glucose oxidation as a more 
oxygen efficient fuel (Opie and Sack, 2002; Taegtmeyer and Lubrano, 2014). However, several studies 
have shown that O2 delivery is not limiting in similar Langendorff heart preparations. When KH buffer 
oxygenated with 95% O2 carbogen gas was delivered at 80 mmHg coronary flow and fractional oxygen 
extraction were sub-maximal, while lactate was not being produced (Edlund and Wennmalm, 1981). 
Fisher & Williamson (1961) demonstrate that it is feasible to supply considerably more O2 to the 
Langendorff heart than the basal oxygen demand, while both Neely et al. (1967) and Wengrowski et 
al. (2014) show that their Langendorff preparation can further increase oxygen consumption in 
response to increased stimulation or pressure. Taken together, this suggests that O2 delivery should 
not be such a limiting factor upon cardiac metabolism that it drives a preference for glucose oxidation 
over FAO. 
Glucose concentration in the KH buffer is almost double that in the blood of a typical rat (Bell et al., 
2011) in order to assure sufficient uptake in the absence of insulin, and this may lead to higher 
proportions of glucose oxidation to FAO. Increasing KH buffer glucose concentration past 11 mM leads 
to no further uptake of glucose in the Langendorff heart (King and Opie, 1998), meaning that cardiac  
glucose uptake is at its maximum non-insulin stimulated rate with this delivery concentration. This in 
turn means that glucose uptake could be exceeding that observed in vivo, possibly leading to further 
inhibition of FAO through the Randle cycle (Hue et al., 2009), and accounting for the greater glucose 
oxidation:FAO ratio in the Langendorff heart relative to in vivo. One way of investigating this further 
would be to lower the concentration of glucose present in the buffer and see whether that altered the 








3.4.3 Future Directions  
While in the healthy heart fatty acids can constitute up to 100% of the substrate oxidised (Lopaschuk 
et al., 2010), in pathophysiological states such as oxygen deprivation, metabolic syndrome or dietary 
manipulation the contribution of glucose and other substrate derived acetyl-CoA to the Krebs cycle is 
thought to be increased (Atherton et al., 2011; Mansor et al., 2013; Veech, 2004). Fat oxidation 
requires 15% more oxygen per gram ATP produced than glucose (Neely et al., 1972; Lopaschuk et al., 
2010), which can offer the cardiac mitochondria incentive to vary the relative contributions of fats and 
glucose to the Krebs cycle when oxygen is a limiting factor (Heather et al., 2012; Horscroft et al., 2015). 
Furthermore, varying the availability of different substrates to the heart which can occur in conditions 
such as diabetes and fasting also dictates the ratio of substrates oxidised (Heather and Clarke, 2011). 
This model offers an accurate way to monitor mitochondrial substrate selection, and could be used to 
investigate cardiac substrate switching in each of these scenarios. 
As a specific example of a further application which could be of great interest, the model could be 
used to assess the proportion of glucose to fatty acid oxidation in the failing heart. In heart failure, the 
heart is incapable of supplying itself with enough blood, and oxygen, to sustain contractile function 
(Dargie 2005). This is thought to lead to an overall reduction of substrate oxidation, but an increase in 
the proportion of glucose:fatty acids oxidised (Neubauer, 2007). If rats with and without heart failure 
were either given U13C labelled glucose in the diet, or the hearts were mounted on a Langendorff rig 
upon termination and perfused with U13C labelled glucose it would be possible to freeze the tissue at 
a steady state and assess the percentage contribution of glucose oxidation to total substrate oxidation 
by the Krebs cycle. This could even be performed at various stages of heart failure in order to track 




Dietary Nitrate Supplementation and the 
Role of Fatty Acid Oxidation in 
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BACKGROUND Dietary supplementation with sodium nitrate protects cardiac mitochondrial complex 
I against hypoxic injury, and increases fatty acid oxidation (FAO) capacity.   
OBJECTIVES The focus of this chapter was to investigate whether the protective effects of dietary 
nitrate supplementation could translate from protection against hypoxia to protection against 
ischaemia/reperfusion, and whether any protective effect was conditional upon substrate supply, 
specifically fatty acid availability.   
METHODS Male Wistar rats had diets supplemented with 0.7 mM NaCl or 0.7 mM NaNO3 for two 
weeks. Hearts excised from these rats were perfused in the Langendorff mode (100 mmHg, 32 min) 
before 32 min low-flow ischaemia (0.3 ml.min-1gww-1), with (n=7 per group) or without (n=7 per group) 
intralipid in the perfusion buffer. Recovery of contractile function was then assessed following 32 min 
reperfusion, before 10 mg left ventricle was permeablised with saponin and mitochondrial respiratory 
function assessed using respirometry. Tissue metabolite levels were measured in coronary effluent 
and myocardium frozen at the end of the reperfusion period using LC-MS/MS and LC-MS.  
RESULTS Intralipid in the perfusion buffer resulted in greater recovery of LVDP following 
ischaemia/reperfusion, yet this was worsened if the rat’s diet had been supplemented with sodium 
nitrate (Interaction, p<0.05). Meanwhile, intralipid decreased the coupling of the mitochondria 
assessed at the end of reperfusion (p<0.01), but neither intralipid nor dietary nitrate supplementation 
resulted in greater recovery of complex I supported oxygen consumption. Intralipid presence in the 
buffer also resulted in greater levels of ATP being present in the myocardium at the end of reperfusion, 
while nitrate supplementation counteracted this (Interaction, p<0.05) and also resulted in lower 
myocardial levels of PCr (Nitrate effect, p<0.01). Intralipid in the perfusion buffer resulted in higher 
myocardial levels of malonyl-CoA (p<0.01) and of alanine (p<0.01) post-reperfusion, suggesting that 
presence of intralipid results in greater substrate oxidation and perhaps increased glycolysis. 
CONCLUSIONS While the presence of intralipid in the perfusion buffer appears to result in greater 
functional recovery of the heart following ischaemia/reperfusion, the cardioprotective potential of 
dietary nitrate supplementation remains unclear.  





In recent years, the metabolic effects of dietary supplementation with sodium nitrate have started to 
become apparent (Carlström et al., 2010; Larsen et al., 2011). Nitrate supplementation has been 
associated with protection of heart and skeletal muscle against hypoxia (Ashmore et al., 2014a), 
induction of adipose tissue browning (Roberts et al., 2015) and enhancement of cardiac contractile 
function (Pironti et al., 2016), traits which suggest that its employment in the treatment of ischaemia 
may be beneficial. The protective effects of nitrate supplementation against a hypoxic challenge show 
particular promise in this regard, given ischaemia includes a severe hypoxic element. 
4.1.1 Protection of the Mitochondrial Electron Transport Chain 
To a certain extent during ischaemia, and especially during any subsequent reperfusion, excess 
generation of reactive oxygen species (ROS) can cause damage to the mitochondrial electron transport 
chain (ETC) (Chen et al., 2003; Kalogeris et al., 2014). Predominantly thought to be produced at ETC 
complex III, ROS mediated damage to this and other ETC complexes as well as to the mitochondrial 
DNA can lead to mitochondrial dysfunction and apoptosis (Halestrap, 1998; Kim et al., 2018). ROS 
production upon reperfusion follows maladaptation to the lack of oxygen supply during ischaemia, 
and could potentially be managed through the manipulation of substrate supply to the mitochondria 
upon reperfusion. 
Supplementation of the diet with nitrate has been shown to protect the function of ETC complex I, 
which otherwise sustains damage during hypoxia. Complex I supported respiration, activity and 
expression were impaired by 14 days exposure to hypoxia at 13% O2, but with nitrate supplementation 
(0.7 mM) full function continued to be observed following the same level of exposure (Ashmore et al., 
2014a). The same study also reported an ablation of hypoxia-induced protein carbonylation (a marker 
of oxidative stress) when the rats’ diets had been supplemented with nitrate, a finding corroborated 
by Monaco et al. (2018), who detected a reduction in H2O2 production. Increased mitochondrial 
efficiency has also been reported in skeletal muscle and heart tissue with dietary nitrate 
supplementation, as well as a lower demand for oxygen and increased mitochondrial biogenesis 
(Carlström et al. 2010; Larsen et al. 2011; Ashmore, Fernandez, Branco-price, et al. 2014).  
Some of the action of nitrate is thought to stem from nitrite and NO activity, which are breakdown 
products of nitrate during hypoxia (Feelisch et al., 2008). This could be a key trait with regards to 
ischaemia and reperfusion, as nitrite in particular is thought to mediate s-nitrosylation of 
mitochondrial complex I whilst also protecting against reperfusion injury (Shiva et al. 2007; Shiva & 
Gladwin 2009). NO is also implicated in cardiovascular signalling through s-nitrosylation (Lima et al. 




2010), the action of which is thought to protect complex I against ischaemia reperfusion injury 
(Chouchani et al. 2014). 
4.1.2 Control of Metabolic Substrate Utilisation 
In its healthy state, the heart gains between 70 and 100% of its ATP through oxidation of fats (Fillmore 
et al., 2014). To consider a heart fully recovered from ischaemia therefore, it might seem logical to 
expect that this metabolic pattern, along with the capacity for metabolic flexibility must be restored.  
Whether maintenance of FAO prior to and following reperfusion is protective against further injury or 
a limit upon the healthy function of the heart is a matter for debate. Etomoxir inhibition of FAO 
through CPT 1 has been shown to boost glucose oxidation on reperfusion and be beneficial to 
functional recovery (Lopaschuk et al., 1990), and there is an argument that FAO is detrimental to 
recovery upon reperfusion (Fillmore et al., 2014). FAO is associated with mitochondrial uncoupling 
and the loss of efficiency and energetics (Cole et al., 2011; Murray et al., 2008), something which the 
reperfused heart with an impaired ETC might be ill able to afford. However, it has also been shown 
that presence of fatty acids in the perfusion buffer is protective against ischaemia/reperfusion injury, 
with improved recovery of contractile function following ischaemia (Lou et al. 2014 A; King et al. 2001).  
Dietary nitrate supplementation has been shown to promote fatty acid metabolism. This has been 
observed across a variety of tissues, including heart, skeletal muscle and adipose tissue (Ashmore et 
al., 2014a, 2015; Roberts et al., 2015). In particular, nitrate has been found to rescue CPT-1 activity 
and FAO in the hypoxic heart (Ashmore et al., 2014a). In skeletal muscle, nitrate has been shown to 
activate PPARα, the “master regulator” of fat metabolism (Ashmore et al., 2015), expression of which 
is downregulated by HIF in response to impaired cardiac oxygen delivery (Papandreou et al. 2006; 
Ravingerova et al. 2011; Cole et al., 2016). It may therefore be that dietary nitrate supplementation 
could reverse hypoxia driven suppression of FAO. If this reversal occurs, nitrate supplementation prior 
to ischaemia and reperfusion may therefore be an ideal vehicle to address the paradigm of whether 
or not an enhanced FAO capacity is cardioprotective. 
4.1.3 Indications for Cardioprotection 
Whilst a more oxidative state in the healthy heart could conceivably be a desirable clinical outcome,  
suppression of oxidative metabolism on reperfusion, both pharmacologically, with agents such as 
isofluorane and morphine, and through ischaemic post-conditioning, has been shown to reduce I/R 
injury (Chiari et al., 2005; Weihrauch et al., 2005; Zhao et al., 2003). Potentially therefore, when 
oxygen is limiting during reperfusion it may not be desirable to increase oxidative metabolism in the 
heart, which may even lead to greater ROS mediated damage or destruction of the ETC. 




The protection of the electron transport chain and modulation of metabolic substrate usage which 
dietary nitrate supplementation mediates could therefore show promise as a preventative treatment 
against ischaemia/reperfusion injury. Certainly its metabolite nitrite has been shown in several studies 
to improve recovery of cardiac function following ischaemia/reperfusion (Bryan et al., 2007a; Pride et 
al., 2014; Shiva and Gladwin, 2009; Shiva et al., 2007). However, there are few studies demonstrating 
a cardioprotective effect of dietary nitrate. One of these was conducted using Langendorff apparatus 
and demonstrates improved recovery of LVDP following ischaemia, yet there were no fatty acids 
present in the perfusion buffer (Jeddi et al., 2016a). With an intervention such as nitrate which has 
extensive metabolic effects as detailed above, this is likely to have overlooked some of its effects in 
the ischaemic heart. The second study was conducted in vivo, and reported a reduced infarction size 
following dietary nitrate supplementation (Bryan et al., 2007b). 
4.1.4 Objectives 
The objective of this chapter was to establish whether dietary supplementation with sodium nitrate 
could protect the rat heart against subsequent ischaemia/reperfusion injury, and if so whether it 
depends upon the availability of exogenous fatty acids. The study was set up to investigate functional 
recovery following ischaemia, with and without intralipid, a triglyceride mixture, in the perfusion 
buffer. 
  





4.2.1 Animal Housing and Dietary Supplementation 
Male Wistar rats (300-350 g) were obtained from a commercial breeder (Charles River, UK). All 
procedures involving live animals were carried out by a licence holder in accordance with UK Home 
Office regulations, and underwent review by the University of Cambridge Animal Welfare and Ethical 
Review Committee. Rats were housed in a temperature, humidity and light controlled environment 
(23°C) with a 12 h/12 h light/dark cycle. 
 
Upon the completion of a one week wash-out period where distilled water and a quality-controlled 
diet were provided ad libitum, the rats’ water was supplemented with either sodium nitrate or sodium 
chloride as a control to account for the concentration of sodium uptake (both 0.7 mM) for two weeks 
preceding termination. This represented a concentration and duration of treatment which had 
previously been shown to alter metabolism in rats (Ashmore et al., 2014a, 2014b, 2015; Roberts et al., 
2015). During this time, the volume of water consumed was measured daily. Rats were terminated 
following the two weeks of water supplementation, and the hearts excised either for perfusion in the 
Langendorff mode as previously described in Chapter 2 (n=7 x 4 groups), or for respirometry (n=5 x 2 
groups) as also described in Chapter 2. 
 
4.2.2 Langendorff Perfusion 
Hearts were perfused in retrograde as described in Chapter 2 (Section 2.1), and subjected to 32 min 
perfusion at 100 mmHg, followed by 32 min low flow ischaemia (0.32 ml/min/gww) and 32 min 
reperfusion at 100 mmHg.  
For the Chloride/Glucose and Nitrate/Glucose groups (n=7), the perfusion medium was 250 mL of 
recirculated KH buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.3 mM CaCl2, 0.5mM EDTA, 25 
mM NaHCO3, 1.2 mM KH2PO4, 11mM Glucose; pH 7.4). The Chloride/Intralipid and Nitrate/Intralipid 
groups (n=7) were perfused with an identical buffer which also contained 0.4 mM equivalent intralipid 
(Appendix III.1). At the end of the perfusion protocol, the left ventricle was rapidly sectioned in 
transverse and snap frozen, with the exception of ~10 mg of left ventricle which was permeablised for 
respirometry. Samples of coronary effluent were collected and snap frozen at 4 minute intervals 
throughout the protocol. 




Follow up groups of hearts (n=5) were perfused with identical buffer conditions to those described 
above, yet the experiment was terminated at the end of the ischaemic period without reperfusion and 
the hearts sectioned and frozen for future analysis with LC-MS   
 
4.2.3 High-Resolution Respirometry 
Tissue permeabilisation and High-Resolution Respirometry was conducted on fresh sections of LV 
from both pre-Langendorff perfusion nitrate and chloride treated hearts, and the post-reperfusion 
hearts as described in Chapter 2 (Section 2.2). The respiratory control ratio (RCR) was calculated as 
an indicator of mitochondrial uncoupling by dividing the rate of oxygen consumption supported by 
malate and octanoyl carnitine in the oxphos state by that supported by the same substrates in the 
leak state. 
 
4.2.4 Mass Spectrometry 
Metabolites were extracted from frozen left ventricle using a Bligh-Dyer method as described in 
Chapter 2 (2.3.2). Levels of metabolites in the post-reperfusion hearts (Krebs cycle intermediates, 
amino acids and malonyl-CoA) were assessed by LC-MS/MS using the C18pfp chromatography method 
coupled to the Thermo Quantiva, while levels of β-hydroxybutyrate and lactate in the ischaemic hearts 
were assessed by LC-MS/MS using the C18pfp method coupled to the Thermo Elite, all as described in 
sections 2.3.3 and 2.3.4. 
Coronary effluent samples (20 µl plus 80 µl 10 mM ammonium acetate/internal standard mix) were 
also analysed for β-hydroxybutyrate and lactate using the c18pfp chromatography method coupled to 











4.2.5 Presentation and Statistics 
Unless otherwise stated, all statistical analysis was performed using two-way ANOVA with Nitrate 
supplementation and Intralipid as the variables. Wherever there was an interaction between the two 
factors, it was further examined through the use of post-hoc T-tests.  
Graphically, the following representations were used for significant effects: 











Significance was denoted as * p < 0.05, ** p < 0.01, *** p < 0.001. 
For data where there was more than one significant effect, both are instead noted upon the graph.  
 
Significance by post-hoc t-test was denoted on graph using the following notation: 
Ω = Relative to Chloride/Glucose 
Δ = Relative to Nitrate/Intralipid 
Θ = Relative to Chloride/Intralipid  
Where: Ω/Δ/θ = p < 0.05, ΩΩ/ΔΔ/θθ = p < 0.01, ΩΩΩ/ΔΔΔ/θθθ = p < 0.001 
 
 





4.3.1 Dietary Supplementation 
Total intake of water across two weeks, and therefore sodium ions and either choride or nitrate ions, 
was identical between the sodium nitrate and sodium chloride supplemented groups of rats (Figure 



















Figure 4.1: Total intake of sodium chloride or sodium nitrate across the two weeks of dietary 
supplementation ±SEM.  




4.3.2 Functional Recovery of the Heart 
Hearts from rats with diets supplemented either with sodium nitrate or sodium chloride were 
subjected to low-flow ischaemia (32 min at 0.3 ml.min-1gww-1) and reperfusion (32 min at a constant 
pressure of 100 mmHg). Pre-ischaemic contractile function was the same across all groups (Table 4.1). 
When intralipid was present in the perfusion buffer, recovery of LVDP in the hearts of nitrate-
supplemented rats was 75% of that exhibited by the control rat hearts following 32 min reperfusion 
(interaction, p < 0.001 (Table 4.2); post-hoc t-test, p < 0.001) (Figure 4.2). Intralipid/chloride hearts 
recovered 33% greater levels of LVDP than glucose/chloride hearts (post-hoc t-test, p < 0.01). 
Meanwhile, the heart rate recovered to the same extent across all four groups (Figures 4.3 & 4.6). 
The rate-pressure product also recovered to a lesser extent in the nitrate/intralipid hearts than in 
chloride/intralipid hearts (Figure 4.4), but there was no difference between the nitrate/glucose and 
chloride/glucose hearts (Figure 4.7) (Interaction, p < 0.05 (Table 4.2)).  
Table 4.1: Pre-Ischaemic Cardiac Function 
 LVDP (mmHg) Heart Rate (bpm) RPP (mmHg.bpm) 
Chloride/Glucose 136.7 ± 7.7 280.1 ± 10.9 37500 ± 2100 
Nitrate/Glucose 129.6 ± 9.6 272.8 ± 13.1 36100 ± 4100 
Chloride/Intralipid 130.4 ± 8.6 277.3 ± 15.6 35700 ± 2200 
Nitrate/Intralipid 131.7 ± 9.7 277.1 ± 8.7 36400 ± 2900 
 
Figure 4.2: Recovery of left-ventricular developed pressure as a percentage of pre-ischaemic levels 




low flow ischaemia, ±SEM. ΩΩ = p < 0.01 relative to 










































low flow ischaemia, ±SEM.  























































In the hearts perfused without intralipid in the buffer, nitrate did not influence recovery of LVDP at 32 
min reperfusion (Figure 4.5). The nitrate/glucose hearts did however recover LVDP to 18% higher 
levels than nitrate/intralipid hearts (post-hoc t-test, p < 0.05).  
 
Heart rate (Figure 4.6) and RPP (Figure 4.7) recovered to the same extent following ischaemia in 

















































Figure 4.5: Recovery of left-ventricular developed pressure as a percentage of pre-ischaemic levels 




low flow ischaemia, ±SEM. Δ = p < 0.05 relative to 
nitrate/intralipid. 




low flow ischaemia, 
±SEM.  
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The percentage recovery of LVDP and RPP for each group, as well as heart rate, at the end of the 
ischaemic period, is summarised in Table 4.2: 
 







































63.1± 4.3 77.3± 
6.2 
83.5± 2.8 63.6± 9.2 Interaction, p<0.001 

















75.8± 4.8 65.1± 
11.4 
Interaction, p<0.05 
Figure 4.7: Recovery of rate-pressure product as a percentage of pre-ischaemic levels following 




low flow ischaemia, ±SEM.  




4.3.3 Buffer Lactate 
Levels of the ischaemic marker lactate, a product of anaerobic glycolysis, were assessed in the 
coronary effluent over the ischaemic period using LC-MS (Figure 4.8). Production of lactate was 
negligible pre-ischaemia, and returned towards baseline following reperfusion, yet rose sharply at the 
onset of ischaemia and was maintained throughout this period. There was no overall difference 
between the groups in the concentration of lactate exuded during ischaemia.  
 
  
Figure 4.8: Levels of lactate in the coronary effluent. Ischaemic period is highlighted in grey. 
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4.3.4 Buffer β-hydroxybutyrate 
A surprising finding was that the ketone body β-hydroxybutyrate was also present in the coronary 
effluent during ischaemia (Figure 4.9). This appeared to follow a broadly similar pattern to lactate, 
with none present in the buffer pre-ischaemia and levels returning swiftly towards baseline post-
ischaemia, yet a sharp rise at the onset of ischaemia and maintenance of this level of production 
through the ischaemic period. There was no overall difference between the groups in concentration 
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Figure 4.9: Levels of β-hydroxybutyrate in the coronary effluent. Ischaemic period is highlighted 
in grey. Results shown as mean ± SEM.  






















4.3.5 Cardiac Mitochondrial Function 
In LV directly extirpated from sodium nitrate and sodium chloride supplemented rats, and examined 
via respirometry (without ischaemia/reperfusion), there was no difference in leak state respiration 
supported by malate and octanoyl-carnitine (Figure 4.10). β-oxidation and complex I supported 
respiration were also unchanged by nitrate supplementation, however complex II supported 
respiration was 35% higher in nitrate supplemented rat hearts compared with those of chloride 











































Figure 4.10: (A) Respiration rates in non-perfused hearts, corrected for wet mass. Malate and 
octanoyl carnitine were added initially to stimulate leak respiration, ADP to stimulate β-oxidation 
supported Oxphos, glutamate to saturate complex I, cytochrome c as a test of membrane integrity, 
succinate to activate complex II, and rotenone to inhibit complex I. (B) The respiratory control ratio 
(RCR) and (C) the FAO ratio. All results displayed as mean ± SEM. Statistical difference between 
nitrate and chloride with Student’s T-test denoted as * = p< 0.05 
* 


























Permeabilised LV muscle fibres from hearts which had been subjected to ischaemia/reperfusion were 
then analysed by respirometry to assess how mitochondrial function and metabolism was affected by 
ischaemia and reperfusion. The presence of intralipid in the buffer during ischaemia/reperfusion 
resulted in compromised β-oxidation and complex I function (Intralipid effect, p<0.05), along with a 
decreased respiratory control ration (RCR) (Figure 4.12, overleaf; Intralipid effect, p<0.01). Complex II 
supported respiration and total (complex I + II supported) respiration following reperfusion was 
unaffected by either intralipid or nitrate supplementation (Figure 4.11, overleaf). There was no 
alteration in the mitochondrial FAO preference ratio between groups. 
  







































Chloride/Glucose Nitrate/Glucose Chloride/Intralipid Nitrate/Intralipid
Figure 4.11: Respiration rates post-ischaemia/reperfusion, corrected for wet mass. Malate and 
octanoyl carnitine were added initially to stimulate leak respiration, ADP to stimulate β-oxidation 
supported Oxphos, glutamate to saturate complex I, cytochrome c as a test of membrane integrity, 
succinate to activate complex II, and rotenone to inhibit complex I. All results displayed as mean ± 
SEM. 2-way ANOVA * = p<0.05, ** = p<0.01 
* 














Figure 4.12: Respiratory control ratios (RCR), and FAO preference. All displayed as mean ± SEM. 2-
way ANOVA ** = p<0.01 

















4.3.6 Recovery of Cardiac Energetics 
ATP and PCr were assessed at the end of reperfusion by LC-MS/MS. Tissue levels of ATP were 1.8 fold 
higher in LV from the intralipid perfused chloride supplemented hearts relative to those perfused only 
with glucose, demonstrating a possible energetic component to intralipid mediated cardioprotection 
(Figure 4.13A). Nitrate supplementation meanwhile resulted in 1.3 fold greater levels of ATP relative 
to chloride when there was no intralipid in the buffer, yet a 30% lower level of ATP relative to chloride 
when intralipid was present in the buffer. This manifested as an effect of nitrate (p<0.05), and an 
interaction between nitrate and intralipid (p<0.05). Chloride/intralipid hearts displayed 1.83 fold 
greater levels of ATP than chloride/glucose hearts (post-hoc t-test, p < 0.05). 
PCr levels meanwhile were similar to chloride/glucose in the chloride/intralipid hearts, but nitrate 
depressed them in both buffer composition types (Figure 4.13B). The effect of nitrate was stronger 








Chloride/Glucose Nitrate/Glucose Chloride/Intralipid Nitrate/Intralipid
ATP
Figure 4.13: Cardiac levels of (A) ATP and (B) PCr displayed relative to chloride/glucose hearts. 
Results displayed as mean ± SEM. 2-way ANOVA outcomes denoted on graph. Ω = p < 0.05 relative 










Chloride/Glucose Nitrate/Glucose Chloride/Intralipid Nitrate/Intralipid
PCr
       Nitrate p<0.05 
Interaction p<0.05 











4.3.7 Malonyl-CoA Regulation of FAO 
In order to investigate mitochondrial fatty acid uptake, levels of malonyl-CoA, the CPT-1 inhibitor, 
were investigated using LC-MS/MS (Figure 4.14). Malonyl-CoA levels were 1.7-fold higher in hearts 
perfused with intralipid relative to those which had only glucose in the buffer (Intralipid effect p<0.01), 








Chloride/Glucose Nitrate/Glucose Chloride/Intralipid Nitrate/Intralipid
Malonyl-CoA
Figure 4.14: Cardiac levels of Malonyl-CoA relative to chloride/glucose hearts. Results displayed as 
mean ± SEM. 2-way ANOVA ** = p<0.01 
** 









4.3.8 Krebs Cycle Intermediates 









































Figure 4.15: Concentrations of Krebs cycle intermediates relative to chloride/glucose hearts. Results 
displayed as mean ± SEM. 2-way ANOVA * = p<0.05, ** = p<0.01 
** 
    Nitrate p<0.05 
Intralipid p<0.05 
 Intralipid p<0.001 
Interaction p<0.05 
* 
       Nitrate p<0.05 
















Cardiac levels of acetyl-CoA were 45%  lower in reperfused hearts from nitrate-supplemented rats 
relative to chloride-supplemented rats, a pattern similar to that seen with the late-Krebs cycle 
intermediates malate and fumarate (Nitrate effect, p<0.01, 0.05 and 0.05, respectively). 
However, the early Krebs cycle intermediates citrate and isocitrate, as well as the complex II substrate 
succinate, were not lower following dietary nitrate supplementation relative to the chloride/glucose 
hearts. They were however markedly raised in the chloride/intralipid hearts compared with 
chloride/glucose hearts, ~2 fold, 3.5 fold and 3.25 fold for each respective intermediate (Intralipid 
effect of p<0.05, p<0.001 and p<0.001, respectively). This effect was not seen in the nitrate/intralipid 
hearts (An effect of both nitrate and intralipid for citrate (both p<0.05); an effect of nitrate (p<0.05), 
intralipid (p<0.001) and an interaction between the two factors (p<0.01) for isocitrate; and an effect 
of intralipid (p<0.001) and an interaction (p<0.05) for succinate). 
 
4.3.9 Post-Reperfusion Alanine Levels 
LV concentration of the amino acid alanine, measured by LC-MS/MS, was 2.25-fold higher in hearts 
where intralipid had been present in the perfusion buffer (Figure 16; Intralipid effect, p<0.01). Alanine 
is synthesised from pyruvate by alanine aminotransferase, and increased levels can often be 









Chloride/Glucose Nitrate/Glucose Chloride/Intralipid Nitrate/Intralipid
Alanine
Figure 4.16: Cardiac levels of alanine displayed relative to chloride/glucose hearts. Results 
displayed as mean ± SEM 2-way ANOVA ** = p<0.01 
** 




4.3.10 Oxidative Stress Markers 
Levels of oxidative stress markers in the reperfused heart were interrogated using LC-MS/MS (Figure 
17). Contrasting effects of nitrate supplementation and intralipid delivery were observed in the 
different oxidative stress markers. Hydroxylysine levels were reduced ~40% when intralipid was 
present in the buffer (p<0.05). Meanwhile, intralipid mediated a roughly 30% increase in 
hydroxytyrosine levels (not significant) and methionine sulphoxide (p<0.05), markers which were 
present in lower levels in hearts which had been supplemented with sodium nitrate (p<0.05 for 
hydroxytyrosine, not significant for methionine sulphoxide). Hydroxyproline levels appeared affected 
by nitrate supplementation, which effected a 20-25% decrease in their presence, although this did not 







































Figure 4.17: Cardiac levels of (A) hydroxylysine, (B) Hydroxyproline, (C) Methionine Sulphoxide 
and (D) Hydroxytyrosine relative to chloride/glucose hearts. Results displayed as mean ± SEM 2-



















Chloride/Glucose Nitrate/Glucose Chloride/Intralipid Nitrate/Intralipid
β-hydroxybutyrate
4.3.11 Ischaemic Levels of Lactate and β-hydroxybutyrate 
In order to further investigate the finding of increased β-hydroxybutyrate in the ischaemic coronary 
effluent, LC-MS was used to analyse tissue from hearts frozen at the end of the ischaemic period for 
lactate and β-hydroxybutyrate (Figure 4.18). Lactate accumulated to a greater extent in hearts from 
the nitrate supplemented groups during ischaemia (p<0.001). This effect was mirrored for β-
hydroxybutyrate (p<0.01), suggesting that its production is perhaps linked to anaerobic metabolism 

































Chloride/Glucose Nitrate/Glucose Chloride/Intralipid Nitrate/Intralipid
Lactate
Figure 4.18: Ischaemic LV levels of (A) lactate and (B) β-hydroxybutyrate displayed relative to 











Whether dietary nitrate supplementation could have a beneficial effect upon recovery from an 
ischaemic insult remains unclear, but results in this chapter suggest a metabolic effects of nitrate 
beyond effects at the electron transport chain, for example through the greater production of lactate 
and β-hydroxybutyrate post-reperfusion. Intralipid meanwhile resulted in greater recovery of 
contractile function following ischaemia/reperfusion, protective effects which reaffirm the contested 
assertion that FAO can be beneficial in recovery from ischaemia/reperfusion. This intralipid mediated 
cardioprotection was reversed by dietary nitrate supplementation. 
4.4.1 Strengths and Limitations of the Study 
The ability to see these metabolic effects illustrated one of the big advantages of using Langendorff 
perfusion as an investigatory tool during this chapter and throughout this thesis. The ability to vary 
which metabolic substrates were available in the buffer in a highly controlled manner allowed the 
interaction between dietary nitrate supplementation and fat oxidation to be detected during cardiac 
recovery following ischaemia. Dietary supplementation with sodium nitrate reversed the 
cardioprotective effects perfusion with intralipid had upon hearts from animals on the control diet, 
even though without triglyceride in the buffer there was no nitrate effect. This kind of effect would 
not be visible in vivo, where the exact proportions of metabolic substrates supplied to the heart in the 
bloodstream are less controlled. Thus, the present study provides mechanistic insight to a previous 
study with dietary nitrite conducted in vivo which reported a reduction of infarct size (although no 
functional data) (Bryan et al., 2007b), and it would be interesting to know how this would alter if the 
proportions of metabolites in the bloodstream were varied. 
Conducting the study ex vivo does have some potential drawbacks however. This study was conducted 
using the Langendorff apparatus partially with the intention of removing the complication non-cardiac 
effects would present, but the effects of dietary nitrate can be systemic rather than purely cardiac 
(Webb et al., 2008). The systemic effects of dietary nitrate supplementation may have unseen 
implications for cardiac recovery, such as the reduction of peripheral tension and therefore work the 
recovering heart is required to perform. Along with any invoked substrate level changes in the blood, 
higher levels of circulating NOx species seen with dietary nitrate supplementation (Pannala et al., 
2003) were also removed from the study once the hearts were excised. The differences observed in 
this study were therefore due only to the more chronic changes that dietary nitrate supplement had 
evoked, which may include protein expression changes, possible angiogenesis and any structural 
remodelling; and which of these occur during nitrate supplementation deserves further elucidation.   




4.4.2 Significance of Results  
Previous studies have recorded two main effects of dietary nitrate supplementation upon the rat heart 
which were likely to have an impact on recovery from ischaemia/reperfusion; protection of 
mitochondrial complex-I against hypoxia and enhanced FAO (Ashmore et al., 2014a, 2015; Roberts et 
al., 2015). 
Protection of complex-I supported respiration was observed in hypoxia, yet this effect did not appear 
to translate into ischaemia. Previously, hearts of rats exposed to reduced oxygen conditions  exhibited 
reduced complex-I supported respiration rates unless their diet had been supplemented with nitrate, 
in which case complex-I function was preserved (Ashmore et al. 2014). However, here there was no 
indication that dietary nitrate supplementation had protected any of the ETC complexes from 
ischaemia. This may be a matter of the hearts in the present study having been subjected to more 
considerable oxidative stress than in the hypoxic study, which negated any protective effect of nitrate 
against less intense insults to complex I. Alternatively, protection of complex I may be a more acute 
effect of nitrate, and may not occur without circulating nitrate/nitrite in the perfusion buffer. It would 
be enlightening to further investigate this to determine whether complex I protection is dependent 
upon circulating NOx species.   
In this study, dietary supplement with sodium nitrate had no effect upon complex I supported 
respiratory capacity in non-perfused hearts. This concurred with other studies which have suggested 
little or no impact of nitrate supplementation upon the mitochondrial complexes (Hezel et al., 2015; 
Monaco et al., 2018), and further suggests that the protection of complex I from hypoxia could be due 
to acute effects of nitrate in circulation. There was an observed increase in complex II supported 
respiration here however, which had not been reported previously.  
The investigation was conducted with and without intralipid in the buffer because dietary nitrate 
supplementation is suggested to enhance FAO, yet no difference in the mitochondrial FAO capacity 
was observed here in either non-perfused hearts or following ischaemia/reperfusion. Previously, 
increased FAO capacity was observed in several tissues, including the heart, following dietary nitrate 
supplementation (Roberts et al. 2015; Ashmore et al. 2014; Ashmore et al. 2015). There is still an 
interaction between nitrate supplementation and intralipid supply on functional recovery from the 
heart however, with nitrate reversing intralipid mediated cardioprotection, so nitrate appears to be 
exerting some effect upon fat metabolism. Respirometry gives a measure of the total capacity for FAO 
rather than the experimentally occurring rate, so it is possible that it is capacity but not rate which is 
unaltered by nitrate supplementation.  It is also the case that a different carnitine was given in this 
study to assess β-oxidation supported respiration (octanoyl carnitine), compared with the Ashmore et 




al. (2014) study, which used palmitoyl carnitine to achieve the same purpose, and this may have 
affected the FAO capacity observed.  
Nitrate supplementation appears to have boosted glycolytic metabolism and the production of lactate 
at the expense of generation of acetyl-CoA upon reperfusion (Figures 4.15 & 4.18). This has then led 
to depletion of Krebs cycle intermediates. Since carbon from glucose metabolism is required in order 
to metabolise acetyl-CoA from fatty acids (Owen et al., 2002), and these fatty acids would usually be 
preferentially oxidised upon reperfusion (Myears et al., 1987), it is possible that this is how nitrate 
supplementation has cancelled out the cardioprotective effects of having intralipid in the perfusion 
buffer.  
The cardioprotective effects of intralipid in the absence of nitrate appear to corroborate previous 
observations. In this study it was used primarily to mimic a physiological mixture of circulating non-
esterified fatty acids and to ensure any effects of nitrate supplementation upon FAO were not missed, 
yet several studies have reported that presence of intralipid in the reperfusion buffer or infusion in 
vivo is cardioprotective (Li et al., 2013; Lou et al., 2014b, 2014a; Mamou et al., 2015; Rahman et al., 
2012). 
Lou et al (2014) suggest that intralipid acts through the inhibition of ETC complex IV, decreasing O2 
consumption; while the findings in this chapter support the observation that intralipid is 
cardioprotective (at least in the absence of nitrate), they differ to this in observing no intralipid 
mediated loss of total respiratory capacity, which would be visible if complex IV functionality was 
impaired. Instead, intralipid enhanced loss of complex I function following reperfusion, which could 
be a potentially cardioprotective mechanism given that complex I inhibition with amytal has previously 
been reported to result in decreased ROS production during ischaemia and improved functional 
recovery following reperfusion (Aldakkak et al., 2008). Intralipid also decreased coupling of the 
mitochondria, possibly due to FAO having been shown to be associated with uncoupling of the 
mitochondria (Cole et al., 2011).      
It is also possible that, if as suggested intralipid confers cardioprotection through ROS mediated effects 
(Lou et al., 2014a), this pathway may be blocked by the antioxidant properties of nitrate. Since it 
appears here that dietary nitrate supplementation reduces several markers of oxidative stress which 
accumulate following reperfusion, it is possible that dietary nitrate supplementation abrogates any 
intralipid stimulated ROS signalling. Nitrate supplementation has also been reported to reduce 
oxidative stress in several other publications (Ashmore et al. 2014; Hendgen-Cotta et al. 2012; Monaco 
et al. 2018; Jeddi et al. 2016), which lends credence to the concept that this could be an interference 
between two ROS-related signalling pathways. 




The main mechanistic story from this chapter appears to be one of cardiac metabolic substrate 
utilisation. The enhanced production of the metabolic by-product malonyl-CoA upon reperfusion 
suggests that intralipid is enhancing substrate oxidation. It is thought that this increased oxidation of 
triglycerides inhibits PDH via the Randle cycle (Hue et al., 2009; Randle et al., 1963), which would tally 
with the increased accumulation of alanine seen here and by Taegtmeyer et al. (1977), suggesting an 
inhibition of complete glucose oxidation. Many studies have previously suggested that fatty acids are 
the preferred metabolic substrate upon reperfusion when available (Liedtke et al., 1988; Lopaschuk 
et al., 2009; Nellis et al., 1991), and these findings support that notion. That this should be protective 
is perhaps more controversial, with extensive literature claiming that ischaemic oxidation of fatty acids 
is pathological (Fillmore et al., 2014; Jaswal et al., 2011; Lopaschuk et al., 2009). The evidence in this 
chapter appears to refute this assertion, offering a different aspect upon the debate. It is also possible 
that this is a result of the heart performing better when intralipid is in the buffer simply because it has 
more available substrate than when perfused with glucose alone, and this helps it restore its ischaemic 
ATP debt. 
Perhaps the most interesting substrate level finding in this study is the detection of β-hydroxybutyrate 
production during ischaemia. The ketone body was observed both being excreted from the heart in 
the coronary effluent, and accumulating in the ischaemic myocardium, yet since it was not present in 
the buffer being delivered to the heart must be generated in the heart during ischaemia. This is 
interesting because ketogenesis is primarily considered to occur in the liver (Cotter et al., 2014), and 
while the heart is known to consume ketone bodies as an metabolic fuel (Aubert et al., 2016; Sato et 
al., 1995), it has never previously been reported that β-hydroxybutyrate is generated in the heart, 
except from when ETC complex I was inhibited using amytal (Krebs et al., 1961). In the ischaemic 
myocardium β-hydroxybutyrate accumulated to the greatest levels in the nitrate supplemented 
groups, in the coronary effluent however it was secreted to the highest level by hearts in the 
chloride/intralipid group, which also recovered LVDP to the greatest extent post-reperfusion. It could 
therefore be possible that generation and excretion of β-hydroxybutyrate during ischaemia is 
beneficial to recovery, a phenomenon which warrants further investigation in order to better 
determine what is driving it to occur. 
4.4.3 Future Directions 
With the conflicting results generated here it is unclear whether dietary nitrate supplementation 
would protect against ischaemia or impair recovery. However, in vivo it may yet prove to be protective, 
given nitrate has more systemic effects including  improvement of vascularisation (Hendgen-Cotta et 
al., 2012; Webb et al., 2008). It would be interesting in the future to see a real time investigation of 




the effects of nitrate/nitrite upon ROS release during ischaemia reperfusion perhaps using fluorescent 
markers of these compounds, and it would also be interesting to see a proteomic study which 
measured protein nitrosothiols formed as a result of dietary nitrate supplementation, as this would 
give an indication of which metabolic and signalling pathways it had an effect upon. 
The implications for intralipid as a possible mediator of cardioprotection appear more conclusive. FAO 
has been painted as a villain during ischaemia/reperfusion (Lopaschuk et al., 2010), yet including this 
chapter a growing amount of evidence points to it having a positive role in recovery of function upon 
reperfusion (King et al., 2001; Lou et al., 2014c, 2014a; Rahman et al., 2012). Intralipid perfusion is 
already routinely used for restoring blood triglyceride content in those with deficiencies, so is safe 
clinically and could be easily administered upon presentation with the symptoms clinically given that 
its proposed signalling effects come post-reperfusion (Lou et al., 2014a). One possible future avenue 
for exploration would be to investigate whether the apparent protective effects of intralipid were due 
to preferential trigyceride oxidation during or after ischaemia, perhaps using isotopic labelling or 
hyperpolarised MRI techniques. It would also be interesting to run a dose-response experiment where 
the concentration of intralipid in the buffer was varied, as this would elucidate whether the protective 
effects seen during this chapter were concentration dependent.
CHAPTER 5 
 
Ketogenesis in the Ischaemic Heart 
  





BACKGROUND The enzymes that catalyse ketogenesis – a pathway thought to occur only in the liver 
when fat oxidation exceeds demand – are also present in the heart. In the previous chapter, I found 
that β-hydroxybutyrate (β-OHB) accumulated in the Langendorff-perfused rat heart during low-flow 
ischaemia, and hypothesised that altered redox state and acetyl-CoA accumulation during ischaemia 
could drive cardiac ketogenesis.  
OBJECTIVES This chapter aimed to investigate ketogenesis in the ischaemic rat heart and the 
underlying mechanism.    
METHODS Hearts were perfused in the Langendorff mode (100 mmHg, 32 min) before 20 min low-
flow ischaemia (0.58 ml.min-1gww-1) and 20 min reperfusion, with some hearts snap-frozen after each 
stage. 13C-labelled glucose or triglyceride were used to determine the source of metabolites, with 
frozen myocardium analysed using LC-MS. In subsequent experiments, hearts were subjected to 32 
min of ischaemia (0.3 ml.min-1gww-1) and 32 min reperfusion, in order to investigate a mechanism. 
Initially, the NAD precursor NMN (nicotinamide mononucleotide, 200 µM) was added to alter redox 
balance. Next, the LDH inhibitor oxamate (50 mM) was added to enhance acetyl-CoA availability. 
Finally, hymeglusin (1 µM), an inhibitor of HMG-CoA synthase, was added to directly inhibit the 
ketogenic pathway.  
RESULTS β-hydroxybutyrate (β-OHB) accumulated in the ischaemic heart to 0.5 mol/g (p<0.01), and 
was secreted into coronary effluent. Acetyl-CoA derived from fat and glucose oxidation contributed 
equally to β-OHB synthesis. NMN increased β-OHB levels by 37% (p<0.01), with no change in NAD, 
suggesting a role for altered NAD/NADH. Oxamate increased β-OHB levels 7-fold (p<0.001) and slowed 
the recovery of contractile function post-ischaemia. Inhibition of ketogenesis with hymeglusin 
resulted in a 33% greater recovery of contractile function post-ischaemia compared with controls. 
CONCLUSIONS Ketogenesis occurs in the ischaemic rat heart and is associated with worsened 
functional recovery upon reperfusion.  





In Chapter 4, I found that the ketone body β-hydroxybutyrate was present in both the coronary 
effluent and LV tissue from the ischaemic heart, yet not that from the aerobically perfused heart. This 
raised interesting questions: Is the β-hydroxybutyrate being produced in the heart, what is the 
metabolic mechanism which underlies this, and how beneficial or detrimental is the process to 
recovery of cardiac function following reperfusion? 
5.1.1 Ketogenesis 
Canonically, β-hydroxybutyrate is thought to be synthesised and secreted predominantly by the liver. 
It has only previously been documented to occur in cardiac tissue following pharmacological inhibition 
of complex I by sodium amytal (Krebs et al., 1961). The process of synthesising ketone bodies, which 
include acetoacetate, acetone and β-hydroxybutyrate, is called ketogenesis. This is commonly thought 
to occur in liver mitochondria when β-oxidation of fats exceeds mitochondrial demand for oxidation 
(McGarry and Foster, 1976). The excess acetyl-CoA produced is amalgamated into acetoacetyl-CoA, β-
Hydroxy β-methylglutaryl-CoA (HMG-CoA) and then acetoacetate, which can be further reduced to β-
hydroxybutyrate (Figure 5.1).  
Figure 5.1: Ketogenesis and Ketolysis. Acetyl-CoA is converted to acetoacetyl-CoA, β-Hydroxy β-
methylglutaryl-CoA (HMG-CoA), Acetoacetate and β-hydroxybutyrate in a series of reversible 
reactions. The enzymes which catalyse this are HMG-CoA synthase, HMG-CoA lyase, and β-
hydroxybutyrate dehydrogenase (BDH1). HMG-CoA can be bypassed when conversion of 
acetoacetate to acetoacetyl-CoA is combined with succinyl-CoA to succinate by the enzyme 
succinyl-CoA-3-oxaloacid CoA transferase (SCOT). 




Despite not being thought of as a ketone-producing organ, the requisite enzymes are present in the 
heart (Cook et al., 2017); yet net ketogenesis has not been shown to occur without artificial 
stimulation. In the perfused rat heart, 14C label originating from palmitate is incorporated into β-
hydroxybutyrate despite no net ketogenesis (Fink et al., 1988), in a process the researchers termed 
pseudoketogenesis. This demonstrates that the enzyme pathway is present and active even if there is 
not a clearly observed function.  
5.1.2 Ketogenesis Could be Favoured by Reductive Ischaemic Conditions  
It has however been demonstrated that ketogenesis can be activated in the heart if the conditions are 
manipulated in the right way. In the 1960s, Krebs et al observed ketone synthesis in heart homogenate 
following the addition of several substrates, including the ETC complex I inhibitor sodium amytal 
(Krebs et al., 1961). They linked this to probable levels of NADH, which normally transfers electrons 
from the Krebs cycle to complex I, a process inhibited by sodium amytal. NADH is also involved in the 
reduction of acetoacetate to β-hydroxybutyrate, and so increased concentrations could underpin 
sodium amytal-driven cardiac ketogenesis. Crucially, rate of electron flux through the ETC is also 
depressed during ischaemia due to low oxygen availability, and as such this could present an 
analogous environment to the one generated by complex I inhibition. 
The heart is also found to accrue late-Krebs cycle intermediates, including succinate, at the expense 
of early intermediates during ischaemia and hypoxia (Bittl and Shine, 1983; Folbergrová et al., 1974; 
Hohl et al., 1987; Sato et al., 1995), and this could help drive ketogenesis. Succinyl-CoA-3-oxaloacid 
CoA transferase (SCOT), the enzyme thought to be primarily responsible for ketone body utilisation in 
the heart, converts acetoacetate and succinyl-CoA to acetoacetyl-CoA and succinate (Dedkova and 
Blatter, 2014). The presence of excess succinate during ischaemia could favour the reverse reaction 
of the reaction, with the concentration gradient forcing the production of acetoacetate and β-
hydroxybutyrate. This would appear to be supported by observations that the stimulated reduction 
of acetoacetate to β-hydroxybutyrate occurs at its optimal rate only in the presence of succinate 
(Krebs et al., 1961; Schönfeld et al., 2010), further suggesting that the ischaemic heart might present 
an environment conducive to ketogenesis.    
5.1.3 Link to Fat Oxidation 
Ketogenesis in the liver is considered to be inextricably linked to fat oxidation (Cook et al., 1978). 
Oxidation of fatty acids produces around 2.4 times more ATP per gram of substrate than glucose 
oxidation (Darvey, 1998), and is therefore a major source of energy. However, some organs, including 
the brain, cannot take up and oxidise fatty acids for energy (Schönfeld and Reiser, 2013; Zhao et al., 




2015). This is circumvented by the liver converting fatty acids into circulating ketone bodies, which 
may be transported across the blood brain barrier by the monocarboxylic acid carrier and are 
consumed preferentially by several organs including the heart (McGarry and Foster, 1976; Veech, 
2004). 
It therefore would appear to follow that if there is cardiac ketogenesis occurring during ischaemia, it 
may result from FAO exceeding cardiac mitochondrial oxidation capacity under these conditions. It 
has been argued that FAO is pathologically stimulated by activation of AMP-activated protein kinase 
(AMPK) during ischaemia, which leads to a decrease in malonyl-CoA, an inhibitor of mitochondrial fat 
uptake via CPT-1 (Lopaschuk et al., 2009). This increase in FAO coupled with cessation of oxidative 
phosphorylation during ischaemia could lead to fat oxidation exceeding the mitochondrial capacity to 
utilise the resulting acetyl-CoA; analogous conditions to that of β-hydroxybutyrate production in the 
liver. 
Oxidation of fatty acids in the heart has been linked to improved recovery from ischaemia/reperfusion 
as documented in Chapter 4 and in other studies (King et al., 2001; Li et al., 2013).  It is possible that 
this could be in part be facilitated by an increased production of β-hydroxybutyrate, which may be 
available upon reperfusion. 
However, a confounding factor to this theory is that β-hydroxybutyrate has been shown to inhibit 
cardiac fatty acid oxidation. Independently of malonyl-CoA, β-hydroxybutyrate administration 
suppressed oxidation of fatty acids in the pig heart in vivo, even following infusion of a fat emulsion 
(Stanley et al., 2003). If FAO is inhibited by β-hydroxybutyrate and FAO is considered protective, then 
there is also an argument to be made that presence of β-hydroxybutyrate may be damaging during 
ischaemia and/or reperfusion.  
5.1.4 Oxidation of β-hydroxybutyrate in the Heart 
Unstimulated ketogenesis may be as yet unreported in the heart, but oxidation of β-hydroxybutyrate 
is well documented and has several beneficial effects upon the function of the healthy heart. In the 
working heart, its administration increases cardiac oxygen efficiency both by itself and in combination 
with insulin (Sato et al., 1995). ATP yielded from β-hydroxybutyrate oxidation is thought to have a 
greater ΔG’ATP than ATP produced from the metabolism of different metabolic substrates due to it 
being a more oxygen efficient fuel (Lammerant et al., 1985; Veech, 2004).  
It is perhaps for these reasons that β-hydroxybutyrate is thought to be taken up and oxidised 
preferentially over glucose in heart tissue (Gormsen et al., 2017).  This could also be explained through 




its action to inhibit glycolysis (Kashiwaya et al., 1994), which allows it to come to predominate 
oxidation in the heart and effectively occupy a dominant position in the Randle cycle.  
β-hydroxybutyrate has also been recently documented to be consumed preferentially during heart 
failure. Aubert et al (2016) observed increased expression of β-hydroxybutyrate dehydrogenase 
(BDH1) and increased oxidation of β-hydroxybutyrate in a transverse aortic constriction and infarcted 
mouse model of heart failure, although it should be noted that BDH1 is a bi-directional enzyme and 
since they were administering β-hydroxybutyrate this does not conclusively prove whether 
ketogenesis or ketolysis is occurring in vivo. In human patients with type 2 diabetes , inhibition of 
glucose reuptake in the kidney resulted in increased levels of β-hydroxybutyrate and almost a 40% 
decrease in mortality rate (Ferrannini et al., 2016). Further, increased rates of β-hydroxybutyrate 
oxidation and increased SCOT expression were seen in the left ventricle of humans with advanced 
stage heart failure (Bedi et al., 2016). Taken together, this suggests β-hydroxybutyrate oxidation finds 
favour in the failing heart, where myocardial blood supply is insufficient to support its own 
requirements. 
5.1.5 A Cardioprotective Role for β-hydroxybutyrate? 
Whilst the presence of β-hydroxybutyrate has been shown to increase cardiac efficiency and function, 
there is no consensus on its effects upon recovery from ischaemia. King et al. (2001) claim that while 
free fatty acids are beneficial, β-hydroxybutyrate itself does not augment recovery from ischaemia, 
and this is supported to an extent by the work of Goodwin and Taegtmeyer (1994), which 
demonstrated no cardioprotective effect upon rats fed a control diet. However, Goodwin and 
Taegtmeyer do note a cardioprotective effect when the rats have been fasted, a result corroborated 
by Zou et al. (2002). A separate study observed a beneficial effect of β-hydroxybutyrate on recovery 
of contractile function only in rats fed a high fat-low-carbohydrate diet and not in controls (Liu et al., 
2016). Fasting increases the expression of enzymes for ketone body oxidation (Grabacka et al., 2016; 
Wentz et al., 2010), while the high fat-low-carbohydrate diet increases HMGCS2 expression, so it is 
possible that any beneficial effects of β-hydroxybutyrate upon functional recovery are only visible 
when there is a greater capacity for, or dependency upon, its oxidation. Cumulatively this evidence 
suggests that metabolic state and ratios of metabolic substrates help to determine the role of β-
hydroxybutyrate in the heart. 
.   
 
 




5.1.6 Signalling roles of β-hydroxybutyrate 
β-hydroxybutyrate has emerged as a signalling molecule involved in the response to oxidative stress 
in recent years. Administration of β-hydroxybutyrate was shown to inhibit histone deacetylases, 
enhancing production of acetylation stimulated genes FOXO3a and MT2, which have antioxidative 
properties (Newman and Verdin, 2017; Newman et al., 2015; Shimazu et al., 2013). β-hydroxybutyrate 
is also a ligand for both the nicotinic acid receptor HCAR2 and free fatty acid receptor 3 (FFAR3) 
(Newman et al., 2015). As well as limiting lipolysis, HCAR2 modulates macrophage function, while 
FFAR3 has suppressive effects upon heart rate and overall sympathetic tone. It therefore seems 
plausible that the production of β-hydroxybutyrate during ischaemia could represent an antioxidant 
and damage limiting response.  
 
5.1.7 Objectives 
The objective of this chapter was to investigate the mechanisms underlying the ischaemic 
accumulation of β-hydroxybutyrate seen in Chapter 4, and whether it has any implications for 
recovery from ischaemia/reperfusion.  
  





Male Wistar rats (300-350 g) were obtained from a commercial breeder (Charles River, UK) and pair-
housed in a temperature (21°C), humidity (46%) and light (12 h/12 h light/dark cycle) controlled 
environment. A standard diet RM1P (65% carbohydrates, 14% crude protein, 3% crude protein, 3% 
fatty acids, Special Diets Services, UK) and water were provided ad libitum. 
 
All procedures involving live animals were carried out by a licence holder in accordance with UK Home 
Office regulations, and underwent review by the University of Cambridge Animal Welfare and Ethical 
Review Committee. 
 
5.2.1 Isolated Heart Perfusion 
Rats were anaesthetised and terminated by use of rising CO2 levels and cervical dislocation. Hearts 
were immediately excised into ice cold KH buffer, and perfused on the Langendorff rig as described in 
Chapter 2 (2.1).  
 
Protocol for the Initial Assessment of Ischaemic Ketogenesis 
All hearts were perfused for 32 min at a constant pressure of 100 mmHg following an initial 
acclimatisation period. Following this, the protocol was terminated for the first group (termed pre-
ischaemic), while the second (ischaemic) and third (reperfused) groups were progressed to a period 
of low flow ischaemia at a flow rate of 0.56 ml.min-1gww-1 for 20 min. Only the third group underwent 
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This ischaemic flow rate was chosen because it resulted in 100% recovery of function following 
reperfusion at 100mmHg; the intention of this was to establish that any alterations to metabolism and 
ketogenesis which were observed would be due to the ischaemic conditions and not due to functional 
damage caused to the tissue. 
The perfusion medium was 250 mL of recirculated KH buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM 
MgSO4, 1.3 mM CaCl2, 0.5mM EDTA, 25 mM NaHCO3, 1.2 mM KH2PO4; pH 7.4) containing 8.25 mM 
glucose, 2.75 mM U-13C labelled glucose (Cambridge Isotopes Ltd) and 0.4 mM equivalent intralipid 
(n=7 for each of the reperfused, ischaemic and pre-ischaemic groups).  
Following the end of the perfusion protocol, the left ventricle was rapidly sectioned in transverse and 
snap frozen with the exception of ~10 mg which was placed on ice-cold biopsy preservation solution 
(BIOPS) before being permeabilised for respirometry.  
 
Further groups were perfused in the absence of intralipid where A) the NAD+ precursor nicotinamide 
mononucleotide (NMN; 200 µM) was added to the buffer at the beginning of the protocol and B) the 
LDH inhibitor sodium oxamate (50mM) were added to the perfusion buffer 12 min before the 
induction of the 20 min low flow ischaemic period. These hearts were sectioned and snap frozen, 
along with controls where the compound was not added, at the end of the ischaemic period. 
 
Protocol for the Assessment of Impact upon Recovery of Function Post-Reperfusion   
A second perfusion protocol was employed in order to investigate the impact of ketogenesis on 
functional recovery from ischaemia/reperfusion. Hearts were perfused at 100 mmHg for 32 min 
following an acclimatisation period, before being subjected to 32 min of 0.3 ml.min-1gww-1 low flow 
ischaemia. This flow rate was chosen because it resulted in 65% recovery of pre-ischaemic function in 
pilot studies, therefore allowing scope for treatments to either improve or further impair contractile 
recovery. A reperfusion period was then initialised whereby 100 mmHg perfusion was restored for 32 
min. 80 µg/ml hymeglusin in 80 µl DMSO vector (n=5), 80 µl DMSO vehicle injection (n=5) or 50 mM 
sodium oxamate (n=5) were added to the perfusion buffer 12 min before the ischaemic period in their 
respective groups, while a control group (n=5) with no additions was performed for comparison with 
the sodium oxamate group. The perfusion medium was 250 mL of recirculated KH buffer (118 mM 
NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.3 mM CaCl2, 0.5 mM EDTA, 25 mM NaHCO3, 1.2 mM KH2PO4; pH 
7.4) containing 11 mM glucose, gassed with 95% O2 and 5% CO2. The hearts were sectioned and frozen 
following the end of the reperfusion period for future analysis. 




For all groups, samples of coronary effluent were taken every four minutes and immediately frozen.  
 
 
5.2.2 High-Resolution Respirometry 
Permeabilision of LV fibres and measurement of respiration rates was conducted as described in 
Chapter 2 (Section 2.2). The ratio of fatty acid oxidation preference (FAO) was calculated by dividing 
the octanoyl carnitine supported oxphos rate by the octanoyl carnitine plus pyruvate supported 
oxphos rate. The respiratory control ratio (RCR) was calculated as an indicator of mitochondrial 
coupling by dividing the rate of oxygen consumption supported by malate and octanoyl carnitine in 
the oxphos state by that supported by the same substrates in the leak state. 
 
5.2.3 Measurement of Metabolite Levels Using Liquid Chromatography-Coupled 
Mass Spectrometry (LC-MS/MS and LC-MS) 
Metabolites were extracted from frozen left ventricle using a Bligh-Dyer method as described in 
Chapter 2 (2.3.2). Levels of metabolites (Krebs cycle intermediates, amino acids and malonyl-CoA) 
were assessed using the C18pfp chromatography method coupled to the Thermo Quantiva, while 
levels of β-hydroxybutyrate and lactate were assessed using the C18pfp method coupled to the 
Thermo Elite, all as described in sections 2.3.3 and 2.3.4. 
Coronary effluent samples (20 µl plus 80 µl 10 mM ammonium acetate/internal standard mix) were 
also analysed for β-hydroxybutyrate using the c18pfp chromatography method coupled to the Thermo 
Elite. 
 
5.2.4 Measurement of Cardiac Triolein Uptake Using LC-MS 
For measurement of the rate of cardiac triolein consumption, buffer samples collected before and 
after the heart were extracted using the tissue extraction method described in Chapter 2 (2.3.2). 
Metabolites were reconstituted in a small volume of methanol/chloroform (1:1) and then diluted into 
isopropyl alcohol/acetonitrile/water (2:1:1), with a dilution of 1 in 10. 
Chromatography parameters 




5 µL of sample was injected onto a C18 CSH column, 75 µM x 100 mm (Thermo Scientific), which was 
maintained at 55°C within an Ultimate 3000 UHPLC system (Thermo Scientific). The mobile phase 
comprised of solvents A (acetonitrile/water 60:40, plus 10 mM ammonium formate) and B 
(acetonitrile/isopropanol 10:90, plus 10 mM ammonium formate). Total run time was 20 minutes, 
with a flow rate of 0.400 µL/min. The initial proportion of solvent B in the run buffer was 40%, which 
was incrementally increased to 43% after 2 min, 50% at 2.1 min, 54% at 12 min, 70% at 12.1 min and 
99% at 18 min, at which point it was returned to 40% for 2 min.  
Mass spectrometry parameters 
Mass spectrometry was then carried out using the Orbitrap Elite Mass Spectrometer (Thermo 
Scientific) in positive mode. Metabolites were ionised by heated electrospray before entering the 
spectrometer. The source temperature was set to 420 °C, and the capillary temperature to 380 °C. The 
full scan was performed across an m/z range of 110-2000. 
Data processing using R 
For processing, spectra were converted from Xcalibur .raw files into .mzML files using MS Convert 
(Proteowizard) for analysis by XCMS within R studio. XCMS software was used to process data and 
identify peaks. Peaks were annotated by accurate mass, using an automated R script and comparison 
to the LipidMaps database. Intensity was normalised to internal standards. Cardiac triolein uptake at 
each time point was calculated by subtracting the concentration of triolein in the coronary effluent 
from that in the reservoir. 
 
5.2.5 Caspase-1 Activity Assay and ELISA for IL-1β  
Preparation of Tissue Homogenates 
Approximately 10 mg of frozen LV from each of the ischaemic hymeglusin-treated and control hearts 
was homogenised with an Eppendorf pestle in an Eppendorf tube containing 300 μl of ice cold 
homogenisation buffer 2 (Appendix V). The samples were then centrifuged (380 × g, 30 s, 4°C) and 
supernatant was collected. This was then centrifuged for a second time (380 × g, 30 s, 4°C) and the 
supernatant collected to obtain a homogeneous suspension. 
Protein Quantification 
Protein concentration of chamber and tissue homogenates was measured using the Quick Start 
Bradford protein assay (Bio Rad) with a standard curve of a range of concentrations (8 standards from 




0 to 2 mg ml-1 in triplicate) of bovine serum albumin (BSA). The assay works on the principle that 
Coomassie Blue is deprotonated in the presence of proteins, leading to a detectable colour change 
with maximal absorbance at 595 nm. A 5 μl volume of homogenates diluted 25 and 50 × in 
homogenisation buffer was added in triplicate to a 96-well microplate. Bradford reagent (200 μl) was 
added to all standards and samples and incubated at room temperature for 5 min. Absorbance at a 
wavelength of 595 nm was then quantified using a microplate reader (ELx800, BioTek). Sample protein 
concentrations were then calculated using the equation generated from the linear line of best fit 
through the readings from the standard curve. 
Caspase-1 Activity Assay 
Caspase-1 activity was quantified using a Caspase-1 Activity Assay kit (BioVision Incorporated, US). 
Briefly, 150µg of tissue lysate was resuspended in 50 µl cell lysis buffer and combined with 50 µl 2X 
reaction buffer (containing 10mM DTT) and 200 µM YVAD-pNA substrate before a 1.5hr incubation at 
37°C. Absorbance at a wavelength of 405 nm was then quantified using a microplate reader (ELx800, 
BioTek). 
ELISA for Il-1β 
Il-1β concentration was determined using an ELISA kit (Cloud Clone Corp) according to the 











5.2.6 Presentation and Statistics 
Where relevant, results are presented as mean ± SEM and Student’s T-test was employed to 
determine statistical significance of differences relative to levels of respiration or metabolites either 
pre-ischaemia or in the control group. Significance was denoted as * p < 0.05, ** p < 0.01, *** p < 
0.001.  
For levels of metabolites in the coronary effluent, significance relative to control is denoted on the 
graph at each time point where there is significance.  
For cardiac function, T-test significance was calculated for the mean LVDP or RPP over a four minute 
period, and the four minute periods where a significant difference was detected were then denoted 
on the graph by 
















5.3.1 Contractile Function 
Cardiac contractile function was fully recovered following reperfusion at 100 mmHg from the 20 min 
0.56 ml.min-1gww-1 ischaemic period (Figure 5.3). Both LVDP and RPP re-attained pre-ischaemic levels 
of function following reperfusion, and maintained this for the full 20 min reperfusion time. 
Table 5.1: Pre-Ischaemic Cardiac Function  
 
   
LVDP (mmHg) Heart Rate (bpm) RPP (mmHg.min) 




























Figure 5.3: Cardiac Contractile Function. Left Ventricular Developed Pressure (LVDP) and Rate 
Pressure Product (RPP) in hearts subjected to a 20 min 0.56 ml.min-1gww-1 ischaemic period then 
reperfused at 100 mmHg for 20 min following an initial 32 min pre-ischaemic perfusion period. 
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5.3.2 Ketone Accumulation 
The ketone body β-hydroxybutyrate accumulated in the ischaemic myocardium, despite being at a 
negligible concentration pre-ischaemia (Figure 5.4A). Following 20 min reperfusion, levels dropped to 
just over the pre-ischaemic concentration, suggesting that the accumulated β-hydroxybutyrate was 
either metabolised or lost from the tissue following restoration of oxygen supply. 
β-hydroxybutyrate was produced to such levels that it was also detectable in the coronary effluent 
(Figure 5.4B). During the ischaemic period (32-52 min), the concentration of β-hydroxybutyrate in the 
coronary effluent was dramatically raised, and continued to increase as the ischaemic period 
progressed, before returning rapidly to pre-ischaemic levels post-reperfusion.  
Figure 5.4: Concentrations of β-hydroxybutyrate in rat heart (A), and in the coronary effluent (B). 



































































5.3.3 Mitochondrial Function 
To determine whether damage to the electron transport chain or a change in substrate oxidation 
preference during ischaemia may contribute to cardiac ketogenesis, high-resolution respirometry was 
employed (Figure 5.5A).  
Complex I supported respiration was broadly conserved across the 20 min period of 0.56 ml.min-1gww-
1 ischaemia, with significant reduction of oxygen consumption visible only following a subsequent 20 
min reperfusion at 100 mmHg. 
Meanwhile, complex II supported respiration was significantly decreased (p<0.01) following the 
ischaemic period, with a further reduction in capacity following reperfusion (p<0.001).  
The FAO ratio was 6% lower in the ischaemic group compared to control (p<0.05, Figure 5.5 B), while 
the RCR was not significantly different between the groups (Figure 5.5 C) 
  






























Figure 5.5: Respiration rates corrected for wet mass (A). Malate and octanoyl carnitine were added 
initially to stimulate leak respiration, ADP to stimulate β-oxidation supported Oxphos, glutamate 
to saturate complex I, cytochrome c as a test of membrane integrity, succinate to activate complex 
II, and rotenone to inhibit complex I. The ratio between octanoyl carnitine and octanoyl carnitine 
plus pyruvate-supported respiration (FAO) as a marker of preference for fatty acid oxidation (B); 
respiratory control ratio (RCR) (C). All displayed as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 
















































5.3.4 Cardiac and Mitochondrial Fat Uptake  
In order to further investigate whether the lower FAO preference seen in the ischaemic and post-
ischaemic groups was reflected by rates of cardiac triglyceride uptake, the rate of triglyceride uptake 
from the buffer and the tissue concentration of malonyl-CoA (which inhibits uptake of acyl-carnitines 
to the mitochondria) were measured, using LC-MS and LC-MS/MS respectively. 
Cardiac uptake of triolein (the predominant component of intralipid) from the perfusion buffer was 
almost completely ablated during the ischaemic period (Figure 5.6). Whilst it was partially restored 
following reperfusion, triolein uptake reached only 28.7% of its pre-ischaemic rates. 
Myocardial malonyl-CoA concentrations were 2.3-fold higher in the ischaemic heart relative to pre-
ischaemia (p<0.01, Figure 5.7). This may limit mitochondrial acyl-carnitine uptake and therefore β-
oxidation, and is in contrast to previous suggestions of a drop in levels, which are thought to underpin 
increased fat oxidation in ischaemia.   
Figure 5.7: Concentration of malonyl-CoA in heart tissue displayed as mean ± SEM. ** p < 0.01 
relative to pre-ischaemic levels.  




























































5.3.5 The Krebs Cycle in the Ischaemic Heart 
Ketogenesis has been linked to the presence of key Krebs cycle intermediates, including succinate. To 
investigate whether this might correspond to a mechanism for ketogenesis, cardiac concentrations of 
Krebs cycle intermediates were measured (Figure 5.8), as well as their isotopic distributions to 
determine whether the proportion of triglyceride or glucose oxidation increased during ischaemia. 
Levels of early-cycle Krebs cycle intermediates (citrate and isocitrate) were depleted relative to pre-
ischaemia at the end of the ischaemic period (both p<0.05).   
In contrast, concentrations of malate were 1.4-fold higher than their pre-ischaemic concentration 
(p<0.05), and those of succinate increased 4.5 fold (p<0.001). Upon reperfusion, concentrations of all 
Krebs cycle intermediates were found to have returned towards pre-ischaemic levels.  
Figure 5.8: Concentrations of Krebs cycle intermediates (units, corrected for tissue mass) displayed 






































5.3.6 Krebs Cycle Intermediate Isotopologue Distributions 
The isotopic distributions of the Krebs cycle intermediates when 25% of the glucose supplied in the 
perfusion buffer was U13C labelled did not change between the pre-ischaemic, ischaemic and post-
ischaemic myocardium. The implication of this is that the proportion of oxidised acetyl-CoA stemming 






















Figure 5.9: Isotopologue distributions of Succinate, Glutamate and Malate in pre-ischaemic, 
ischaemic and post-ischaemic hearts. Displayed as mean ± SEM.  
Pre-Ischaemic Ischaemic Post-Reperfusion 
Pre-Ischaemic Ischaemic Post-Reperfusion 
Pre-Ischaemic Ischaemic Post-Reperfusion 




5.3.7 α Values Before, During and After Ischaemia 
Values for α, the proportion of acetyl-CoA entering the Krebs cycle, were calculated from the 
isotopologue distributions of Succinate, Glutamate and Malate (Figure 5.9) by use of the model 
outlined in Chapter 3 (Table 5.2). These values further support the conclusion that there was no 
change in the percentage contribution of glucose to the acetyl-CoA oxidised during ischaemia relative 
to pre-ischaemic or post-ischaemic conditions.  
 
Table 5.2: α values Calculated for the Pre-Ischaemic, Ischaemic and Post-Ischaemic Myocardium 
 Pre-Ischaemic Ischaemic Post-Ischaemic 
α 0.145±0.009 0.142±0.005 0.143±0.008 
   




5.3.8 Labelling of β-hydroxybutyrate  
When 25% of the glucose delivered in the perfusion buffer was U13C labelled, ~28% of the total β-
hydroxybutyrate concentration in the ischaemic heart tissue was U13C labelled (Figure 5.10). This 
meant 13.8% of the acetyl-CoA monomers incorporated into β-hydroxybutyrate were amu 2+ labelled 
with 13C  (Figure 5.11), a value which closely corresponds to the value for α of 0.145±0.009 obtained 
from the Krebs cycle intermediate labelling data. This suggests that there is no greater contribution 
from either glycolysis or FAO towards ketogenesis, but rather that the process incorporates acetyl-

















































































Proportion of Acetyl-CoA Isotopologues 
Incorporated into Ischaemic β-hydroxybutyrate
Figure 5.10: Isotopologue distribution of β-hydroxybutyrate in pre-ischaemic, ischaemic and post-
ischaemic hearts. Displayed as mean ± SEM.  
Figure 5.11: Proportional incorporation of unlabelled and m/z+2 isotopologues of acetyl-CoA into β-
hydroxybutyrate during ischaemia. Displayed as mean ± SEM.  





Alanine -> Aspartate -> Succinate? 
Previous studies have suggested a shuttle between aspartate and succinate as a source of the 
succinate accumulation during ischaemia, bypassing the early part of the Krebs cycle (Chouchani et 
al., 2014; Drake et al., 2013). Alanine, which may be converted to aspartate, is elevated in the 
ischaemic heart, and offers a possible source of carbon flux to the Krebs cycle through aspartate 
(Sookoian and Pirola, 2012). However, the isotopic distribution of aspartate did not vary in ischaemia 
(Figure 5.12). Nor did it align with that of alanine, which is a glycolytic product of pyruvate and 
therefore ~75% unlabelled, 25% U13C labelled in line with the glucose intake. Aspartate displayed a 
higher concentration of 1+ labelling, a distribution which also did not match that of succinate (Figure 
5.9), suggesting a limited role for both alanine -> aspartate and aspartate -> succinate fluxes in either 


























Figure 5.12: Isotopologue distributions of Alanine and Aspartate in pre-ischaemic, ischaemic and 
post-ischaemic hearts. Displayed as mean ± SEM.  




5.3.9 NAD/NADH Levels Influence Rate of Ketogenesis 
Nicotinamide mononucleotide (NMN), an NAD+ precursor shown to boost levels of available NAD in 
the heart, was added to the perfusion buffer 32 min prior to onset of ischaemia. In frozen LV tissue, 
analysed for β-hydroxybutyrate at the end of the ischaemic period using LC-MS, levels were 37% 
higher than in control hearts (Figure 5.13; p<0.01).  This suggests that ketogenesis could be driven by 
the reductive environment during ischaemia, with greater levels of NAD+ resulting in greater 
accumulation of NADH in ischaemia and greater reduction of acetoacetate to β-hydroxybutyrate; 




















































Figure 5.13: Concentration of β-hydroxybutyrate and the ratio of NADH/NAD+ in ischaemic heart 
tissue perfused with and without 200 µM nicotinamide mononucleotide (NMN) relative to control, 





































5.3.10 LDH Inhibition 
Inhibition of LDH Boosts Ketogenesis 
Administration of 50 mM sodium oxamate via the perfusion buffer 12 min before the onset of 
ischaemia led to 5.3-fold greater accumulation of β-hydroxybutyrate following the ischaemic period 
(Figure 5.14). Sodium oxamate is a competitive LDH inhibitor which prevents the diversion of pyruvate 
to lactate, allowing more to be converted to acetyl-CoA. This finding suggests that ischaemic 
















































Figure 5.14: Concentration of β-hydroxybutyrate in ischaemic heart tissue perfused with and 
without 50 mM Sodium Oxamate relative to control, displayed as mean ± SEM. *** p < 
0.001 relative to control.  
*** 




LDH Inhibition Influenced Ischaemic Secretion of Lactate and β-hydroxybutyrate 
During the ischaemic period, hearts given sodium oxamate secreted less lactate into the coronary 
effluent than control hearts (Figure 5.15). Peak secretion of lactate reached only 60% of the levels 
released by the control group (p<0.01), and this rate was not maintained. 
Meanwhile, β-hydroxybutyrate secretion was initially 3.3-fold higher in the oxamate treated group 
(Figure 5.16, p<0.01). This rate of release then dropped away rapidly, while the rate of control group 
































Figure 5.15: Concentrations of lactate in the coronary effluent during the ischaemic period. 
Displayed as mean ± SEM. ** p < 0.01, *** p < 0.001 relative to control. 
 
 
Figure 5.16: Concentrations of β-hydroxybutyrate in the coronary effluent during the ischaemic 







































LDH Inhibition Impaired Cardiac Function 
Following addition of sodium oxamate (50mM) to the perfusion buffer at 20 min, cardiac LVDP and 



































































































50 mM Sodium 
Oxamate Addition 
Figure 5.17: Cardiac Contractile Function. Left Ventricular Developed Pressure (LVDP), Heart Rate 
and Rate Pressure Product (RPP) in hearts subjected to a 32 min 0.3 ml.min-1gww-1 ischaemic 
period before reperfusion at 100 mmHg for 32 min, following an initial 32 min pre-ischaemic 
perfusion period. Sodium oxamate (50mM) was added to the perfusion buffer at 20 min in the 
oxamate group. Results displayed as mean ± SEM 




Impact of LDH Inhibition on Functional Recovery 
Following 32 min reperfusion, control hearts and those given 50 mM sodium oxamate recovered the 
same percentage of their pre-ischaemic LVDP and RPP (both p>0.05, Figure 5.18). However, to recover 
to the LVDP and RPP they displayed at 32 min reperfusion, the sodium oxamate hearts took 13 and 14 
minutes longer than controls (p<0.001 and p<0.01 respectively).    
Figure 5.18: Left-ventricular developed pressure and rate pressure product as a percentage of pre-
ischaemic levels following 32 min 0.3 ml.min-1gww-1 low flow ischaemia, and the time taken to 
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LDH Inhibition Increased Contracture of the Heart During Ischaemia 
During an ischaemic period, hearts undergo contracture due to the loss of ion homeostasis. After being 
in ischaemia for 8 min, hearts given sodium oxamate underwent a sudden contraction with a force of 
76 mmHg, which control hearts did not (p<0.0001). The contracture of the sodium oxamate hearts 
remained greater at the end of the ischaemic period (p<0.001), a fact which may go some way towards 




































Cardiac Contracture During Ischaemia





ischaemia, presented as mean ± SEM. *** p < 0.001, **** p < 0.0001 relative to control. 
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5.3.11 Inhibition of HMG-CoA Synthase with Hymeglusin 
Ketone Accumulation  




low flow ischaemia, the accumulated 
concentration of β-hydroxybutyrate was 32% lower when 80 µg.L-1 of the HMG-CoA Synthase inhibitor 
hymeglusin was added to the perfusion buffer 10 min before the onset of ischaemia (p<0.05, Figure 
5.20). This verified A) that some, though not all, ischaemic ketogenesis was due to flux through HMG-
CoA synthase, and B) that 80 µg.L-1 hymeglusin in the perfusion buffer was sufficient to achieve at least 















































Figure 5.20: Concentration of β-hydroxybutyrate in ischaemic heart tissue perfused with and 
without hymeglusin, relative to control. Displayed as mean ± SEM. * p < 0.05 relative to control.  





Inhibition of HMG-CoA Synthase with hymeglusin resulted in a 23% greater recovery of left ventricular 
developed pressure following 32 min reperfusion at 100 mmHg from 32 min 0.3 ml.min-1gww-1 
ischaemia (Figure 5.21, p<0.05). Recovery of rate pressure product was also 34% greater in the hearts 
administered hymeglusin (p<0.05). Hymeglusin administration had no effect upon pre-ischaemic 
LVDP, heart rate or RPP (Table 5.3).         
                        
Table 5.3: Pre-Ischaemic LVDP, Heart Rate and RPP   
 LVDP (mmHg) Heart Rate (bpm) RPP (mmHg.bpm) 
Control 120.2 ± 14.1 305 ± 15 36900 ± 4800 
Hymeglusin 107.3 ± 7.5 284.9 ± 9.2 29700 ± 3300 
Figure 5.21: Left-ventricular developed pressure as a percentage of pre-ischaemic levels following 




low flow ischaemia, presented as mean ± SEM. * p < 0.05 relative to 
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The Ischaemic Inflammasome 
β-hydroxybutyrate has been demonstrated to inhibit the formation of the inflammasome, a process 
which occurs in the ischaemic heart (Yamanashi et al., 2017; Youm et al., 2015) and has previously 
been reported to be cardioprotective (Sandanger et al., 2016). To determine whether this might be a 
mechanism for the influence of β-hydroxybutyrate upon cardiac recovery from 
ischaemia/reperfusion, the activation of Caspase-1, the end effector of the inflammasome, and the 
concentration of its substrate, IL-1β, were assayed (Figure 5.22). Caspase-1 activity was 1.85 fold 
higher in the hymeglusin treated ischaemic heart relative to control (p<0.05), suggesting that β-
hydroxybutyrate does indeed inhibit the inflammasome. Meanwhile, concentrations of IL-1β were 








































































Figure 5.22: (A) Activity of Caspase-1 and (B) Concentration of IL-1β in ischaemic heart tissue 
perfused with and without hymeglusin, relative to control. Displayed as mean ± SEM. * p < 0.05 









In the rat heart, the ketone body β-hydroxybutyrate accumulates during ischaemia in a process which 
is not specifically linked to FAO. The ischaemic accumulation of β-hydroxybutyrate can be increased 
through inhibition of LDH by sodium oxamate addition, in association with delayed recovery of 
contractile function following reperfusion. Meanwhile, inhibition of HMG-CoA synthase resulted in 
lower ischaemic accumulation of β-hydroxybutyrate, and greater functional recovery following 
reperfusion, suggesting that cardiac ketogenesis could be a detrimental process during ischaemia. 
5.4.1 Strengths and Limitations of the Study 
Use of Langendorff perfusion was a strength of this study which enabled establishment of 
reproducible intensities of ischaemia in which cardiac supply of metabolic substrates could be 
carefully controlled. This was a big advantage in comparison to in vivo studies in which the degree of 
ischaemia is more variable or β-hydroxybutyrate produced and consumed by other tissues would have 
complicated the picture. For example, Bedi et al., (2016), and Aubert et al., (2016) have both 
documented increased BDH1 & 2 expression and β-hydroxybutyrate levels in failing human hearts and 
those of mice with transverse aortic constriction (TAC). However, since these studies were conducted 
in whole organisms the source of the β-hydroxybutyrate was not clear, and it was assumed to be 
coming from the liver since ketogenesis has only previously been documented in the heart following 
pharmacological inhibition of complex I with amytal. Knowing now that ketogenesis can occur in the 
heart, their papers do not exclude the possibility that it may have been cardiac ketogenesis, rather 
than ketolysis, which was occurring. The experiments presented in this chapter have the advantage 
that, with no β-hydroxybutyrate being delivered to the hearts in the perfusion buffer, it can clearly be 
seen that ketogenesis is occurring in the heart.   
It would have been more ideal to be able to investigate the functional implications of ischaemic 
ketogenesis with the use of a more established and better characterised pharmacological agent. 
However, there are no such commercially available compounds with a direct action, and so the more 
experimental compound hymeglusin was employed. Hymeglusin has been developed and used in the 
inhibition of cholesterol synthesis (Le Foll et al., 2014; Greenspan et al., 1987), which shares a common 
enzyme (HMG-CoA synthase) with the ketogenesis pathway, and so was identified as a potential 
inhibitor to investigate ischaemic ketogenesis. Its use here, in concentrations calculated to 
approximate or exceed that which prevented cholesterol synthesis in the aforementioned studies, has 
achieved only partial inhibition of the ketogenesis which occurs during ischaemia. Nonetheless, it has 
succeeded in lowering the amount of β-hydroxybutyrate synthesised during ischaemia, and this was 




enough to see a functional effect upon cardiac recovery. This has been a success in that it has 
suggested that ketogenesis is a detrimental process during cardiac ischaemia, which is potentially 
surprising due to the well documented oxygen-efficient properties of β-hydroxybutyrate as a cardiac 
substrate (Sato et al., 1995; Veech et al., 2001), but perhaps less so when considering that it can form 
poly- β-hydroxybutyrate, which can permeabilise membranes and stabilise the opening of the mtPTP 
(Dedkova and Blatter, 2014; Newman et al., 2015). Unanswered questions are still present due to 
hymeglusin not achieving full inhibition of ketogenesis however: how much of the β-hydroxybutyrate 
synthesis which still occurs stems from flux through HMG-CoA synthase, and might some of it stem 
from other routes such as reverse flux through SCOT? Would total ablation of ischaemic ketogenesis 
have an enhanced protective effect or might some level of ketogenesis be beneficial? It would be good 
to have been able to address these questions through full inhibition of HMG-CoA synthase, as well as 
inhibitors of other ketogenic/ketolytic enzymes such as SCOT, but unfortunately these were not 
commercially available. Knockout models such as the SCOT knockout mice used by Cotter et al., (2013) 
and Schugar et al., (2014) could also be of help in more totally ablating a potential arm of ketogenesis 
to determine its effect upon cardiac recovery; yet it is worth noting that such knockout models may 
also exhibit altered overall metabolism. 
However, while the Langendorff could be used to consistently impose an ischaemic environment, 
when the fresh or frozen ischaemic tissue was used for other analyses these exact conditions could 
not necessarily be maintained. It is possible for example that with the permeabilised fibre 
respirometry some of the oxygen sensitive post-translational modifications which can affect the ETC 
(Papanicolaou et al., 2014) were lost due to the ready availability of oxygen in the Oxygraph chamber. 
Some ischaemic loss of complex II supported respiration was observed, but how much of this was due 
to damage, how much to post-translational modification and how much to alterations we cannot 
visualise because respirometry cannot be conducted in ischaemic conditions will remain unclear. The 
capabilities are not currently available for these experiments, but it would be good in future to be able 
to conduct proteomic analysis of the ETC, Krebs cycle and ketogenic enzymes to see whether post-
translational modifications affect the ketogenic pathway during ischaemia and aid the diversion of 
acetyl-CoA to β-hydroxybutyrate. 
 
5.4.2 Significance of Results 
At the less severe ischaemic flow rate employed in this chapter, cardiac mitochondrial function was 
broadly preserved during the ischaemic period, with ETC damage only sustained upon reperfusion. 
The only complex to show decreased activity at the end of the ischaemic period itself was complex II, 




and this loss of function was still less severe than that seen after reperfusion. That mitochondrial 
damage was detected upon reperfusion in itself is nothing surprising – it is well documented that most 
reactive oxygen species are produced upon reperfusion (Raedschelders et al., 2012). However, what 
is interesting is that this loss of mitochondrial capacity occurred despite 100% recovery of cardiac 
contractile function. The 20 min 0.56 ml.min-1gww-1 ischaemic protocol was used since this protocol 
allowed full recovery of pre-ischaemic function in pilot studies, and as such the observation of the 
metabolic response to the ischaemic and post-ischaemic states was not complicated by damage to 
the myocardium. It seems though that flux capacity of the electron transport chain does not directly 
correlate to cardiac function in this scenario, with impaired complex I and complex II supported 
respiration alongside anaerobic respiration apparently still sufficient to produce enough ATP for 
contractile function to remain unaffected.  
During ischaemia, late-stage Krebs cycle intermediates accumulated at the expense of early 
intermediates. Malate, fumarate and succinate were present in higher concentrations at the end of 
ischaemia, while citrate and isocitrate were depleted. This could be due to lower acetyl-CoA flux into 
the mitochondria, with less citrate being generated and thus greater accumulation of the later 
intermediates. This corresponds with the respirometry data since the only mitochondrial difference 
between the ischaemic and pre-ischaemic hearts was a loss of complex II function. If there is reduced 
utilisation of oxaloacetate and subsequent accumulation of malate, this may feedback upon complex 
II to limit oxidative metabolism and result in the more dramatic accumulation of succinate. 
Malonylation of complex II is known to occur (Papanicolaou et al., 2014), and could represent a 
mechanism through which mitochondrial metabolism adapts to hypoxic conditions. Meanwhile, the 
accumulation of succinate could contribute towards ketogenesis. 
There are two mechanisms through which accumulation of succinate in ischaemia may drive 
ketogenesis. The first is that SCOT generates succinate from succinyl-CoA during ketolysis, a process 
which may be reversed if the concentration of succinate becomes large enough to begin driving the 
reaction kinetics. The second relates to NADH levels, as Krebs postulated, driving a reduction of 
acetoacetate to β-hydroxybutyrate (Krebs et al., 1961; Schönfeld et al., 2010). The potential of this as 
a driving factor for the reaction was tested here through the addition of NMN. When perfused into 
rats it had taken only 30 min for the NAD precursor to be converted to NAD (Birrell and Hirst, 2013; 
Karamanlidis et al., 2013; Yano et al., 2015), and so addition to the perfusion buffer 32 min before 
ischaemia would be sufficient to determine whether greater availability of NAD+ would enable a 
greater level of reduction to NADH during ischaemia and drive more β-hydroxybutyrate production. 
Increased availability of NAD+ precursors did appear to lead to increased ketogenesis, suggesting that 
the increased NAD+ may become reduced in reductive ischaemic conditions and drive ketogenesis – 




increased NAD+/NADH ratios would drive the reaction in the other direction. The implication is that 
NADH levels and reduction of acetoacetate to β-hydroxybutyrate plays a large part in ischaemic 
ketogenesis. However, the ratio of NADH/NAD+ in the ischaemic heart tissue was not found to be 
altered by NMN. This could be because the majority of NAD+ is reduced during ischaemia, and 
therefore there was no detectable difference; it may have been more enlightening to have measured 
this prior to onset of ischaemia in order to visualise the effect of NMN upon cardiac NAD+ pools. 
Are Fatty Acids the Source of Ischaemic β-hydroxybutyrate? 
Whilst in the liver, β-hydroxybutyrate synthesis is thought to come from excess fat oxidation (McGarry 
and Foster, 1976) although this may reflect the fact that more fatty acid than glucose is metabolised 
in the liver. In Chapter 4 I demonstrated that the presence of fat in the perfusion buffer does not affect 
the level of β-hydroxybutyrate produced in ischaemia. The results in this chapter suggest that a higher 
ratio of fat to glucose oxidation during ischaemia does not underpin ketogenesis, but also call into 
question whether there is increased preference for fat oxidation in ischaemia. 
Fatty acid uptake to both cell and mitochondria appeared to be limited during ischaemia. Cardiac fatty 
acid uptake was 200-fold lower during the ischaemic period, even accounting for the decreased flow 
of buffer through the heart. This suggests that fatty acid uptake is actively limited during ischaemia, 
and is no longer under the influence of concentration in the blood/perfusate only. Further, malonyl 
CoA levels are seen here to be raised during ischaemia, rather than lowered as claimed previously 
(Kantor et al., 1999; Lopaschuk et al., 2009; Wall and Lopaschuk, 1989). Rather than a decrease in 
malonyl-CoA levels enhancing FAO capacity as these papers claim, this would suggest that fatty acid 
uptake to the mitochondria is inhibited. This is further supported by the lower fraction of complex I 
activity which can be accounted for by FAO in the ischaemic heart. Since fatty acid uptake during the 
ischaemic period is lower, it suggests that cardiac ketogenesis (which only occurs during the ischaemic 
period) may not be driven by fatty acid uptake and oxidation exceeding capacity for oxidation of the 
resultant acetyl-CoA in the Krebs cycle. 
Carbon labelling analysis of Krebs cycle intermediates and of β-hydroxybutyrate itself also 
demonstrated no reliance of ischaemic ketogenesis upon FAO. The proportion of acetyl-CoA which 
was incorporated into the Krebs cycle and arose from either fatty acids or from glucose does not 
change in ischaemia. β-hydroxybutyrate labelling suggests that the proportional contribution of fatty 
acid- and glucose-derived acetyl-CoA to ketogenesis is also matched to the generation of acetyl-CoA 
from each in the system. The conclusion which can be drawn from this is that ketogenesis is dependent 
upon acetyl-CoA alone, with no preference for its metabolic precursor. 




Knowing this, the aim of using sodium oxamate was to divert more pyruvate into the mitochondria 
rather than allowing it to be metabolised anaerobically, and determine the effect on ketogenesis. 
Sodium oxamate is a competitive inhibitor of LDH which has previously been used in the Langendorff 
preparation (Yoshioka et al., 2012). Its addition twelve minutes before the onset of ischaemia resulted 
in a 530% increase in the amount of β-hydroxybutyrate which had accumulated in the heart at the 
end of the ischaemic period, as well as higher levels initially being lost in coronary effluent. Ischaemic 
ketogenesis seems therefore perfectly capable of utilising carbon derived from glycolysis – so much 
so that it may even constitute a mechanism for lowering acetyl-CoA levels when it cannot be oxidised 
in ischaemia, performing a similar function to that which lactate production performs with pyruvate. 
It would be of interest to investigate whether activation of the PDC with dichloroacetate (DCA) had an 
impact upon the rate of β-hydroxybutyrate synthesis, as this would increase the amount of acetyl-CoA 
available for ketogenesis, and DCA has been shown to improve cardiac functional recovery following 
a hypoxic insult in animals previously exposed to chronic hypoxia (Handzlik et al., 2018).  Another 
potential avenue for exploration would be to measure the relative oxidation of glucose and fatty acids 
immediately following reperfusion; it may be that LDH inhibition is affecting glucose oxidation as well 
as anaerobic glycolysis, and the availability of glucose upon reperfusion has been reported by some to 
be critical to functional recovery (Lopaschuk et al., 1990).  
Is Ketogenesis Beneficial or Detrimental to Recovery From I/R? 
 It is difficult to draw conclusions on the functional repercussions of ischaemic ketogenesis from the 
oxamate study. Hearts given sodium oxamate eventually recovered contractile function to the same 
extent as control hearts. However, there was a delay in this occurring, with these hearts taking 15 
minutes longer to reach the same level of RPP recovery. This could have been due to the increased 
concentration of ketone bodies present or flux through the ketogenic pathway preventing ketolysis; 
however, these conclusions cannot conclusively be drawn given the effects of oxamate upon lactate 
production. The slower recovery could be a result of the greater contracture exhibited by hearts given 
oxamate during ischaemia, with a longer recovery time required for the tissue to relax. Contracture is 
the contraction of the heart during ischaemia, onset of which is thought to relate to depletion of 
cardiac ATP levels (Hearse et al., 1977; Piper et al., 2004) – as would happen when the ischaemic heart 
can no longer gain energy from glycolysis. The onset and magnitude of contracture are thought to be 
related to the influx of calcium to the cell, which can no longer be reversed due to the inactivity of the 
ATP dependent Ca2+ pumps (Hearse et al., 1977). Since the ATP for ion homeostasis is thought to be 
supplied by cytosolic glycolysis (Mcnulty et al., 2000; Weiss and Hiltbrand, 1985), it could be that the 
contracture observed to be associated with oxamate treatment in this chapter is a result of LDH 
inhibition preventing glycolytic ATP production. It could take time following ischaemia to restore this 




energy deficit, offering a possible explanation for the longer time taken to recover contractile function. 
Lactate itself is also normally utilised by the heart early upon reperfusion (Aquaro et al., 2015; de 
Groot et al., 1995), so its absence may compromise recovery by limiting the heart’s access to an easily 
oxidisable substrate. A cleaner investigation was therefore needed to draw conclusions about the 
functional effects of ischaemic ketogenesis. 
Hymeglusin, a HMG-CoA Synthase inhibitor, was used to inhibit ketogenesis and resulted in a 33% 
greater recovery of RPP following 32 mins reperfusion. The concentration of hymeglusin used may 
have been sub-optimal as it was based on studies of its effects upon cholesterol synthesis (Greenspan 
et al., 1987) and on brain ketogenesis (Le Foll et al., 2014) in-vivo in the rat, yet it did result in a 
decrease of ischaemic β-hydroxybutyrate accumulation of 32%, achieving the aim of inhibiting 
ketogenesis. It therefore appears that ischaemic ketogenesis may be detrimental to cardiac function. 
This is interesting given the myriad beneficial effects that β-hydroxybutyrate has been reported to 
possess, such as antioxidant activity and inhibition of inflammasome formation which could all be 
hypothesised to be beneficial during ischaemia (Kashiwaya et al., 1994; Newman and Verdin, 2017; 
Veech et al., 2001). Perhaps it is the fact that ketogenic flux inhibits the reverse reaction of β-
hydroxybutyrate consumption as a fuel during ischaemia, or formation of the potentially pro-
apoptotic poly-β-hydroxybutyrate (Dedkova and Blatter, 2014) which are the mechanisms for this. 
Either way, it seems that inhibition of ketogenesis might be a beneficial strategy in the treatment of 
ischaemia.  
One possible explanation for the adverse effects of ketogenesis is its inhibitory effect upon the 
inflammasome. β-hydroxybutyrate has been shown to inhibit the formation of the NLRP3 
inflammasome, which acts through caspase-1 mediated cleavage of IL-1β (Yamanashi et al., 2017; 
Youm et al., 2015). In this chapter, this is also shown, with greater caspase-1 activity and 
cleavage/excretion of IL-1β in hymeglusin treated hearts where β-hydroxybutyrate levels are lower. 
Inflammasome formation has previously been reported to be cardioprotective (Sandanger et al., 
2016), so this could underpin any detrimental effects of β-hydroxybutyrate upon recovery of 
contractile function. 
In conclusion, ischaemic ketogenesis occurs in the rat heart, indiscriminately of whether the source 
carbon is derived from glucose or fatty acid catabolism. Data presented in this chapter suggests that 
this process may be detrimental to the functional recovery of the heart following reperfusion. 
 
 




5.4.3 Future Directions 
This study has suggested that ketogenesis occurs in, and is detrimental to, the heart during ischaemia, 
and it would be interesting to further investigate the process in other cardiac conditions where 
metabolic substrate supply might exceed mitochondrial oxidative capacity. In particular, metabolism 
in both the diabetic and failing hearts is limited at the ETC, which could potentially stimulate cardiac 
ketogenesis. The type 1 diabetic heart exhibits higher capacity for FAO (Bayeva et al., 2013; Friederich 
et al., 2009), yet a decreased ETC capacity compared with non-diabetic controls (Duicu et al., 2017; 
Kiebish et al., 2012; Loiselle et al., 2014; MacDonald et al., 2011; Pham et al., 2014). Further, and 
making the model of particular interest, the expression of ketogenic enzymes is enhanced (Cook et 
al., 2017; and see Chapter 6). In the failing heart, the heart cannot supply itself with enough blood 
(and oxygen) to meet its own energetic demand, leading to a decreased ETC rate of activity which 
could result in diversion of acetyl-CoA away from the Krebs cycle and towards β-hydroxybutyrate. TAC 
models of the failing heart have also exhibited greater expression of BDH1, and while this was linked 
to greater oxidation of β-hydroxybutyrate (Aubert et al., 2016; Bedi et al., 2016), the enzyme catalyses 
a bidirectional reaction so this is likely to potentiate ketogenesis. These investigations would be best 
carried out in the ex vivo heart, as in vivo there would be uncertainty as to which organ any β-
hydroxybutyrate detected in the heart had originated from. Perfusion of type 1 diabetic hearts and 
failing hearts in the Langendorff mode would allow certainty that any β-hydroxybutyrate was indeed 
being produced in the heart, and would also allow investigation of whether these hearts were capable 
of producing more β-hydroxybutyrate than controls during ischaemia. 
A proteomic study would also be of interest, in order to determine whether the point at which the 
heart switches from oxidising to producing ketone bodies during ischaemia is controlled by post-
translational modification. Accumulation of various metabolic intermediates such as succinate, malate 
and acetyl-CoA may lead to post-translational modification of ketogenic enzymes during ischaemia 
(Papanicolaou et al., 2014; Quant et al., 1990). If this were detected, further enzyme activity assays 
could potentially be conducted to investigate whether the modification had an effect upon enzyme 
activity; although it would be difficult to maintain ischaemic conditions during these assays so these 
assays would be enlightening only if the modifications were robust enough to withstand tissue 
preparation. 
If ketogenesis is a response of the myocardium to glucose and FAO exceeding mitochondrial oxidative 
capacity, it could be interesting to see the effects upon rate of ketogenesis if the heart were not 
supplied with any exogenous substrate just before and during ischaemia. Excess supply of substrates 
to the Krebs cycle during ischaemia could be detrimental, and leads to diversion of glucose-derived 




pyruvate to lactate and alanine (Lloyd et al., 2004), with both glucose and FAO derived acetyl-CoA also 
now shown to be diverted to β-hydroxybutyrate during ischaemia. Limiting metabolic substrate supply 
to the heart could perhaps lead to a more manageable amount of substrate metabolism being derived 
from endogenous sources only. The experiment should be easy to conduct in the Langendorff 
perfused heart, as internal triglyceride and glycogen stores are capable of sustaining a rat heart for up 
to thirty minutes without external supply of metabolic substrate, a process which is evinced during 




Isoprenaline Mediated Stimulation of 
Cardiac Metabolism in the 
Pancreatectomised Rat  





BACKGROUND The type 1 diabetic heart is characterised by metabolic remodelling, including a loss 
of metabolic flexibility, which may alter the response to stress. It is unknown whether any impaired 
ability to respond to stress may result in the higher rates of mortality from cardiovascular 
complications seen in diabetic patients. 
OBJECTIVE This study aimed to determine how the type 1 diabetic heart responds to chronic 
stimulation with the β-agonist isoprenaline (Iso).  
METHODS Partially pancreatectomised (90% removal, Px) and sham-operated rats were 
administered Iso daily (10x1 mg/kg) or vehicle i.p. between 5 and 7 wks post-operation. Respirometry, 
mass spectrometry and RNAseq were performed on left ventricle following termination at 10 wks. 
RESULTS Rodent mortality following the first dose of isoprenaline was 43% in the sham rats, while 
there was no loss of life in the Px rats. Mitochondrial respiratory capacity was impaired following Px, 
with a substrate switch towards fatty acid oxidation (FAO) alongside greater expression of FAO-related 
enzymes and evidence of oxidative stress. Iso treatment also impaired respiratory capacity, but 
enhanced flux through glycolysis with increased aldolase expression (p<0.001). In the hearts of Iso-
treated Px rats (p<0.0001), mitochondrial respiratory capacity was preserved, and whilst myocardial 
PCr was depleted following Px, this too was conserved in Iso-treated Px rats. Uncoupling of adrenergic 
signalling through repression of adenylyl cyclase by both Iso and Px may underpin this apparent 
protection.  
CONCLUSION Isoprenaline administration conserved mitochondrial respiratory capacity and 
energetics in the type 1 diabetic heart.  





Increasingly referred to as an epidemic in the western world, diabetes mellitus can exert a direct effect 
upon the myocardium to cause diabetic cardiomyopathy (Bugger and Abel, 2014). Diabetes stems 
from an inability to regulate blood glucose through response to insulin, whether this be through 
decreased cellular sensitivity to insulin as in type 2 diabetes, or the pancreatic inability to produce 
sufficient insulin which defines type 1 diabetes and is the strata of disease which will be addressed in 
this chapter.  
 
6.1.1 Type 1 Diabetes Mellitus 
Type 1 diabetes mellitus results from impaired pancreatic function, meaning that lack of insulin 
secretion prevents efficient cellular uptake of glucose (Katsarou et al., 2017). It is characterised by 
elevated concentrations of blood glucose, which also lead to heightened blood lipid levels. While type 
2 diabetes is a state which stems from poor diet control and a sedentary lifestyle, type 1 diabetes is a 
consequence of a destruction of pancreatic cells by an auto-immune response (Van Belle et al., 2011). 
Insulin produced in the pancreas stimulates uptake of glucose in non-diabetic humans and rats, and 
when its production is impaired in type 1 diabetes this leads to an inability to regulate blood glucose 
levels. This hyperglycaemia and hyperlipidaemia which characterise type 1 diabetes generate a state 
of nutrient excess, which leads to the perturbation of cardiac metabolism (Stanley et al., 1997a).  
Type 1 diabetes is associated with an increased risk of developing heart failure. Type 1 diabetic men 
were 9.4 times as likely and type 1 diabetic women 39.1 times as likely to develop heart failure than 
their non-diabetic counterparts in the under 40 age group of the Diabetes UK cohort (Laing et al., 
2003). In addition, 40% of those presenting with acute heart failure syndrome have a history of 
diabetes (Gheorghiade and Pang, 2009). The outcome of this heart failure was also worsened by 
diabetes, with diabetic heart failure patients twice as likely to die from or be hospitalised by their 
condition as non-diabetic heart failure patients (Macdonald et al., 2008). There are arguments that 
this mortality is correlated with levels of blood glucose (Lehto et al., 1999), and some that this is not 
the case, but that instead increased resistance to insulin stimulation increases risk of death from CVD 
(Orchard et al., 2003). Moreover, some of the mortality and incidence of heart failure arising from 
type 1 diabetes does not stem from an intermediary cardiovascular complication such as infarction 
(Bertoni et al., 2003; Schilling and Mann, 2012). 
 





6.1.2 Diabetic Cardiomyopathy 
Such cases have been hypothesised to be a condition termed diabetic cardiomyopathy, a direct 
diabetic instigation of left ventricular dysfunction in the absence of intermediary effectors such as 
myocardial infarction (Rubler et al., 1972; Schilling and Mann, 2012). The molecular mechanisms 
behind this are not yet fully understood, yet many factors have been proposed to contribute. In 
particular, mitochondrial dysfunction, oxidative stress, lipotoxicity, increased fatty acid oxidation, 
hyperglycaemia and advanced glycation end products are thought to feature strongly in the 






Hyperglycaemia induced ROS production has the potential to elicit a state of oxidative stress which, 
amongst other complications, engenders impaired contractile function. ROS production has been 
documented to arise from both the polyol and hexosamine pathways during hyperglycaemia (Wold et 
Figure 6.1: Pathways and factors which have been implicated in the genesis of diabetic 
cardiomyopathy 




al., 2005), yet the principal source is thought to lie at the mitochondrial inner membrane with the ETC 
(Nishikawa et al., 2000). Prolonged exposure to high glucose levels causes the mitochondria to 
undergo rapid morphological fission, which is necessary if not sufficient for the generation of ROS (Yu 
et al., 2006, 2009). It is mooted that there is a certain threshold of mitochondrial proton gradient 
above which the half-life of ROS-producing components such as ubisemiquinone is prolonged, and 
that hyperglycaemia pushes the proton gradient above this level through over-generation of electron 
donors to the ETC (Szabo, 2009). Whether or not this the underlying mechanism, collapsing this 
gradient through over-expression of UCP-1 in human aortic endothelial cells prevented 
hyperglycaemia-induced ROS production, while over-expression of MnSOD, the mitochondrial form of 
superoxide dismutase, prevented ROS signalling and increased PKC activation (Yao and Brownlee, 
2010). This ROS production from hyperglycaemia in the type 1 diabetic heart has been found to impair 
contractile function, and hence the dysfunctional metabolism of glucose may underlie diabetic 
cardiomyopathy (Ceylan-Isik et al., 2006) 
Metabolic Substrate Preference 
Over-reliance upon fatty acid oxidation is a hallmark of the diabetic heart, and can also be responsible 
for ROS generation and loss of efficiency. The primary cause for this is a combination of increased 
circulating levels of fatty acids coupled with an impaired ability to take up and oxidise glucose in the 
absence of insulin (Bayeva et al., 2013). Fatty acid uptake contrasts with that of glucose because it is 
not primarily under hormonal control, instead being transported into the cell via the CD36 transporter 
in proportion to plasma fatty acid concentrations (Stanley et al., 1997a). Myocardial levels of CD36 are 
increased in the diabetic heart, whilst plasma free fatty acid levels are also elevated since insulin-
mediated inhibition of lipolysis no longer occurs (Stanley et al. 1997; Heather et al. 2006).  
Modulation of PDH activity also contributes to a loss of metabolic flexibility in the diabetic heart. 
Accumulation of acetyl-CoA, as a product of β-oxidation, feeds back to inhibit PDH (Hansford and 
Cohen, 1978), whilst increased levels of the inhibitory PDH kinase (PDK) isoform 4, which is suppressed 
by insulin, are also seen the diabetic heart (Kim et al., 2006; Wu et al., 1998). Crucially, even if hearts 
from type 1 diabetic rats are perfused in the absence of any lipids, glucose oxidation rates remain low 
and supply less than 20% of the heart’s energy requirements (Wall and Lopaschuk, 1989). This suggests 
that reduced PDH flux is due to metabolic remodelling and not purely the balance of mitochondrial 
substrate availability.  
TCA cycle activity appears unaffected in the diabetic heart, so the shift in origin of acetyl-CoA appears 
to be the major effect upon mitochondrial metabolism. There is no difference in activity of TCA cycle 




enzymes (Chen et al., 1984; Glatz et al., 1994), but total ATP production is depressed (Wall and 
Lopaschuk, 1989). 
Lipotoxicity 
The increased uptake of fatty acids, coupled with mismanagement of their storage, is thought to lead 
to lipotoxic damage which may drive development of cardiomyopathy. Lipid content and steatosis 
increases in the type 1 diabetic heart, preceding the onset of left ventricular dysfunction (Ritchie et 
al., 2017). FAO is less oxygen efficient than glucose oxidation and results in greater ROS production 
(Hinkle, 2005), however it appears that any lipotoxic effects are a symptom of mismanagement and 
cytosolic accumulation rather than oxidation (Scherer et al., 2016). Accumulation of lipid droplets and 
associated disruption of cardiomyocyte function could impair contractility leading to cardiomyopathy. 
Mitochondrial Dysfunction 
Mitochondrial dysfunction may be the unifying factor between these hallmarks of diabetic 
cardiomyopathy and the development of contractile dysfunction. Overall mitochondrial respiratory 
capacity is depressed in the streptozotocin (STZ) type 1 diabetic heart (Flarsheim et al., 1996; Lashin 
et al., 2006). This is associated with an increased ratio of FAO to glucose oxidation (Chatham and 
Forder, 1997; Depre et al., 2000; Finck et al., 2002; Flarsheim et al., 1996; How et al., 2007). 
Meanwhile, the ROS production associated with both hyperglycaemia (Yao and Brownlee, 2010) and 
increased FAO is mitochondrial and has been associated with the loss of ETC function (Lashin et al., 
2006). Furthermore metabolic dysfunction precedes the onset of the loss of contractile function and 
its reversal prevents the onset of contractile dysfunction (Nielsen et al., 2002), and it therefore seems 
likely that metabolism and the mitochondria are central effectors of diabetic cardiomyopathy. 
 
6.1.3 The Need for More Representative Animal Models 
Reported features of type 1 diabetic cardiomyopathy can vary quite widely, and a consideration worth 
taking into account is that this may be due to inconsistencies in animal models. STZ models of type 1 
diabetes are widely used, easy to implement and allow diabetes to be instigated at different 
timepoints during the study (Bugger and Abel, 2009). The model involves administration of the 
genotoxic glucose analogue streptozotocin, which causes destruction of the insulin secreting 
pancreatic β cells following selective uptake by GLUT2 transporters which are most highly expressed 
in β cells. However, STZ has a number of off-target effects including genotoxicity (Bolzán and Bianchi, 
2002), influence upon liver metabolism of glucose and lipids (Kume et al., 2005), and depression of 




cardiac contractile function (Wold and Ren, 2004), all of which may lead to misinformative findings in 
the heart. A more reliable animal model is needed to fully investigate type 1 diabetic cardiomyopathy; 
because if cardiomyopathy is defined as a direct impact of diabetes upon contractile function and 
streptozotocin also impacts cardiac contractility, how may the effects of the diabetes be discerned 
from those of the drug?   
 
6.1.4 Objectives  
Diabetic patients have an increased risk of mortality from cardiovascular causes, which potentially 
stems from diabetic cardiomyopathy and a loss of metabolic flexibility (Bugger and Abel, 2014). The 
purpose of this chapter was therefore to test the hypothesis that this increased mortality rate 
originated from decreased ability to respond to metabolic stimuli by challenging the type 1 diabetic 
rat with the β-adrenergic agonist isoprenaline.  
A secondary objective was to characterise a 90% pancreatectomy rat model of type 1 diabetes, which 
was chosen for this study to discount the off target effects of the more commonly used STZ induced 
model. 90% pancreatectomy has been used previously as a model for pancreatic regeneration (Yu et 
al., 2015), and resulted in a stable hyperglycaemic phenotype. However, it had not yet been 
characterised metabolically. In choosing to utilise this model, the aim was also to test the hypothesis 












6.2.1 Animal Housing and Treatment  
All treatment of live animals discussed in this chapter was carried out by and at Gubra ApS, Horsholm, 
Denmark under their licence. Termination of the animals, tissue collection, respirometry analysis, 
mass spectrometry and the analysis of data collected through RNAseq was conducted by myself. 
 
6.2.2 Experimental Design 
Sprague-Dawley rats were either 90% pancreatectomised (Px) or sham operated. Following an 
overnight full-fast with grids installed in the cages, the rats were operated upon under isofluorane 
induced anaesthesia by Dr Philip Pedersen at Gubra ApS. Pancreatectomy (90%) was performed by 
ligation and then removal of the tail, body and a part of the pancreatic head by gentle abrasion with 
dental applicator. The 10% of the pancreas which remained was the portion between the duodenal 
loop and the pancreatic duct. The major blood vessels to the stomach, spleen and gut were left intact 
so no other organs are compromised. The sham operation consisted of anaesthesia and ligation of the 
portion of the pancreas described above, a ligature which was then removed in order to leave behind 
a fully functional pancreas. The rats were not offered food from one day before until one day after 
the surgery, whereupon they were offered 5 g of chow. From the second day after surgery food was 
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Figure 6.2: Timeline of Key Events in the Experimental Protocol 




Animals from each group then underwent a daily subcutaneous administration of either isoprenaline 
(1 mg/kg) or vehicle (saline solution) for 10 days, commencing 5 weeks post-operation. Blood glucose 
and bodyweight were monitored throughout. At 10 weeks post-operation, rats were euthanised with 
rising concentrations of CO2 followed by cervical dislocation. Hearts were extracted, and the left 
ventricle sectioned before being either snap frozen for further analysis (RNAseq and Mass 
Spectrometry) or transferred fresh into ice cold BIOPS solution (Appendix 2.2) for immediate analysis 
of mitochondrial respiratory function with high-resolution respirometry.    
 
6.2.4 Blood Glucose Measurement 
Performed by the Animal Technician Staff at Gubra ApS 
Blood samples were collected weekly from tongue blood in heparinized glass capillary tubes, and 
immediately suspended in glucose/lactate system solution buffer (EKF-diagnostics, Germany). Blood 
Glucose was then measured using a BIOSEN c-Line glucose meter (EKF-diagnostics, Germany). 
 
6.2.5 Echocardiography 
Performed by Louise Thisted and Dr. Nora Zois, with assistance from the author 
Echocardiography was performed on the rats 9 weeks post-operation by use of a Philips iE33 
Ultrasound echocardiograph and a 12-4 MHz probe (Philips S12-4 sector array transducer). The rat 
was lightly anaesthetized using 1.5-3% isofluorane, and the chest of the rat was shaved. The rat was 
then placed on a hot water pad in the supine position. Ultrasound gel was preheated to 37°C in a warm 
water bath and applied to the rat’s chest. The rat underwent echocardiography under continuous 
electrocardiographic measurements and a minimum of 5 heart cycles were saved in each projection 
(parasternal and apical positions, respectively). Echocardiographic images were saved and processed 
off-line in order to quantify left ventricular function and dimensions. Fractional shortening was 
calculated by subtracting the left ventricular diameter in systole (LVIDs) from the left ventricular 
diameter in diastole (LVIDd) and expressing this as a fraction of LVIDd. A measure of ejection fraction 
was derived by dividing the stroke volume by the end-diastolic volume. 
 
 




6.2.6 High-Resolution Respirometry 
Permeablision of LV fibres and measurement of respiration rates was conducted as described in 
Chapter 2 (Section 2.2). The ratio of fatty acid oxidation preference (FAO) was calculated by dividing 
the octanoyl carnitine supported oxphos rate by the octanoyl carnitine plus pyruvate supported 
oxphos rate. 
 
6.2.7 Liquid Chromatography-Coupled Mass Spectrometry (LC-MS/MS and LC-
MS) 
Metabolites were extracted from frozen left ventricle using a Bligh-Dyer method as described in 
Chapter 2 (2.3.2). Levels of glycolytic intermediates and energetic compounds (ATP and PCr) were 
assessed using the BEH amide column chromatography method as described in sections 2.3.3 and 
2.3.4. Levels of oxidative stress markers (LysOH and Glutathione) were assessed using the C18pfp 
chromatography method coupled to the Thermo Quantiva, while levels of β-hydroxybutyrate and 




RNA extraction, cDNA generation and next-generation sequencing was performed at Gubra ApS as 
follows: 
RNA was purified from homogenized tissue using the NucleoSpin RNA Plus kit (MACHEREY-NAGEL 
GmbH). 500ng purified RNA from each sample was used to generate a cDNA library using the 
NEBNext® Ultra™ II Directional RNA Library Prep Kit from Illumina (New England Biolabs). The cDNA 
library was then sequenced on a NextSeq 500 using NextSeq 500/550 High Output Kit V2 
(Illumina). Sequencing was carried out for 75 cycles and 2 x 8 index cycles. 
The sequencing data was aligned to the genome of the rat obtained from the Ensembl database using 
the Spliced Transcripts Alignment to a Reference (STAR) software. For the bioinformatic analysis, the 
quality of the data was evaluated using the standard RNA-sequencing quality control parameters, the 
inter- and intra-group variability was evaluated using principal component analysis and hierarchical 
clustering. Analysis of the data was then performed by the present author. 




6.2.9 LV Histology 
Performed by the histology group at Gubra ApS 
The half of the ventricle designated for histological staining was fixed in 4 % paraformaldehyde, 
embedded in paraffin and cut into 3-4 µm sections. Slides with paraffin embedded sections were de-
paraffinated in xylene and rehydrated in a series of graded ethanol. The slides were incubated in 
Weigert’s iron hematoxylin (Sigma-Aldrich), washed in tap water, then stained with Picro-sirius red 
(Sigma-Aldrich) and washed twice in acidified water. Excess water was removed by shaking the slides 
and the slides were then dehydrated using three washes of 100% ethanol, cleared in xylene and 
mounted with Pertex to be allowed to dry before scanning. Histological scoring was performed on 
Picro-Sirius Red stained sections by a trained histopathologist. All histological assessments were 
performed by a pathologist blind to treatment. Imaging analysis for quantitation of collagen levels 
were performed using HDevelop Image Analysis Toolbox (MVTec, Munich, Germany) or Visiomorph 
(Visiopharm, Hørsholm, Denmark) software. Area fraction was calculated as by calculating the staining 
area as a percentage of the whole-sectional area (area fraction). 
 
  




6.2.10 Statistical Analysis 
Unless otherwise stated, all statistical analysis was performed using two-way ANOVA with 
Isoprenaline treatment and Pancreatectomy as the variables. Significant effects and interactions were 
further examined using Tukey’s post-hoc test.  
Graphically, the following representations were used for significant effects: 












For data where there was more than one significant effect, both are instead written upon the graph. 

















6.3.1 Core Dataset 
Blood Glucose Levels 
Blood glucose levels remained constant throughout in sham operated rats. An initial rise to a plateau 
around 25 mM in both Px groups clearly demonstrated hyperglycaemia and an inability to regulate 
blood glucose (Figure 6.3). There was no noticeable effect of isoprenaline treatment upon blood 



























Sham/Vehicle Px/Vehicle Sham/Iso Px/Iso
Figure 6.3: Concentration of glucose in the blood for the 10 weeks between Px or sham operation 
and termination.   




Body and Heart Weight 
On termination, bodyweight was 33% lower in the pancreatectomised rats than in the sham-operated 
rats (Figure 6.4B, p<0.0001). This bodyweight difference was due to slower growth rather than weight 
loss (Figure 6A). Total heart weight on termination was 25% lower as an effect of pancreatectomy 
(Figure 6C, p<0.0001), whilst the ratio of LV mass to total heart weight was the same across all groups 















































Figure 6.4: (A) Rat bodyweight measured daily following surgery; (B) Mass of rat upon termination; 
(C) Total heart weight on termination; (D) Ratio of LV mass to total heart weight. Masses and ratios 
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Following a period of lower food intake immediately following pancreatectomy, the Px rats consumed 
around 40% more food than Sham–operated rats over the ten weeks following the operation (Px 
Effect, p<0.0001) (Figure 6.5). When coupled with the fact that these animals had a lower bodyweight 
than the Sham operated group, and grew at a slower rate (Figure 6.4), this suggests that the Px rats 
were less effective at extracting nutrients from the food and had to eat more in an attempt to 








































Figure 6.5: (A) Daily food intake following surgery; (B) Total food intake. Masses displayed as mean 
± SEM. 2-way ANOVA, **** p<0.0001  
B 
A 





Of the total cohort of rats which underwent isoprenaline administration (n=43), including those 
destined for other experimental endpoints at Gubra ApS than those detailed in this chapter, there 
were 9 deaths following administration of the first dose of isoprenaline (Figure 6.6). All 9 of these 
deaths occurred in the Sham/Iso group, meaning that of the 21 animals originally destined for this 
group, 43% succumbed to the initial administration of isoprenaline. By contrast, there were no 
fatalities sustained by the 22 rats comprising the Px/Iso group. This indicated two things: firstly, that 
the 1 mg/kg dose of isoprenaline represented a severe insult; and secondly that the 
pancreatectomised group were more resilient to this stimulus, whether through a lower contractile 
ability to respond or a desensitisation to adrenergic stimulation.    

































6.3.3 Tissue Fibrosis 
Left ventricles were stained with picro-sirius red by the histology department at Gubra ApS for imaging 
of tissue fibrosis (Figure 6.7 A).   
Figure 6.7: Transverse sections of LV stained with picro-sirius red. 
A 




Cardiac tissue taken from the groups administered isoprenaline was more fibrotic than the vehicle 
treated groups (Figure 6.7 B&C). Picro-sirius red staining showed a greater mass of collagen (Iso effect, 
p<0.0001) and a greater area fraction of collagen in the isoprenaline treated groups (Iso effect, 










































Figure 6.7: (B) Collagen area fraction and (C) collagen mass measured by quantification of Picro-
sirius Red staining.  Displayed as mean ± SEM. 2-way ANOVA **** = p<0.0001 
    Px  p<0.01 
Iso p<0.0001 
B
  A 
C 





Isoprenaline administration also impacted upon cardiac contractile function as measured using 
echocardiography by Louise Thisted (Figure 6.8). Fractional shortening and ejection fraction were 
compromised in the Iso treated groups relative to those administered vehicle (Effect of Iso, p<0.0001 
for both parameters). This suggests that the fibrosis incurred following chronic isoprenaline 
administration (Figure 6.7) may impede the ability of the heart to contract fully or as vigorously as in 

































Figure 6.8: Fractional shortening, FS (LVIDd – LVIDs/LVIDd *100) and ejection fraction, EF 
(Teichholz formula). Displayed as mean ± SEM. 2-way ANOVA **** = p<0.0001 
 




6.3.5 Mitochondrial Function 
Leak state β-oxidation limited oxygen consumption, measured using high-resolution respirometry, 
revealed a significant interaction between isoprenaline administration and pancreatectomy (p<0.01). 
Explicitly, the Px/Vehicle group displayed significantly lower oxygen consumption than the 
Sham/Vehicle group (Tukey’s, p<0.05), and the Sham/Iso group was also lower than the Sham/Vehicle 
group. The two factors combined in the Px/Iso group however displayed a rate of oxygen consumption 
significantly greater than the Sham/Iso group (Tukey’s, p<0.05), and not significantly different to 
Sham/Vehicle, suggesting a reversal of the effects seen with Px or Iso alone. 
The same broad pattern and interaction continued to be exhibited in the Oxphos state, for β-oxidation 
limited oxygen consumption, β-Oxidation plus Pyruvate, Complex I activity, Total Oxphos and Complex 
II activity (Interactions p<0.01, p<0.001, p<0.001, p<0.0001 and p<0.0001 respectively), such that both 
Px and Iso decreased mitochondrial respiratory capacity, whilst the two factors in combination at least 










































Figure 6.9: Respiration rates corrected for wet mass.  Rates displayed as mean ± SEM. 2-way 
ANOVA ** = p<0.01, *** = p<0.001 and **** = p<0.0001 





 Of particular note was the difference in the FAO ratio, or the proportion of complex I activity 
accounted for by β-oxidation (Figure 6.10). The Px/Vehicle group had a significantly higher FAO ratio 
than the Sham/Vehicle group (Tukey’s, p<0.01). This was also higher than in the Sham/Iso group 
(Tukey’s, p<0.0001), and the Px/Iso group (Tukey’s, p<0.001). This was an effect of pancreatectomy 
(p<0.01) and an effect of isoprenaline (p<0.001).  There was no effect of either pancreatectomy or 









Figure 6.10: The ratio between octanoyl carnitine and octanoyl carnitine plus pyruvate supported 
respiration (FAO) as a marker of preference for fatty acid oxidation; and the respiratory control 
ratio (RCR).  Ratios displayed as mean ± SEM. 2-way ANOVA effects denoted on graph. 














6.3.6 Tissue Energetics 
To further understand the implications of the altered mitochondrial capacity, high energy phosphate 
levels were investigated.  
Tissue levels of ATP were 80% higher in the Sham/Iso group relative to control, and 140% higher in 
the Px/Iso group. Statistically, there was an effect of Isoprenaline treatment (p<0.01), with no Px effect 
(Figure 6.11).  
Phosphocreatine levels were lower in the Px/Vehicle group relative to Sham/Vehicle, with only 60% 
of the levels present in the non-pancreatectomised heart. This effect was nullified by isoprenaline 
















































Figure 6.11: Concentrations of ATP and PCr in cardiac tissue relative to control. Concentrations 
displayed as mean ± SEM. 2-way ANOVA * = p<0.05, ** = p<0.01. 
** * 




6.3.7 Oxidative Stress 
Levels of oxidised glutathione were 1.6 times greater in the two Px groups relative to those which 
were sham operated (p<0.001, Figure 6.12 overleaf).  
This change was reflected in another oxidative stress marker, LysOH, where concentrations were 
approximately three- and two-fold greater in the Px/Vehicle and Px/Iso groups than in the 
Sham/Vehicle group (p<0.05, Figure 6.12 B).   
Mitochondrial Amidoxime Reducing Complex 1 on the other hand, a mitochondrial antioxidant 
enzyme, was expressed at ~1.5 times higher levels in the isoprenaline treated groups than in the 
vehicle treated groups (p<0.001, Figure 6.12 C). 
Isoprenaline administration also increased expression of the mitochondrial superoxide generator 
NADPH Oxidase 4 (Figure 6.12 D, p<0.01), also ameliorating a 2.9 fold loss of expression in the 
Px/Vehicle group (Px effect, p<0.001).  
  



























































Figure 6.12: Concentrations of (A) Glutathione and (B) LysOH in cardiac tissue relative to control. 
Expression levels of (C) Mitochondrial Amidoxime Reducing Complex 1 and (D) NADPH Oxidase 4. 
Concentrations and expression levels displayed as mean ± SEM. 2-way ANOVA * = p<0.05, ** = 































































6.3.8 Glucose Uptake Related Gene Expression 
Expression of the glucose transporter, GLUT1, was decreased in Px/Vehicle animals relative to 
Sham/Vehicle, enhanced in the Sham/Iso group and decreased to a lesser extent in the Px/Iso group. 
This was an effect of both Iso and Px (p<0.01 and p<0.0001). 
Insulin receptor transcripts were lower only in the Sham/Iso group relative to control, displaying both 
and effect of isoprenaline administration and an effect of pancreatectomy (both p<0.05). 
TBC1D4, a GTPase which inhibits the translocation of glucose transporters to the cellular membrane, 
displayed lower levels of transcripts again only in the Sham/Iso group relative to Sham/Vehicle (Px 







































































Figure 6.13: Expression levels of (A) GLUT1, (B) the Insulin Receptor and (C) TBC1D4 in cardiac 
tissue. Expression levels displayed as mean ± SEM. 2-way ANOVA * = p<0.05, ** = p<0.01, *** = 
p<0.001 and **** = p<0.0001 
Px  p<0.05 
Iso p<0.05 
Px  p<0.0001 
Iso p<0.01 








6.3.9 Fat Oxidation Enzymes 
In order to investigate the mechanism behind the altered mitochondria fatty acid oxidation 
preference, gene expression levels of FAO related genes were examined. 
Expression levels of CPT1b, HOADa and ACADvl were greater as an effect of pancreatectomy (~1.2 fold 
p<0.0001, ~1.65 fold p<0.0001 and ~1.4 fold p<0.0001 respectively).  
Conversely, ACADs expression was repressed by around 20%, also as an effect of pancreatectomy 





































































































Figure 6.14: Expression levels of (A) CPT1b, (B) HOADa, (C) ACADvl and (D) ACADs in cardiac tissue. 
Expression levels displayed as mean ± SEM. 2-way ANOVA * = p<0.05, ** = p<0.01, *** = p<0.001 











6.3.10 PPAR Expression 
Fat oxidation comes under the control of the Peroxisome Proliferator Activated Receptors (PPAR), the 
expression of which was thus examined. 
Expression of the three main PPAR isoforms, α, β/δ and γ, was analysed employing RNAseq. PPAR β/δ 
was only expressed in the diabetic myocardium to 75% of the levels present in the Sham/Vehicle 
hearts. A similar but more pronounced expression shift was exhibited with PPAR α, with only 63% of 
the levels of Sham/Vehicle RNA transcribed in the Px/Vehicle group. In contrast, PPAR γ was expressed 
at 1.45 fold higher levels in the Px/Vehicle hearts than in the Sham/Vehicle ones, although this change 










































































Figure 6.15: Expression levels of (A) PPAR β/δ, (B) PPARα and (C) PPAR γ in cardiac tissue. 
Expression levels displayed as mean ± SEM. 2-way ANOVA * = p<0.05, ** = p<0.01, *** = p<0.001 




Px  p<0.0001 
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6.3.11 Myotype Switching and Uncoupling Proteins 
Expression of myosin Heavy Chain 7 increased in pancreatectomised hearts (p<0.0001; ~1.6 fold) when 
interrogated with RNAseq. Meanwhile, Myosin Heavy Chain 6 expression was suppressed (p<0.0001; 
~2.4 fold). 
The uncoupling proteins UCP2 and UCP3 both displayed greater levels of expression in the Px/Vehicle 
heart than in the Sham/Vehicle hearts (3.8 fold and 1.7 fold respectively). While this was an overall 
effect of diabetes with both (p<0.0001 and p<0.01 respectively), UCP2 was not expressed to a greater 









































































































Figure 6.16: Expression levels of (A) Myosin Heavy Chain 7, (B) Myosin Heavy Chain 6, (C) 
Uncoupling Protein 3 and (D) Uncoupling Protein 2 in cardiac tissue. Expression levels displayed as 










6.3.12 Glycolytic Alterations 
Levels of glycolytic intermediates were measured using LC-MS. Those intermediates prior to the 
enzyme aldolase were found to be increased as an effect of pancreatectomy (glucose-6-phosphate 
p<0.01; Fructose-1,6-bisphosphate p<0.05) (Figure 6.17, overleaf). Transcript levels for the initial 
enzyme involved in glycolysis, hexokinase (HK), were also found to be greater in the 
pancreatectomised groups (Px effect, p<0.001).  
Transcript levels of the enzyme aldolase, however, were greater in the groups which had been 
administered isoprenaline (Iso effect, p<0.001). This was especially true for the Px/Iso group, which 
had aldolase (Aldol) transcript levels 1.75 times higher than those observed in the Px/Vehicle group. 
Following aldolase, glycolytic intermediates were more prevalent in the Isoprenaline-treated groups 
than the vehicle treated groups. Expression of dihydroxyacetone phosphate, glyceraldehyde-3-
phosphate and 2-phosphoglycerate/3-phosphoglycerate (chemically indistinguishable using this 
detection method because they have an identical molecular mass) were all observed to be higher (Iso 
effect, p<0.05, p<0.01 and p<0.01 respectively). 
This suggests that despite higher flux through the early part of glycolysis in the pancreatectomised 
groups, induction of aldolase expression by isoprenaline administration serves to increase glycolytic 
flux in the Iso groups, potentially acting to help restore metabolic flexibility in the Px/Iso group.  
 





Figure…  Concentrations of glycolytic intermediates and expression levels of selected 
glycolytic enzymes in cardiac tissue. Concentrations displayed as mean ± SEM. 2-way 
ANOVA * = p<0.05, ** = p<0.01, *** = p<0.001 and **** = p<0.0001 
Figure 6.17: Concentrations of glycolytic intermediates (right) and expression lev ls of selected 
glycolytic enzymes (left) in cardiac tissue. Levels displayed as mean ± SEM. 2-way ANOVA * = p<0.05, 
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6.3.13 Regulation of Pyruvate Metabolism 
Transcript levels of PDH Kinase 1, PDH Phosphatase Regulatory Subunit, Alanine Transaminase 2 and 




















































PDH Phosphatase Regulatory 
Subunit
Figure 6.18: Expression levels of (A) Pyruvate Dehydrogenase Kinase 1, (B) Pyruvate 
Dehydrogenase Phosphatase Regulatory Subunit, (C) Alanine Transaminase 2, and (D) Pyruvate 
Dehydrogenase Kinase 2 in cardiac tissue. Expression levels displayed as mean ± SEM. 2-way 





























































6.3.14 Adrenergic Signalling 
Expression of β-adrenoceptor 1A was decreased by 28% in the Sham/Iso group compared to 
Sham/Vehicle yet not in any other groups, manifesting as an effect of both Px and Iso (both p<0.05).  
Meanwhile, Adenylyl Cyclase transcript levels were decreased in both the Px/Vehicle and Sham/Iso 
groups relative to Sham/Vehicle, with an even greater decrease visible in the Px/Iso group. Again both 
Px and Iso demonstrated an effect with 2-way ANOVA (both p<0.05). 
Phosphodiesterase 3a expression was 1.28 fold greater in the Px/Vehicle group relative to 
Sham/Vehicle. However, isoprenaline administration decreased expression by around 20%, leading to 









































































Figure 6.19: Expression levels of (A) β adrenoceptor 1A, (B) Adenylyl Cyclase and (C) 
Phosphodiesterase 3a in cardiac tissue. Expression levels displayed as mean ± SEM. 2-way ANOVA 
* = p<0.05, ** = p<0.01, *** = p<0.001 and **** = p<0.0001 
Px  p<0.05 
Iso p<0.05 
Px  p<0.01 
Iso p<0.05 









Ketogenesis in the Type 1 Diabetic Heart? 
It was demonstrated in Chapter 4 and Chapter 5 that ketogenesis occurs in the ischaemic rat heart. 
In the type 1 diabetic heart, where oxidation capacity for fatty acids is higher and mitochondrial 
respiratory capacity lower than in the Sham/Vehicle group, a similar process may occur. Certainly, 
transcript levels for the “ketogenic” enzymes HMG-CoA lyase and synthase is higher as an effect of 
pancreatectomy (Figure 6.20, both p<0.0001), and that for the “ketolytic” enzyme SCOT is lower (px 
effect, p<0.0001). Tissue levels of β-hydroxybutyrate are higher in the hearts of pancreatectomised 
rats (p<0.01). However, it cannot be concluded from this that ketogenesis is occurring, as the enzymes 
involved are bidirectional and the β-hydroxybutyrate may have originated in other tissues.    
Figure 6.17: Concentration of β-hydroxybutyrate and expression levels of β-hydroxybutyrate 
dehydrogenase 1 (BDH1), HMG-CoA lyase, HMG-CoA synthase and succinyl-CoA-3-oxaloacid CoA 
transferase (SCOT) in cardiac tissue. Expression levels displayed as mean ± SEM. 2-way ANOVA ** = 
p<0.01 and **** = p<0.0001 
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Both isoprenaline administration and pancreatectomy impaired mitochondrial respiratory capacity in 
the rat heart. Further, pancreatectomy enhanced gene expression of FAO related enzymes, and meant 
that a greater proportion of maximal complex I supported respiration was accounted for by FAO. 
However, in combination pancreatectomy and isoprenaline administration interacted to result in 
preserved respiratory capacity and tissue energetics relative to the states engendered by either 
pancreatectomy or isoprenaline administration individually. 
6.4.1 Strengths and Limitations of the Study 
A great strength of this study came from the fact that it employed a combination of gold standard 
techniques which complemented each other well. The RNAseq gene expression data offered valuable 
insight into the metabolomics data, as particularly well exemplified by the identification of aldolase as 
the glycolytic gene which was expressed to a greater extent in the isoprenaline treated groups. This 
offered a great mechanistic explanation as to why the later glycolytic intermediates were present in 
greater concentrations in these groups. Likewise, data obtained from both techniques played a great 
part in elucidating the functional changes observed through the use of respirometry: for example, the 
gene expression data showed greater expression of FAO related genes which is likely to underlie the 
greater FAO preference which respirometry revealed in the Px/Vehicle group, despite an overall 
suppressed capacity. Metabolite data meanwhile revealed that a possible mechanism for restoration 
of metabolic flexibility in the Px/Iso group came from enhanced glycolytic flux, and that the higher 
mitochondrial respiratory capacity preserved the concentration of PCr produced. 
Something which would have further complimented the dataset would have been the measurement 
of rates of metabolic flux as they occur in vivo or ex vivo. Respirometry offers a great insight into the 
maximal capacity of the mitochondria to sustain oxygen consumption supported by the different 
fluxes and pathways; however, these measurements are made under saturating concentrations of 
substrates and oxygen, and in the absence of physiological regulation, meaning that these 
measurements consider maximal capacity for flux through the pathways rather than the rates which 
occur in vivo. Gene expression data has similar shortcomings, with transcript levels not necessarily 
corresponding to actual protein levels, which in turn do not necessarily correspond to enzyme activity 
levels. Metabolite measurements using mass spectrometry do offer insight into the total pool sizes 
present in vivo at the time of termination, but not into the rate at which those metabolites are being 
turned over. It would therefore be good to investigate the rates of metabolic fluxes occurring in these 
animals when metabolism is not frozen, perhaps using hyperpolarised metabolites to trace flux in vivo 




using MRI as employed by Le Page et al. (2015), or U13C labelling to assess contribution of glucose and 
fatty acid oxidation to the Krebs cycle using the model described in Chapter 3. 
6.4.2 Consistency of the Physiological Models 
Pancreatectomy as a Model of Type 1 Diabetes 
Partial pancreatectomy rapidly induced hyperglycaemia, with fasted blood sugar levels plateauing at 
around 25 mM from four weeks post-operation. This was similar to that reported in a previous study 
of the 90% pancreatectomised rat (Yu et al., 2015). The greater levels of early glycolysis seen here 
were also observed in pancreatectomised humans (Del Prato et al., 1983), and this also correlates with 
patients with type 1 diabetes. Greater dependence upon FAO and loss of metabolic flexibility has also 
been reported in STZ models of type 1 diabetes (Arikawa et al., 2007; King et al., 2001; Le Page et al., 
2015; Ritchie et al., 2017). It appears therefore that the 90% pancreatectomised rat model generated 
at Gubra ApS is a robust metabolic model of type 1 diabetes. 
However, in this model no loss of contractile function resulted from the pancreatectomy alone (Figure 
6.8) despite this being regularly reported in STZ models (Joffe et al., 1999; Nielsen et al., 2002). It is 
worth noting that in two other non-STZ models of type 1 diabetes, the partial insulin gene knockout 
Akita mice and the OVE2 knockout (Bugger et al., 2008; Liang et al., 2002; Lu et al., 2007), impaired 
contractile function was also either not noticeable or mild. There are therefore two possibilities: The 
first is that the 90% pancreatectomised rat was simply measured too early for contractile function 
alterations to have manifested, which would be addressable by running another study in which 
contractile function was assessed later; and the second is that the contractile effects of type 1 diabetes 
observed with the STZ models are in fact an effect of STZ not diabetes per se (Wold and Ren, 2004), 
and that true contractile dysfunction does not occur in the type 1 diabetic rodent heart.  
Repetitive Isoprenaline Administration as a Metabolic Stressor 
This study generated a model of isoprenaline induced cardiac dysfunction with similarities and 
differences to those reported previously. Jin et al. (2006) observed a similar loss of contractile function 
(impaired ejection fraction and fractional shortening) in dogs infused subcutaneously with 
isoprenaline. However, Desrois et al. (2014) delivered 5 mg/kg isoprenaline to rats daily via 
subcutaneous infusion, and observed an enhanced ejection fraction and ventricular mass over a 7 day 
period, which contrasts with the identical ventricular mass and decreased ejection fraction seen here. 
This data was obtained at the point of isoprenaline infusion though, while in this chapter the 
isoprenaline administration last occurred 4.5 weeks prior to termination, so if ventricular hypertrophy 
had occurred it could have subsided to be replaced by fibrosis and impaired ejection fraction by the 




time of termination. Desrois et al. also observed no alterations to blood glucose concentration and 
bodyweight between isoprenaline and control groups, which corroborates the finding that Iso affected 
neither of these parameters in this chapter. In a similar model to Desrois et al., Heather et al (2009) 
observed fibrosis in the isoprenaline treated group similar to that reported in this study, as well as 
decreased FAO and decreased sensitivity to insulin which could corroborate the decreased insulin 
receptor expression (Figure 6.13) observed in this study. Cardiac fibrosis alongside contractile 
dysfunction following isoprenaline administration has also been reported in Sprague Dawley rats 
(Zhou et al., 2017) and mice (Brooks and Conrad, 2009). Death rate following subcutaneous 
isoprenaline injection had previously been reported at 10% for a single 100 mg/kg dose (Grimm et al., 
1998), which is lower than the 43% mortality rate observed in this study; albeit in female rats rather 
than the male ones used here. Acikel et al. (2005) reported 33% mortality following a 150 mg/kg dose, 
although this is a greater dose than that employed in this chapter. 
Pancreatectomy and Repetitive Isoprenaline Stimulation 
The model of combining 90% pancreatectomy with 10 days of isoprenaline administraton has never 
been reported before. While possessing some characteristics previously reported in both models of 
type 1 diabetes and isoprenaline induced heart failure, it possesses some characteristics which set it 
apart from both. In line with both the Px/Vehicle group and a previous 90% pancreatectomy paper (Yu 
et al., 2015), the Px/Iso rats were hyperglycaemic with a fasted blood glucose concentration around 
25 mg/L.  However, unlike the Px/Vehicle rats and previously reported STZ type 1 diabetes models 
(Arikawa et al., 2007; King et al., 2001; Le Page et al., 2015; Ritchie et al., 2017)., they did not appear 
to have lost metabolic flexibility.     
   
6.4.3 Significance of Results 
Mitochondrial Capacity and Energetics 
Total mitochondrial respiratory capacity and the function of complexes I and II was impaired in both 
the Px/Vehicle and Sham/Iso groups relative to Sham/Vehicle. Respiratory capacity has not previously 
been characterised in 90% pancreatectomised rats, yet the STZ model has in multiple cases been found 
to exhibit lower total respiratory capacity than that of controls (Duicu et al., 2017; Kiebish et al., 2012; 
Loiselle et al., 2014; MacDonald et al., 2011; Pham et al., 2014). The results in this chapter show that 
the 90% pancreatectomy model generated at Gubra ApS displays a similar impairment of respiration 
capacity to this other established model of type 1 diabetes. A further insight into the metabolic 
impairment of the type 1 diabetic rat was also offered: the FAO preference ratio, or the proportion of 




complex 1 activity which could be saturated by fat oxidation alone, was significantly higher in the 
diabetic rats, indicating greater reliance on fat oxidation.  
The Sham/Iso groups also displayed diminished mitochondrial oxygen consumption capacity 
compared with Sham/Vehicle, suggesting they too had compromised mitochondrial function. While 
the mitochondrial oxygen consumption following chronic administration of isoprenaline is not well 
characterised, it has previously been shown that ETC complexes and Krebs cycle enzymes are less 
active (Punithavathi et al., 2010). In combination with the depressed respiratory capacity seen here, 
this suggests that isoprenaline administration instigated mitochondrial dysfunction.   
However, the reduction in mitochondrial function observed in both the Px/Vehicle and Sham/Iso 
groups was partially abolished in the Px/Iso rat hearts. Leak state and oxphos respiration, along with 
the capacity of both complex I and complex II, were not significantly different in the Px/Iso group 
compared with Sham/Vehicle hearts. This suggests that whatever the source of the stress which 
causes loss of mitochondrial function in Px/Vehicle and Sham/Iso hearts, the two counteract each 
other in combination. An interesting lead into the mechanism behind this is the fact that the FAO ratio 
was not increased (and was if anything decreased) between the Sham/Vehicle and Sham/Iso groups, 
suggesting the possibility that isoprenaline administration also reverses the dependency of type 1 
diabetic hearts upon fat oxidation. 
 
Metabolic Flexibility 
Examination of FAO enzyme expression helps give insight into the mechanism behind the higher 
proportion of mitochondrial respiratory capacity accounted for by FAO in the Px/Vehicle heart. 
Transcripts encoding the majority of enzymes and proteins involved in the importation of fats to the 
mitochondria and the β-oxidation of fats (ACADs and HOAD) were upregulated in the Px groups; 
although perhaps less so in the Px/Iso group. This upregulation may explain the increased FAO ratio 
in the Px/Vehicle group, as the extra facility for β-oxidation allows it to account for more of the 
mitochondrial ETC capacity. Nevertheless, the Px/Iso groups still exhibit an upregulation of fatty acid 
oxidation genes. This suggests that if they have a greater metabolic flux through the fat oxidation 
pathways and yet the mitochondrial capacity is not as saturated by this as in the Px/Vehicle group, 
then other metabolic pathways may also be upregulated in the Px/Iso animals in order to balance out 
the fluxes. 
This is best demonstrated in the glycolytic pathway, where an upregulation of aldolase appears to 
underpin enhanced glycolytic flux in the Iso treated hearts. Prior to aldolase, the early glycolytic 




intermediates appear in greater concentrations in the Px groups; yet following aldolase, which is a 
hypoxia regulated enzyme, there is greater flux through glycolysis in the isoprenaline treated groups. 
Others have indicated that adrenergic stimulation induces an increased glycolytic rate (Clark and 
Patten, 1984; Depre et al., 1998), and it appears that this may be allowing the Px/Iso group to 
counterbalance enhanced expression of FAO enzymes relative to Sham/Vehicle with similarly higher 
glycolytic flux, restoring some metabolic flexibility and allowing for conservation of mitochondrial 
function.. 
This case is further supported by the expression of enzymes which control entrance of pyruvate into 
the mitochondria and oxidative phosphorylation. Inhibitory enzymes, such as PDH kinases 1&2 which 
phosphorylate and inactivate PDH, and the subunit by which PDH phosphatase (which reverses this 
inhibition) is itself phosphorylated and inactivated, are downregulated in hearts which underwent 
isoprenaline administration. PDH flux has previously been reported to be enhanced by isoprenaline 
(Hiraoka et al., 1980), and this lower expression of PDH kinases 1 and 2 may underlie a mechanism. 
This suggests that the enhancement of glycolytic flux does not purely support anaerobic metabolism, 
and that the pyruvate is fated to be oxidised in the mitochondria. 
A further glucose metabolism related gene of interest is the glucose transporter, GLUT1. GLUT1 is 
responsible for glucose uptake from the blood, and has also been reported to be downregulated in an 
STZ model of diabetes (Šoltésová et al., 2013). However, in the Sham/Iso group, GLUT1 transcripts 
were  higher than in Sham/Vehicle, suggesting that isoprenaline stimulates a greater uptake of glucose 
and corroborating a previous finding that isoprenaline led to greater expression of GLUT1 in the heart 
(Egert et al., 1999). The insulin receptor is also downregulated in the Sham/Iso group alone, which is 
an indicator that perhaps control of glucose uptake is wrested from insulin signalling by a response to 
isoprenaline. In the Px/Iso group, these two stimuli appear to balance each another out, with 




The mechanism for this apparent protection of the diabetic heart is therefore intriguing. Previous 
studies have demonstrated that the diabetic heart is less responsive to β-adrenergic stimulation (and 
specifically with isoprenaline) than the healthy heart (Roth et al., 1995), which would help explain the 
lack of mortality in the Px/Iso group compared with the sham-operated rats. Adrenoceptors can be 
desensitised, either at the membrane or at the expression level in response to prolonged and 




excessive stimulation. Β-adrenoceptor A1 is expressed to a lesser extent than Sham/Vehicle in the 
Sham/Iso but not the Px/Iso group. This mirrors findings that β-adrenoceptors are downregulated in 
the isoprenaline induced failing heart (Yin et al., 2016), and suggests that isoprenaline stimulation of 
the β-adrenoceptor may not be having the same intensity of effect in the pancreatectomised animals. 
It has been reported before both ex vivo and in vivo that diabetic hearts are less sensitive to 
isoprenaline stimulation than their non-diabetic counterparts (Gtzsche, 1983; Roth et al., 1995). While 
β-adrenoceptor levels themselves have remained unchanged in the diabetic heart, a functional 
uncoupling between the β-adrenoceptor and downstream effectors including adenylyl cyclase has 
been reported (Bockus and Humphries, 2015; Gtzsche, 1983). This would appear to be evident in the 
findings of this study too, given that while β-adrenoceptor expression remains unchanged in the 
Px/Vehicle heart relative to Sham/Vehicle, adenylyl cyclase expression is suppressed.  This suppression 
is further exhibited in the Sham/Iso group, presumably as a continuation of the isoprenaline mediated 
desensitisation, and in the Px/Iso group the effects are additive. It is therefore probable that decreased 
sensitivity of the Px heart to isoprenaline, coupled with the phenomenon that isoprenaline stimulation 
is augmented by insulin (Almira and Misbin, 1989) means that isoprenaline does not exert such a 
damaging effect upon Px hearts as it does upon the sham operated ones. This would explain the lack 
of mortality in the Px/Iso group as well as the observation that the Px/Iso group exhibits better 
preserved cardiac mitochondrial function and energetics than the Sham/Iso group. Further, the extra 
adenylyl cyclase downregulation from isoprenaline administration could then protect the diabetic 
heart from subsequent progression of the disease through chronic adrenergic stimulation. 
 
6.4.4 Future Directions 
The exact mechanism through which isoprenaline and pancreatectomy mutually protect the heart 
from the detrimental effects of the other is of great interest and deserving of further investigation. It 
would be interesting to conduct an experiment in which Px and Sham hearts were perfused in 
Langendorff mode and then exposed to isoprenaline stimulation in order to directly establish the 
acute effects of isoprenaline in each situation upon both contractility and substrate oxidation, perhaps 
again using U-13C labelled substrates. Similarly, use of increasing doses of dobutamine as used by Choi 
et al. (1997) would allow a dose response curve and assessment of β-receptor desensitisation to be 
conducted, an assessment which could also be used to analyse whether the Iso administered groups 
were less susceptible to chronic β-adrenergic stimulation  




Another potential follow up experiment would be to terminate the experiment and assess the hearts 
immediately after Isoprenaline administration. The insights gained from this would be twofold. Firstly, 
if the Px groups displayed similar respiratory capacity and energetics to those of the Px/Iso group at 
ten weeks, it could be that isoprenaline administration arrested the progression of type 1 diabetes in 
the heart. If, on the other hand, respiratory capacity and energetics were already further deteriorated 
than observed here in the Px/Iso group, then the implication would be that Iso reversed the process. 
Secondly, it would show how the results presented here sit on the timeline of recovery from 
isoprenaline administration, determining whether they initially manifested the hypertrophy seen in 
previous papers (Desrois et al., 2014; Grimm et al., 1998; Heather et al., 2009), but over the following 








7.1 SUMMARY OF FINDINGS 
The studies presented in this thesis aimed to investigate the manipulation of cardiac metabolism in 
various pathological states. Initially, the effects of dietary nitrate and intralipid on the recovery of the 
heart from ischaemia/reperfusion were examined. When this revealed that ketogenesis occurred in 
the ischaemic heart, the next step was to interrogate this the mechanism underlying this process, and 
the implications for cardiac recovery. In the final chapter, metabolism was investigated in the diabetic 
heart, examining how the type 1 diabetic heart responded to metabolic stress.  
In Chapter 3, a method was developed for the interpretation of 13C labelling patterns in the Krebs 
cycle, in order to determine the proportional oxidation of different substrates.  
Chapter 4 presented a study into the effects of dietary nitrate supplementation upon the heart’s 
capacity to recover from ischaemia/reperfusion. Sodium nitrate supplementation enhanced the 
functional recovery of the heart following reperfusion in the absence of triglyceride in the perfusion 
buffer. However, when triglyceride was added to the perfusion mix, nitrate supplementation impaired 
the recovery of the heart. The intralipid by itself had cardioprotective effects. Neither the effects of 
dietary nitrate supplementation nor intralipid protected mitochondrial respiratory capacity, which 
was the same in all groups following reperfusion. However, a surprising effect of nitrate 
supplementation appeared to be the enhancement of levels of the ketone body β-hydroxybutyrate 
present in the ischaemic myocardium, despite none being present in the initial composition of the 
buffer. This suggested that ketogenesis had occurred in the ischaemic heart 
Ischaemic ketogenesis was further investigated in Chapter 5. Unlike in the liver, ischaemic ketogenesis 
in the heart was not a result of fat metabolism exceeding metabolic demand, with the proportion of 
fatty acid to glucose oxidation remaining unaltered during ischaemia. It appeared instead that 
ketogenesis in the heart was driven by a combination of the reductive environment and accumulation 
of acetyl-CoA induced by ischaemia. Diverting greater levels of pyruvate to acetyl-CoA through the 
inhibition of LDH increased the concentration of β-hydroxybutyrate. Furthermore, inhibition of 
ketogenesis, using the HMG-CoA synthase inhibitor hymeglusin, improved functional recovery of the 
heart following reperfusion, suggesting that the accumulated of β-hydroxybutyrate is detrimental. 
This comes despite the observation that β-hydroxybutyrate suppresses inflammasome activation, 
with hymeglusin engendering an increased inflammatory state in the ischaemic heart tissue. 
Chapter 6 investigated the resilience of the type-1 diabetic heart against chronic stimulation with 
Isoprenaline. Mitochondrial respiratory capacity was impaired in the rat heart following 90% 
pancreatectomy, with a substrate switch towards fatty acid oxidation being observed alongside 
greater expression of FAO-related enzymes and evidence of oxidative stress. Isoprenaline treatment 




also impaired respiratory capacity, but enhanced flux through glycolysis through increased aldolase 
expression. In the hearts of Isoprenaline treated pancreatectomised rats, mitochondrial respiratory 
capacity was preserved, and whilst myocardial PCr was depleted following pancreatectomy, this too 
was conserved when pancreatectomised rats had been administered isoprenaline. Uncoupling of 
adrenergic signalling through repression of adenylyl cyclase by both isoprenaline and pancreatectomy 
may underpin this apparent protection.      
 
7.2 CRITIQUE OF EXPERIMENTAL TECHNIQUES 
7.2.1 Langendorff Perfusion 
Control over supply of metabolic substrates 
In this thesis, the Langendorff method of heart perfusion has conferred the great advantage that it 
has allowed the control of substrate supply to the heart. By varying the supply of substrates in the 
buffer supplied to the Langendorff heart, the capacity to study how metabolite supply influences 
cardiac function and metabolism in a controlled manner was gained. This kind of study is not practical 
in the in vivo heart, given the impossibility of removing all fatty acids from the circulating blood supply, 
or precisely regulating the concentration of fats in the blood. It is a strength of several studies which 
have examined ex vivo cardiac function with and without various fats in the buffer (King et al., 2001; 
Lou et al., 2014a), allowing determination of the effect upon the heart, and in this thesis allowed the 
elucidation of the interaction between dietary nitrate supplementation and cardiac triglyceride use 
(Chapter 4). It also allowed measurement of cardiac triglyceride uptake, as we know the concentration 
of lipid entering and leaving the heart varies, and the identification of cardiac ketogenesis because it 
was possible to say with certainty that no β-hydroxybutyrate was being supplied to the heart from 
other tissues. Perfusion with oxygenated KH buffer is removed from a physiological situation however. 
Aside from being less effective at transporting oxygen than blood, the 11 mM glucose used here in the 
buffer in order to ensure cardiac glucose uptake must be high compared to blood glucose levels, in 
part to overcome the lack of insulin to stimulate glucose uptake. All manners of other substrates and 
cardio-effective hormones circulate in the blood, and it is both a disadvantage and an advantage to 
exclude these from the system: reproducibility and simplicity of the experiment confer greater power 
to see metabolic alterations, yet the system is further removed from the conditions present in vivo 
and this caveat must be considered when drawing conclusions from the Langendorff perfused heart. 
 





The Langendorff heart preparation also offers a reproducible framework for investigating the effects 
of drugs and other compounds on the heart (Lateef et al., 2015). In a similar manner to metabolites, 
pharmacological compounds could be added to the perfusion buffer at any point during the perfusion 
protocol. This allowed effects on the function and metabolism to be taken into account, as well as 
more subtle effects such as how they influence the heart’s ability to recover from a period of 
ischaemia. Introducing these compounds to the Langendorff preparation had several other 
advantages; it negated the effect of any systemic effects  the compound may have, allowing 
characterisation of the cardiac effects alone; and it meant that the concentration of the drug 
administered could be much more easily controlled without the influence of pharmacokinetic effects. 
The setup also allowed easy use of non-clinically approved compounds, such as hymeglusin, as there 
could be no off-target side effects (Verdouw et al., 1998).  
Low-Flow Ischaemia 
In contrast to total global ischaemia, during which all supply of buffer to the heart ceases, the 
ischaemia reperfusion protocols used in this thesis involved low-flow ischaemia. It is rare during a 
clinical case of ischaemia that all blood flow to the heart is removed; more usually the vessel is partially 
occluded with a diminished supply of blood still and low-flow ischaemia replicates this (Verdouw et 
al., 1998). During aerobic perfusion at 100 mmHg the rate of coronary flow was as high as 40 ml/min, 
however during low-flow ischaemia this could fall to 0.5 ml/min. However, this low flow rate still 
allows delivery of some substrate, whilst ischaemic products and biomarkers are washed out, and can 
be detected using LC-MS allowing insight into the metabolic response to ischaemia. 
Strengths and Limitations of the Langendorff Heart as a Model of Ischaemia/Reperfusion 
Investigation of Ischaemia/Reperfusion using the Langendorff preparation is common. Whilst there 
are other models for investigating ischaemia/reperfusion including in vivo ligation of the coronary 
arteries, Langendorff perfusion offers clear advantages. In the in vivo scenario, an anaesthetised rat 
has its chest opened and one of the coronary arteries is ligated. This could be argued to be more 
physiological than the Langendorff ischaemia/reperfusion model, however the presence of 
anaesthetic plus the severe physiological stress of having the chest cavity opened could have a large 
influence upon results. Presence of actual blood rather than perfusion buffer could be considered an 
advantage or a disadvantage, being more physiological and having a greater oxygen carrying capacity 
than KH buffer yet offering less control over its constituents. Low flow ischaemia in the Langendorff 
heart also allows the infliction of a more consistent degree of ischaemia than is possible in vivo, 




allowing more consistent results to be obtained and offering more power to see differences between 
experimental groups. The fact that the heart is still part of a closed circulation and under the influence 
of anaesthetic and the nervous system in vivo also makes it harder to interpret measurements of 
cardiac function than the more comprehensively analysable Langendorff heart. The Langendorff 
perfused heart therefore has limitations, but represents a more controlled experimental platform for 
investigation of ischaemia/reperfusion.  
 
7.2.2 High Resolution Respirometry 
Suitability of Preparation of the Biological Samples for Respirometry 
Although the most physiological quantitation of respirometry in biological samples would be in vivo 
or in intact tissue, in practice this is less practical and does not have the resolution to see alterations 
in the mitochondrial machinery. Measurement of oxygen consumption in the whole animal cannot 
distinguish between tissues and does not allow the use of compounds like mitochondrial complex 
inhibitors to investigate ETC flux in more depth. Meanwhile, intact cells enable the investigator to 
distinguish which tissue they originate from, but are not permeable to certain inhibitors and 
substrates, limiting the number of assays which can be used. Both methods also fail to account for the 
concentration of endogenous metabolites, ADP and other metabolically active components, meaning 
it is difficult to accurately quantitate what the limiting factor on mitochondrial function is. 
For these reasons, permeabilisation of cardiac fibres was chosen as the method through which to 
measure mitochondrial oxygen consumption in this thesis. Conducting respirometry upon isolated 
mitochondria has other advantages, including the ability to quantify the mitochondrial density of the 
tissue, isolate separate sub-populations of mitochondria and offer a direct measurement of how many 
molecules of ADP are consumed per oxygen atom. However, mitochondria are not isolated organelles 
within the cell, operating in a system with the cytoskeleton and cytoplasmic enzymes to effect 
transportation of substrates and products into and out of the mitochondria. Isolation of mitochondria 
can result in both deformation of their structure and destruction of the network they operate in within 
the cell, while the choice to use permabilised LV fibres meant that these systems remained intact 
(Kuznetsov et al., 2008). Washing the permeabilised tissue preparation in this state also removed 
endogenous substrates and ADP, meaning that measurements could be made in the confidence that 
leftover metabolites from before the preparation would not affect respiration. 
 





Strengths and Limitations of the Measurement of Mitochondrial Oxygen Consumption 
Since oxygen consumption at the ETC is a function of electron flux, it offers a reliable way to observe 
respiratory capacity, flux through various metabolic pathways and the function of different ETC 
complexes. However, given that it was measured ex vivo, and in the presence of saturating 
concentrations of experimentally administered substrates, the respirometry employed in this thesis 
indicates maximal cellular capacity for respiration rather reflecting respiration in vivo. Oxygen level 
was also maintained in the oxygraph chambers throughout the protocol, which is a necessity of 
measuring oxygen consumption to overcome diffusion gradients yet means that limitations of oxygen 
concentration which occur in vivo or in conditions such as ischaemia are not replicated. Further, post 
translational modifications such as the phosphorylation of PDH may be lost outside of the 
physiological system. Given all of the above, it is important to note that the respirometry data 
presented in this thesis represents the maximal capacity of the system for oxygen consumption in the 
given conditions, and that it has the caveat of not necessarily being a representation of the rates which 
occur in vivo.  
 
7.2.3 Mass Spectrometry 
Metabolic profiling using liquid chromatography coupled mass spectrometry has worked well 
combined with both langendorff perfusion and high resolution respirometry in this thesis. Mass 
spectrometry allows assessment of levels of metabolites present in a tissue at the point the sample 
was frozen, so metabolite levels following, for example, the imposition of ischaemic conditions using 
the Langendorff protocol, can be directly assessed at the point of analysis. Measurement of 
compounds in this way allows only the measurement of metabolite levels, and not of the flux through 
the pathway under those conditions. Thus a metabolite may be present in higher levels due to greater 
flux through the pathway, or because inhibition of an enzyme has led to its accumulation. Combination 
of this technique with measurements of maximal metabolic rates, such as those obtained through 
respirometry, or with carbon labelling flux analysis such as that used in Chapter 3, can help to 
overcome this issue.   
A potential drawback of using this kind of mass spectrometry is that it is a semi-quantitative technique 
rather than one which allows easy quantitation of metabolite levels. Due to variations between 
sample batches, it is possible to directly compare levels of metabolites between samples run at the 
same time, but not with those run at different time points. This means the results may be assessed 




relative to those in a control sample, but that for quantification of metabolites and comparison of 
concentrations between different metabolites a concentration ladder of known concentrations would 
have to be run for each compound on each experimental run in order to make the technique 
quantitative. Owing to the sheer number of metabolites assessed in each sample, alongside the 
number of extra sample runs this would represent, this would be prohibitive. However, in this thesis 
the semi-quantitative analysis was not a limitation, as I was assessing how different experimental 
conditions altered metabolite levels relative to those in control samples.    




7.3 THIS THESIS IN THE CONTEXT OF THE WIDER FIELD 
7.3.1 Fat Oxidation in the Ailing Heart 
Pathological, Beneficial or is the Key a Balanced Diet? 
While there have been some papers pronouncing the benefits of FAO in ischaemia, there is also a large 
volume of work indicating that excess FAO is detrimental (Lopaschuk et al., 2009). Controversy 
therefore remains.  
The work presented in Chapters 4 and 5 appears to contradict the school of thought that FAO occurs 
excessively and is pathological during ischaemia on several counts. Hearts perfused with intralipid in 
the buffer appeared to recover contractile function to a greater extent than those given only glucose 
in the perfusion buffer upon reperfusion from ischaemia, and while exhibiting increased mitochondrial 
uncoupling they also appeared to have enhanced ATP production. This suggests a cardioprotective 
effect of circulating triglycerides, which has also been observed in several other studies involving FAO 
during ischaemia (King et al., 2001; Li et al., 2013; Lou et al., 2014c, 2014a; Rahman et al., 2012)  
Meanwhile, despite claims that FAO increases during ischaemia due to decreased malonyl-CoA 
production (Fillmore et al., 2014), in Chapter 5 malonyl-CoA was seen to be increased in the ischaemic 
heart. This would suggest a decrease in capacity for FAO through inhibition of CPT-1 (Hue et al., 2009), 
which was supported by the finding that cardiac uptake of triolein was almost completely attenuated 
during ischaemia, and that the proportional contribution of acetyl-CoA derived from glucose oxidation 
relative to that derived from FAO was unchanged. A lack of increase in FAO during ischaemia is a 
finding mirrored in older studies (Opie et al., 1973; Whitmer et al., 1978), and makes sense when 
considering that with oxygen as a limiting factor during ischaemia, there is a benefit to a switch 
towards more oxygen-efficient substrates.  
This discrepancy may be due to experimental differences. Kudo et al. (1995) observed decreased 
malonyl-CoA concentrations during ischaemia, and then a further fall after reperfusion. They did 
however use a more severe ischaemic protocol than that used during this thesis (30 min total global 
ischaemia), which immediately presents two possible reasons as to why they observed decreased 
ischaemic malonyl-CoA levels. The first is that they may simply have caused more damage to the 
myocardium, which would reduce the overall oxidative capacity of the heart and therefore ability to 
synthesise malonyl-CoA. Secondly, through obstructing all substrate delivery to the heart during the 
ischaemic period, they would have removed the supply of the substrates from which malonyl-CoA is 
synthesised. This also limited their ability to measure cardiac fatty acid uptake during ischaemia, and 
extrapolated from the increased rate of fatty acid uptake upon reperfusion to assume that FAO had 




also increased in the ischaemic heart. Notably, they also observed no difference in either CPT-1 or ACC 
activity levels at the end of ischaemia relative to pre-ischaemia. The low-flow ischaemia used in this 
thesis offers a different capacity to observe metabolism in the ischaemic heart, with a severe 
reduction in flow rate resulting in an ischaemic heart, yet not denying the myocardium the metabolic 
substrates which would be available to it in the physiological setting and allowing measurement of 
metabolic flux and substrate uptake throughout the ischaemic period. 
Taken together, it seems that FAO may have become an unfairly maligned villain during cardiac 
ischaemia. While the data presented in this thesis cannot contest that which has been observed in 
total global ischaemia, in the model of low-flow ischaemia employed here and previously (King et al., 
2001; Li et al., 2013; Lou et al., 2014c, 2014a; Opie et al., 1973; Rahman et al., 2012; Whitmer et al., 
1978), FAO during ischaemia has been found not only to not be increased, but also to be conducive to 
enhanced functional recovery. The implications of this are that clinically reperfusing patients with fatty 
acids or pharmacologically attempting to enhance FAO may in fact be beneficial in cases presenting 
with ischaemic heart disease.     
Separately, in the diabetic myocardium, increased FAO capacity was only associated with impaired 
mitochondrial respiration and energetics when glycolytic flux was not increased in tandem. In Chapter 
6 it was demonstrated that in the 90% pancreatectomised rat increased FAO capacity was observed 
through both mitochondrial oxygen consumption rates and FAO associated gene expression. This 
correlated with impaired mitochondrial respiratory capacity and energetics. Yet in pancreatectomised 
rats which were repetitively administered isoprenaline between 5 and 7 weeks post-operation, overall 
mitochondrial respiratory capacity was conserved whilst FAO associated gene expression and oxygen 
consumption were still enhanced. Suggestion that enhanced capacity for, and rate of, FAO results in 
lipotoxicity and associated pathology (Bayeva et al., 2013) may therefore only hold if there is a 
concurrent loss of metabolic flexibility. Restoration of flexibility may be an important avenue to 
explore in terms of treatment of diabetes mellitus, and therefore future exploration using tools such 
as inducible knockout models for both the glycolytic and FAO pathways to further establish the 
importance of flexibility over one pathway or the other could offer much insight.  
7.3.2 The Heart as a Setting for Ketogenesis 
Net ketogenesis has never before been reported to occur in the intact heart. The work I present in this 
thesis is the first to my knowledge to do so, and goes further yet in attempting to establish the 
mechanism for this ketogenesis, and whether it is beneficial or detrimental to recovery from 
ischaemia/reperfusion. The requisite enzymes are all known to have been present in the heart, so why 
has nobody observed cardiac ketogenesis before? 




Most probably, nobody has thought to look. Krebs et al. (1961) came close when homogenised ovine 
heart tissue to observe that sodium amytal, a mitochondrial complex I inhibitor, resulted in the 
reduction of acetoacetate to β-hydroxybutyrate. They did not, however, investigate whether this 
process occurred in any pathophysiological situations in the intact heart.  
Conversely, Fink et al. (1988) demonstrated that there was bidirectional flux through the ketogenic 
pathway in the perfused working rat heart through measuring dilution of a (3R)-hydroxybutyrate 
tracer pool, yet did not observe any net accumulation of ketone bodies in the heart. The conclusion 
this paper drew was therefore that this process was negligible, and reflected the fact that the capacity 
of the reversible enzyme SCOT was 60 times greater than cardiac uptake of β-hydroxybutyrate could 
account for. While they speculate that the rate of what they term “pseudoketogenesis” is not 
necessarily the same under all experimental conditions, they did not attempt to manipulate these 
conditions to investigate whether the acetoacetate to β-hydroxybutyrate direction of the reaction 
could become dominant in some scenarios. 
My work in Chapter 5 is based on novel observations, but addresses the gaps in both of these studies. 
Like Krebs et al. I demonstrate that net ketogenesis can occur in cardiac tissue; yet unlike that study I 
also demonstrate that net ketogenesis does occur in the intact, perfused, heart, without 
pharmacological stimulation, and is therefore a relevant process to ischaemic heart disease. Like Fink 
et al. meanwhile, I demonstrate flux through the ketogenic pathway in a perfused (but not working) 
heart model; yet unlike them I have manipulated the conditions of the heart both pharmacologically 
and through the induction of ischaemia to demonstrate that ketogenesis can become significant in 
certain conditions. Because of these points of difference, I can conclude for the first time that net 
ketogenesis can and does occur in the ischaemic heart, without any pharmacological stimulation being 
necessary. 
The Physiological Implications of Ischaemic Ketogenesis 
No work has ever before been done to attempt to establish whether ischaemic ketogenesis is 
beneficial or detrimental to recovery following reperfusion. Whilst there are papers which have sought 
to address whether exogenous β-hydroxybutyrate could protect the heart against ischaemia/ 
reperfusion (Goodwin and Taegtmeyer, 1994; King et al., 2001; Liu et al., 2016; Zou et al., 2002), there 
are none which examine the capacity of endogenously produced ketone bodies to do so. It may have 
been reasonable to expect that the increased availability of an oxygen efficient substrate upon 
reperfusion might aid recovery, yet several studies have shown that exogenous provision is not 
cardioprotective unless previous fasting has upregulated ketolytic enzymes in the heart (Goodwin and 
Taegtmeyer, 1994; Zou et al., 2002). These studies were performed without the awareness that 




ketogenesis actually occurs during ischaemia, and my work in Chapter 5 addresses functional recovery 
in the knowledge that this does occur for the first time. It demonstrates that increased availability of 
endogenously produced β-hydroxybutyrate upon reperfusion in the presence of sodium oxamate is 
associated with worsened recovery from ischaemia reperfusion, whilst partial inhibition of 
ketogenesis enhances functional recovery. This thesis therefore presents the novel finding that 
ketogenesis during ischaemia is likely detrimental to recovery. While there is not yet evidence upon 
which to base a hypothesis that this ketogenesis may be significant to human health, this finding is 
certainly worthy of further examination in the attempt to develop treatment of ischaemic heart 
disease. 
7.3.3 Does Impairment of Contractile Function Truly Occur in the Type 1 Diabetic 
Rodent Heart? 
A 90% pancreatectomy model of the type 1 diabetic heart has been described before (Yu et al., 2015), 
but the work presented in Chapter 6 of this thesis is the first ever to characterise its metabolic 
phenotype and assess its mitochondrial function. As with the well characterised streptozotocin 
induced model of type 1 diabetes (Flarsheim et al., 1996; Lashin et al., 2006; Chatham and Forder, 
1997; Depre et al., 2000; Finck et al., 2002; How et al., 1904; Nielsen et al., 2002), there is severe 
impairment of mitochondrial respiratory capacity, and a greater reliance upon FAO. Unlike some of 
these cases of streptozotocin induced type 1 diabetes though, over a period of 10 weeks the 90% 
pancreatectomised model did not develop contractile impairment, or cardiomyopathy. There are 
several possible reasons for this discrepancy; one being that 90% removal of the pancreas is a very 
harsh treatment, and that the condition of the rats deteriorates too swiftly for them to develop 
cardiomyopathy. However, there is a distinct lack of any evidence that cardiomyopathy has been 
developed in any rodent model other than those induced by streptozotocin. Since streptozotocin is 
known to have direct effects upon cardiac contractility (Wold and Ren, 2004), I believe it likely that 
most rodent incidence of diabetic cardiomyopathy are in fact the result of direct off target effects of 
streptozotocin. Diabetic cardiomyopathy in the rodent heart may well be a myth. 
7.3.4 Structural Effects of Isoprenaline Administration upon the Heart 
Several papers have previously examined the potential of isoprenaline administration to induce heart 
failure (Jin et al., 2006; Desrois et al., 2014; Heather et al., 2009; Zhou et al., 2017). However, the work 
presented in this thesis is the first to my knowledge to investigate this from a number of angles. No 
other work has previously subjected rats to daily bolus injections of isoprenaline over a ten day period; 




no other work has then allowed the rats 3.5 weeks without injection to recover; and no other work 
has examined the mitochondrial and metabolic effects of this administration to such depth. 
The hearts examined in this thesis show similar induction of fibrosis to those seen in studies where 
isoprenaline was delivered through continuous infusion via an osmotic pump for 7 days (Desrois et al., 
2014; Heather et al., 2009). There was no evidence though, of the ventricular hypertrophy observed 
in these studies, which both examined the hearts immediately following the end of the 7 day infusion 
period. This suggests that either constant infusion of isoprenaline leads to greater wall stress and 
remodelling than repetitive bolus dose administration which may allow the heart to recuperate 
between doses rather than develop hypertrophy, or that the 3.5 weeks between isoprenaline 
administration and termination in this study was long enough for hypertrophy to be reversed. Desrois 
et al. (2014) and Heather et al. (2009) also infused 5mg.kg bodyweight-1day-1 isoprenaline, a greater 
overall dose of isoprenaline than the 1mg.kg bodyweight-1day-1 injections detailed in this thesis which 
could also explain our study not replicating the hypertrophy they observe. The delivery of isoprenaline 
was also spread out across the whole day in these papers, which may lessen the systemic shock and 
help explain how they record lower initial mortality than that observed with the bolus doses 
administered in this thesis.   
 














7.4 FUTURE DIRECTIONS 
The work presented in this thesis has presented several novel discoveries which are worth expanding 
further, not least the finding that ketogenesis occurs in the ischaemic rat heart and that isoprenaline 
preserves mitochondrial function in the type 1 diabetic rat heart. 
If a year’s further funding and time were available to these projects, I would identify further 
investigation of β-hydroxybutyrate metabolism in the type 1 diabetic heart as a priority, as these 
experiments could elucidate several of the unanswered questions presented by the findings of this 
thesis. Firstly, catheterisation of the rat heart and sampling of blood would allow investigation of 
whether the type 1 diabetic heart produced β-hydroxybutyrate under physiological conditions. 
Secondarily, mounting of the hearts for Langendorff perfusion would allow further verification of 
whether this occurred in normoxic conditions, and interrogation of how rates of ketogenesis were 
altered during ischaemia. Given that the data in Figure 6.17 suggests HMG-CoA synthase expression 
is increased in the 90% pancreatectomised rat heart and SCOT expression is decreased this 
observation should also cast further insight into which of the two enzymes contributes most greatly 
to cardiac ketogenic flux. Conducting these investigations whilst U13C glucose is present in the 
perfusion buffer would also be revealing in terms of further characterising how the ratio of FAO to 
glucose oxidation is altered in the type 1 diabetic heart; findings produced with this data could also 
be used to further validate the model presented in Chapter 3. 
Hearts perfused in Langendorff mode could also be further stimulated with isoprenaline to investigate 
how the responses of sham and pancreatectomised hearts to the agent differs in real time. One of the 
biggest unanswered questions in Chapter 6 is why none of the pancreatectomised rats succumbed to 
isoprenaline when so many of the sham operated ones did; there are many possible answers to this 
including that desensitisation of β adrenoceptors in the pancreatectomised heart may reduce the 
stimulatory effect of isoprenaline, or that the energetically impaired state renders the 
pancreatectomised heart less able to respond to said stimulation. Investigation of the effects of 
isoprenaline stimulation on the two groups with and without β blockers in the perfusion buffer would 
establish whether or not desensitisation contributes to the difference. 
If a greater length of time, and further resources were available, a priority would be to confirm 
whether the observation of ischaemic ketogenesis extends to the in vivo heart and to humans. In the 
rat, this could be done by cannulation of the heart followed by in vivo partial occlusion of the 
descending coronary artery. Blood samples taken before and after the heart could be examined using 
LC-MS in order to determine the rate of ketogenesis. Following reperfusion, the whole heart could be 
removed, fixed and stained to assess whether ketogenesis had any impact upon infarct size, given that 




in vivo immune cells play a part in the process and the inhibitory effects of β-hydroxybutyrate upon 
the inflammasome would have a greater effect upon the outcome than in the Langendorff perfused 
heart. 
Given ethical considerations, attempts to confirm ischaemic ketogenesis in humans would be difficult 
given that initiating ischaemic periods in live humans is frowned upon. If the earlier suggested study 
into ketogenesis in type 1 diabetes bore fruition, this would be much easier to follow up in humans 
and would take priority given that it would involve only blood samples from across the heart 
catheterisation of patients, a routine operation which many of these patients already undergo. With 
the ischaemic heart however, unless relying on tissue from patients who have passed away from their 
ischaemic incident (which would be difficult to find controls for), a proxy would be required. One 
possibility here is to attempt to obtain tissue samples from ex vivo transplant hearts which are kept in 
cold ischaemia. 
Further work to be done expanding on the findings of this thesis could centre around establishing the 
heart’s status of substrate supply during ischaemia/reperfusion, and whether supplementation or 
deprivation of substrate to the heart could improve prognosis. In Chapter 4, presence of intralipid in 
the perfusion buffer was cardioprotective, yet while there is an argument that this could be due to 
cardioprotective effects of triglycerides, it could also be argued that when more substrate is available 
to a heart which is potentially nutrient deprived it will recover better. Reperfusing hearts from 
ischaemia while increasing the concentration of glucose and intralipid available to them without 
varying the proportions at which they are present in the buffer would be a good way to address 
whether this had any impact upon functional recovery. If a greater functional benefit were to be 
gained by instead varying the proportion of triglyceride to glucose in the buffer, it may be concluded 
to be an effect of intralipid rather than substrate availability; otherwise, substrate supply itself may 
be limiting.  
  




7.5 CONCLUDING REMARKS 
This thesis has studied metabolic aspects of ischaemic and diabetic heart that have not previously 
been explored. The emergence of ketogenesis as a process which occurs not only in the liver, but also 
in the ischaemic heart is a novel finding which may hold potential both as an avenue for easily effected 
metabolic interventions, and as an insight into the ischaemic metabolism. FAO appears to be less 
detrimental in either ischaemic or diabetic heart disease than previously projected, with its occurrence 
potentially beneficial to the ischaemia/reperfusion recovery process and not so damaging if elevated 
in a type 1 diabetic heart so long as metabolic flexibility is maintained. These findings, coupled with a 
novel method of analysing stable isotope labelling data from the Krebs cycle, represent a novel 
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II.1 Composition of the Krebs-Henseleit Buffer 
Table 1: The basic composition of the Krebs-Henseleit buffer (KH) used to sustain the heart. The 
buffer is composed at pH 7.4, and may contain additional substrates/components depending upon 
the experiment.   
Constituent Concentration (mM) Function 
Sodium Chloride 
(NaCl) 
118 Controlling buffer osmolarity; 
Source of Na+ for ion homeostasis 
Potassium Chloride 
(KCl) 
4.7 Source of K+ for ion homeostasis 
Magnesium Sulphate 
(MgSO4) 
1.2 Source of Mg2+ for ion homeostasis 
EDTA 0.5 Ion chelator 
Anticoagulant 
Glucose 11 Metabolic substrate 
Sodium Bicarbonate 
(NaHCO3) 
25 pH buffer 
Calcium Chloride 1.3 Provides Ca2+ for cardiac contractile function 
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II.2 Composition of Buffers Used for Respirometry 
BIOPS 
Table 2: Composition of BIOPS for the preservation of biological samples and permeabilisation of 
fibres. pH 7.1 
Constituent Concentration (mM) Function 
CaK2EGTA 2.77 Source of Ca2+ and K+ for regulation of ion gradients 
EGTA functions as an ion chelator 
K2EGTA 7.23 Further source of K+ and EGTA 
Na2ATP 5.77 Source of ATP to allow survival of tissue 
MgCl2.6H2O 6.56 Source of Mg2+ to augment enzyme function 
Taurine 20 Muscle relaxant – depresses action potentials 
ROS scavenger 
Na2PCr 15 Source of PCr for tissue energetics 
Imidazole 20 Interferes with protein interactions to preserve tissue 
state 
Dithiothreitol 0.5 Reduces disulphide bonds, further preventing protein-
protein interaction 
MES Hydrate 50 pH buffer 
 
  




Table 3: Composition of MiR05, the mitochondrial respiration medium. A muscle relaxant 





EGTA 0.5 Ion chelator 
MgCl2.6H2O 3 Mg2+ to augment enzyme function 
K-Lactobionate 60 Source of K+ for intracellular ion homeostasis 
Taurine 20 Muscle relaxant – depresses action potentials 
ROS scavenger 
KH2PO4 10 Phosphate source for ADP phosphorylation 
HEPES 20 pH buffer 
D-Sucrose 110 Impermeant for maintenance of osmolarity 
BSA 1g/l Ion chelator; binds free fatty acids 
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II.3 Measured SRM Transitions 
C18Pfp Method 
Table 4: SRM Transitions measured using the C18pfp method 












MDA 0 6.5 Positive 73.152 45.222 10.253 125 
Alanine 0 6.5 Positive 90.1 44.275 11 30 
[13C1]Alanine_1 0 6.5 Positive 91.1 44.275 11 30 
[13C1]Alanine_2 0 6.5 Positive 91.1 45.275 11 30 
[13C2]Alanine_1 0 6.5 Positive 92.1 45.275 11 30 
[13C2]Alanine_2 0 6.5 Positive 92.1 46.275 11 30 
[13C3]Alanine 0 6.5 Positive 93.1 46.275 11 30 
Crn 0 6.5 Positive 114.1 86.141 11 49 
ProIS 0 6.5 Positive 121.15 74.188 17 46 
NicAm 0 6.5 Positive 123.152 80.165 19.556 30 
NicAc 0 6.5 Positive 124.07 80.111 20.82 168 
Vald8 0 6.5 Positive 126.1 80.2 10 41 
Cr 0 6.5 Positive 131.975 43.111 29.972 30 
Asn 0 6.5 Positive 133.1 116.049 8 42 
Asn_2 0 6.5 Positive 133.2 60 20 44 
Asn_1 0 6.5 Positive 133.2 74.12 16 44 
Aspartate 0 6.5 Positive 134.175 74.175 15 31 
[13C1]Aspartate_1 0 6.5 Positive 135.175 74.175 15 31 
[13C1]Aspartate_2 0 6.5 Positive 135.175 75.175 15 31 
[13C2]Aspartate_2 0 6.5 Positive 136.175 74.175 15 31 
[13C2]Aspartate_1 0 6.5 Positive 136.175 75.175 15 31 
[13C2]Aspartate_3 0 6.5 Positive 136.175 76.175 15 31 
[13C3]Aspartate_2 0 6.5 Positive 137.175 75.175 15 31 
[13C3]AspartateC3 0 6.5 Positive 137.175 76.175 15 31 
[13C4]Aspartate 0 6.5 Positive 138.175 76.175 15 31 
Leud10 0 6.5 Positive 142.025 96.2 8 35 
Glutamate 0 6.5 Positive 148 84.15 16 46 
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[13C1]Glutamate_1 0 6.5 Positive 149 84.15 16 46 
[13C1]Glutamate_2 0 6.5 Positive 149 85.15 16 46 
[13C2]Glutamate_1 0 6.5 Positive 150 85.15 16 46 
[13C2]Glutamate_2 0 6.5 Positive 150 86.15 16 46 
Methionine 0 6.5 Positive 150.05 61.16 23 36 
[13C3]Glutamate_1 0 6.5 Positive 151 86.15 16 46 
[13C3]Glutamate_2 0 6.5 Positive 151 87.15 16 46 
[13C4]Glutamate_1 0 6.5 Positive 152 87.15 16 46 
[13C4]Glutamate_2 0 6.5 Positive 152 88.15 16 46 
[13C5]Glutamate 0 6.5 Positive 153 88.15 16 46 
Glu13C515NP 0 6.5 Positive 154.1 89.094 15 47 
LysOH 0 6.5 Positive 163.2 100.1 16 48 
MetSO 0 6.5 Positive 166 149.109 12 48 
GuaO 0 6.5 Positive 168 151.1 19 84 
Phed5 0 6.5 Positive 171.1 125.15 13 41 
TyrOH 0 6.5 Positive 198.1 152.1 12 57 
TyrNO2 0 6.5 Positive 227.1 181.1 12 83 
GSH 0 6.5 Positive 308.1 233.104 13 68 
cAMP 0 6.5 Positive 330.1 136.21 25 91 
NsoGSH 0 6.5 Positive 337.13 307.054 10.253 122 
cGMP 0 6.5 Positive 346 152.108 21 86 
AMP 0 6.5 Positive 348.1 136.123 20 82 
Ribofl 0 6.5 Positive 377.161 243.071 21.73 249 
GSSG 0 6.5 Positive 613.2 355.161 22 106 
NAD 0 6.5 Positive 664.1 136.237 43 103 
FAD 0 6.5 Positive 786.2 348.153 20 146 
Pyr 0 6.5 Negative 87 43 10 43 
PyrNF 0 6.5 Negative 87 87 0 43 
PyrU13C 0 6.5 Negative 90 45 10 43 
PyrNFU13C 0 6.5 Negative 90 90 0 43 
2OHBA 0 6.5 Negative 103.025 57.169 12 44 
3OHBA 0 6.5 Negative 103.025 73.143 10 40 
[13C1]3OHBA_1 0 6.5 Negative 104.025 73.143 10 40 
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[13C1]3OHBA_2 0 6.5 Negative 104.025 74.143 10 40 
[13C2]3OHBA_1 0 6.5 Negative 105.025 74.143 10 40 
[13C2]3OHBA_2 0 6.5 Negative 105.025 75.143 10 40 
[13C3]3OHBA_1 0 6.5 Negative 106.025 75.143 10 40 
[13C3]3OHBA_2 0 6.5 Negative 106.025 76.143 10 40 
[13C4]3OHBA 0 6.5 Negative 107.025 76.143 10 40 
Fum/kVal 0 6.5 Negative 115 71.172 7 50 
[13C1]Fumarate_1 0 6.5 Negative 116 71.172 7 50 
[13C1]Fumarate_2 0 6.5 Negative 116 72.172 7 50 
[13C2]Fumarate_1 0 6.5 Negative 117 72.172 7 50 
Succinate 0 6.5 Negative 117 73 10.2 45 
[13C2]Fumarate_2 0 6.5 Negative 117 73.172 7 50 
[13C1]Succinate_1 0 6.5 Negative 118 73 10.2 45 
[13C3]Fumarate_1 0 6.5 Negative 118 73.172 7 50 
[13C1]Succinate_2 0 6.5 Negative 118 74 10.2 45 
[13C3]Fumarate_2 0 6.5 Negative 118 74.172 7 50 
[13C2]Succinate_1 0 6.5 Negative 119 74 10.2 45 
[13C4]Fumarate 0 6.5 Negative 119 74.172 7 50 
[13C2]Succinate_2 0 6.5 Negative 119 75 10.2 45 
[13C3]Succinate_1 0 6.5 Negative 120 75 10.2 45 
[13C3]Succinate_2 0 6.5 Negative 120 76 10.2 45 
[13C4]Succinate 0 6.5 Negative 121 76 10.2 45 
Oxaloacetate 0 6.5 Negative 131 87.084 10 33 
[13C1]Oxaloacetate_1 0 6.5 Negative 132 87.084 10 33 
[13C1]Oxaloacetate_2 0 6.5 Negative 132 88.084 10 33 
Pyr + formic 0 6.5 Negative 133 87 5 30 
[13C2]Oxaloacetate_1 0 6.5 Negative 133 88.084 10 33 
[13C2]Oxaloacetate_2 0 6.5 Negative 133 89.084 10 33 
Malate 0 6.5 Negative 133 115.081 12 51 
[13C4]MalateC4 0 6.5 Negative 133 119.081 12 51 
[13C3]Oxaloacetate_1 0 6.5 Negative 134 89.084 10 33 
[13C3]Oxaloacetate_2 0 6.5 Negative 134 90.084 10 33 
[13C1]Malate 0 6.5 Negative 134 116.081 12 51 
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[13C4]Oxaloacetate 0 6.5 Negative 135 90.084 10 33 
[13C2]Malate 0 6.5 Negative 135 117.081 12 51 
[13C3]Malate 0 6.5 Negative 136 118.081 12 51 
AKG 0 6.5 Negative 145 101.123 8 42 
[13C515NN ]Glu 0 6.5 Negative 152.1 134.102 13 55 
Suc+formic 0 6.5 Negative 163 117 5 30 
Aco 0 6.5 Negative 173.05 85.129 15 39 
AscA 0 6.5 Negative 175.304 115 12.629 127 
Oxal+formic 0 6.5 Negative 177 131 5 30 
Mal+formic 0 6.5 Negative 179 133 5 30 
Cit/Icit 0 6.5 Negative 191 111 15 53 
AKG+formic 0 6.5 Negative 191 145 5 30 
[13C1]Citrate_1 0 6.5 Negative 192 111 15 53 
[13C1]Citrate_2 0 6.5 Negative 192 112 15 53 
[13C2]Citrate _1 0 6.5 Negative 193 112 15 53 
[13C2]Citrate _2 0 6.5 Negative 193 113 15 53 
[13C3]Citrate _1 0 6.5 Negative 194 113 15 53 
[13C3]Citrate _2 0 6.5 Negative 194 114 15 53 
[13C4]Citrate _1 0 6.5 Negative 195 114 15 53 
[13C4]Citrate _2 0 6.5 Negative 195 115 15 53 
[13C5]Citrate _1 0 6.5 Negative 196 115 15 53 
[13C5]Citrate _2 0 6.5 Negative 196 116 15 53 
[13C6]Citrate  0 6.5 Negative 197 116 15 53 
PCr 0 6.5 Negative 210 79.028 16 50 
Aco+formic 0 6.5 Negative 219 173.1 5 30 
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BEH Amide Method 
Table 4. SRM Transitions measured using the BEH Amide method. 












Putr1 0 6 Positive 89.252 30.333 20.264 68 
Putr2 0 6 Positive 89.252 48.151 10.253 68 
Putr3 0 6 Positive 89.252 72.169 10.253 68 
AlphaKBA_3 0 6 Positive 103.639 43.986 38.719 56 
AlphaKBA_1 0 6 Positive 103.639 58 13.944 56 
AlphaKBA_2 0 6 Positive 103.639 62.875 10.253 56 
gammaANBA_2 0 6 Positive 104.039 40.986 19.91 30 
gammaANBA_3 0 6 Positive 104.039 42.857 27.494 30 
DMG_2 0 6 Positive 104.039 44 39.579 54 
gammaANBA_1 0 6 Positive 104.039 58 10.253 30 
DMG_1 0 6 Positive 104.039 58 14.146 54 
DMG_3 0 6 Positive 104.039 62.889 10.253 54 
HTaur_2 0 6 Positive 110.122 30.058 11.365 51 
HTaur_3 0 6 Positive 110.122 44.986 18.444 51 
HTaur_1 0 6 Positive 110.122 91.946 10.253 51 
AcPutr1 0 6 Positive 131.23 72.097 16.017 108 
AcPutr2 0 6 Positive 131.23 90.556 10.253 108 
AcPutr3 0 6 Positive 131.23 114.111 10.253 108 
Asp 0 6 Positive 134.175 74.175 15 31 
Hypx 0 6 Positive 137.07 119.058 20.315 88 
Lys/Gln 0 6 Positive 147.1 84.169 16 48 
Glu 0 6 Positive 148 84.15 16 46 
Gua 0 6 Positive 152.1 135.077 19 84 
Glu13C515NP 0 6 Positive 154.1 89.094 15 47 
SAla_2 0 6 Positive 154.122 71.889 14.5 132 
SAla_1 0 6 Positive 154.122 112.889 10.253 132 
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SAla_3 0 6 Positive 154.122 133.373 10.253 132 
gammaGluCys_3 0 6 Positive 251.191 98.875 25.169 82 
gammaGluCys_2 0 6 Positive 251.191 168.903 14.096 82 
gammaGluCys_1 0 6 Positive 251.191 210.071 10.253 82 
78DHNP1 0 6 Positive 256.161 165.04 22.135 249 
78DHNP2 0 6 Positive 256.161 208.04 16.118 249 
78DHNP3 0 6 Positive 256.161 238.071 10.253 249 
Ads 0 6 Positive 268.1 136.1 18 68 
Ins 0 6 Positive 269.152 137.111 10.253 104 
Guas 0 6 Positive 284.1 152.102 15 80 
CMP 0 6 Positive 324.1 112.194 15 62 
UMP 0 6 Positive 325 97.179 15 64 
cAMP 0 6 Positive 330.1 136.21 25 91 
cGMP 0 6 Positive 346 152.108 21 86 
AMP 0 6 Positive 348.1 136.123 20 82 
AMP_IS 0 6 Positive 363.1 146.123 20 82 
GMP 0 6 Positive 364.1 152.197 16 67 
SAH 0 6 Positive 385.1 136.132 20 73 
SAM 0 6 Positive 399.1 250.147 16 79 
CDP 0 6 Positive 404 112.132 19 71 
UDP 0 6 Positive 405 97.062 16 74 
TPP 0 6 Positive 426.061 304.96 16.522 249 
ADP 0 6 Positive 428 136.174 24 91 
Fol_2 0 6 Positive 442.1 176.071 37.86 83 
Fol_1 0 6 Positive 442.1 295.071 16.876 83 
Fol_3 0 6 Positive 442.1 401.04 11.517 83 
GDP 0 6 Positive 444 152.08 18 83 
DHF_2 0 6 Positive 444.026 324.889 19.101 97 
DHF_3 0 6 Positive 444.026 365.946 13.994 97 
DHF_1 0 6 Positive 444.026 402.889 10.253 97 
MeTHF_3 0 6 Positive 460.109 179.986 37 88 
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MeTHF_1 0 6 Positive 460.109 313.04 19.708 88 
MeTHF_2 0 6 Positive 460.109 418.942 10.253 88 
CTP 0 6 Positive 484 112.234 21 91 
UTP 0 6 Positive 485 378.973 20 73 
 CDP-ch 0 6 Positive 489.1 184.111 38 89 
ATP 0 6 Positive 508 136.189 32 102 
ATP_IS 0 6 Positive 513 141.189 32 102 
GTP 0 6 Positive 524 152.106 24 95 
 UDP-glcNAC 0 6 Positive 608.1 99 16 90 
NAD 0 6 Positive 664.1 136.237 43 103 
NADH_3 0 6 Positive 666.183 301.929 37.961 100 
NADH_2 0 6 Positive 666.183 513.942 25.118 100 
NADH_1 0 6 Positive 666.183 649.014 15.966 100 
NADP 0 6 Positive 744.1 136.2 46 121 
NADPH_2 0 6 Positive 746.057 301.929 34.826 126 
NADPH_3 0 6 Positive 746.057 427.929 24.966 126 
NADPH_1 0 6 Positive 746.057 728.942 17.129 126 
CoA 0 6 Positive 768.374 261.111 28.051 249 
FAD 0 6 Positive 786.2 348.153 20 146 
AcCoA 0 6 Positive 810.225 303.049 33.41 147 
IBCoA 0 6 Positive 838.178 331.154 30.427 145 
IVCoA 0 6 Positive 852.087 345.222 30.629 145 
AcAcCoA 0 6 Positive 852.1 345.2 34 142 
MalCoA 0 6 Positive 854.1 347.201 27 161 
SucCoA 0 6 Positive 868.1 361.214 34 163 
HMGCoA 0 6 Positive 912.191 405.222 33.309 249 
Pyr 0 6 Negative 87 43 10 43 
Pyr 0 6 Negative 87 87 0 43 
AlphaKBA_N1 0 6 Negative 101.213 56.986 10.253 47 
AlphaKBA_N2 0 6 Negative 101.213 59.952 10.253 47 
AlphaKBA_N3 0 6 Negative 101.213 73.058 10.506 47 
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HTaur_N1 0 6 Negative 108.213 63.946 15.865 45 
Fum 0 6 Negative 115 71.172 7 50 
Suc 0 6 Negative 117 73 15 60 
SucIS 0 6 Negative 121 76 10.2 45 
Oxal 0 6 Negative 131 87.084 10 33 
Mal 0 6 Negative 133 115.081 12 51 
AKG 0 6 Negative 145 101.123 8 42 
MelA 0 6 Negative 147.152 59.111 12.022 84 
Glu13C515NN 0 6 Negative 152.1 134.102 13 55 
PEP 0 6 Negative 167 79.081 14 45 
DHAP 0 6 Negative 169 97.143 12 48 
GA3p 0 6 Negative 169.009 97 10.253 54 
Aco 0 6 Negative 173.05 85.129 14.5 39 
2PG/3PG 0 6 Negative 185 97.065 16 53 
Cit/Icit 0 6 Negative 191 111 15 53 
Ery4p 0 6 Negative 199.009 97 10.253 98 
PCr 0 6 Negative 210 79.028 16 50 
MelA5p 0 6 Negative 227.122 97 17.23 141 
Ribo5p 0 6 Negative 228.948 97 14.854 151 
Ribu5p 0 6 Negative 229.283 97 10.253 121 
DMApp 0 6 Negative 244.939 79 22.135 124 
IPpp 0 6 Negative 245.252 79.058 22.084 135 
G6P/F6P 0 6 Negative 259 97.077 17 60 
BPG 0 6 Negative 265 97.084 22 80 
6pGlcA 0 6 Negative 275.039 97 17.584 187 
MelApp 0 6 Negative 307.039 209 14.348 217 
CMPN 0 6 Negative 322.1 97.005 24 102 
UMPN 0 6 Negative 323 97.034 23 94 
cAMPN 0 6 Negative 328.1 134.115 26 108 
FBPN 0 6 Negative 339 97.084 22 83 
cGMPN 0 6 Negative 344 150.099 25 124 
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AMPN 0 6 Negative 346.1 134.111 34 108 
AMPN_IS 0 6 Negative 361.1 144.111 34 108 
GMPN 0 6 Negative 362.1 211.079 20 98 
CDPN 0 6 Negative 402 158.926 27 115 
UDPN 0 6 Negative 403 158.971 28 103 
TPP_N 0 6 Negative 424.03 303.111 15.36 168 
ADPN 0 6 Negative 426 134.136 25 120 
GDPN 0 6 Negative 442 150.096 27 120 
DHF_N1 0 6 Negative 442.183 176.044 26.382 133 
DHF_N2 0 6 Negative 442.183 265.03 19.253 133 
DHF_N3 0 6 Negative 442.183 313.097 18.848 133 
MeTHF_N2 0 6 Negative 458.109 278.014 18.393 142 
MeTHF_N1 0 6 Negative 458.109 279.04 18.596 142 
MeTHF_N3 0 6 Negative 458.109 329.032 26.382 142 
CTPN 0 6 Negative 482 158.921 30 110 
UTPN 0 6 Negative 483 158.986 31 117 
ATPN 0 6 Negative 506 158.983 32 123 
ATPN_IS 0 6 Negative 511 158.983 32 123 
GTPN 0 6 Negative 522 158.999 35 129 
UDPglc 0 6 Negative 565.078 323 23.449 249 
UDP-glcNACN 0 6 Negative 606.1 159 28 103 
 
  




III.1 Intralipid and U-13C Triglyceride Mixture Compositions 
 
Table III.1: Composition of Intralipid. 
Constituent % of Intralipid Represented 
Egg Yolk Phopholipids 1.2 
Glycerin 2.25 
Soybean Oil (Lipid composition of which is as follows:) 20% 
Linoleic Acid 44-62 
Oleic Acid 19-30 
Palmitic Acid 7-14 
Linolenic Acid 4-11 
Stearic Acid 1.4-5.5 
 
 
Table III.2: Composition of U-13C Triglyceride Mixture (Cambridge Isotopes). 
Fatty Acid Relative Area Carbon Number Sites of Unsaturation 
palmitolenic 8.3% 16 2 
hiragonic 6.4% 16 3 
palmitoleic 5.7% 16 1 
 1.0% 16  0  
palmitic 19.6% 16 0 
margaric 1.5% 17 0 
linoleic 23.2% 18 2 
oleic 25.6% 18 1 
eliadic 1.9% 18 1 
 3.6% 18 0 
stearic 2.9% 18 0 
 
  




V.1 Homogenisation Buffer Composition 
 
Table V.1: Homogenisation Buffer Composition. 
Constituent Concentration 
HEPES 20 mM 
EDTA 1 mM 
Triton 0.1% 
 
 
